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Abstract 
  
The preservation of haemostatic integrity is secured by the activities of von Willebrand 
factor (VWF). Upon vascular damage, VWF acts as a molecular bridge facilitating the 
initial adhesion and aggregation of platelets to the site of vessel injury, and 
consequently thrombus formation ensues. Furthermore, VWF is the faithful carrier of 
procoagulant factor VIII in plasma, thereby prolonging its half-life, and efficiently 
localising FVIII to the incipient platelet plug. The arrest of bleeding and maintenance of 
blood volume constancy is critically dependant on VWF; as is exemplified by von 
Willebrand disease (VWD) – the most common inherited bleeding disorder in man, 
resulting from defective or deficient VWF protein. Much of the function of VWF has 
been revealed, however, detailed insight into the molecular structure that enables 
VWF to orchestrate haemostatic processes, in particular FVIII stabilisation in plasma, is 
lacking. The high resolution NMR structure of the major FVIII binding region (D') on 
VWF, and the dynamics and flexibility of its substructure, are presented in this thesis. 
The complex disulphide-bonded D' region is composed of a two subdomain 
architecture – TIL’E’. Domain TIL' lacks extensive secondary structure, is strikingly 
dynamic on at least two timescales measured by NMR relaxation experiments, and this 
region is coincident with the clustering of pathological mutations leading to decreased 
FVIII binding affinity (type 2N VWD). This indicates that the conformational 
fluctuations and backbone malleability of domain TIL' collocate with biological activity. 
In contrast, the structured domain E’, is rigid and contains the most commonly 
occurring and clinically mildest type 2N VWD mutation. These findings provide 
important insights into VWFFVIII complex formation and represent a first step towards 
revealing the molecular basis of the bleeding diathesis type 2N von Willebrand disease.  
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1. Introduction 
Antiquity established the mythic and moral symbolism of blood that to this day subtly 
endures. The Egyptians saw blood as the carrier of the vital human spirit and would 
bathe in the liquid as a restorative. It is because blood conveyed strength to the 
Romans that gladiators were said to have drunk the blood of fallen opponents. Doctors 
from the medieval to the Victorian era assumed blood to have fantastical powers, 
draining it to remove evil humors, transfusing it to pacify the deranged. Contemporary 
culture also attaches great value to blood, with the blood of Christ as among the 
holiest sacraments, blood libel as the most insidious slander, and the blood-drinking 
vampire as the most odious demon. The narrative of blood and its metamorphosis 
from a mystical substance into a vital component of human anatomy has been an 
undercurrent to the history of medicine and civilisation1.  
 
1.1 Haemostasis and the coagulation cascade 
The cessation of blood loss from a damaged vessel to maintain blood volume 
constancy, haemostasis, is one of the most important physiological mechanisms. 
Haemostasis is accomplished by a complex network of intricately choreographed 
processes that principally involve the endothelium, platelets, and the coagulation 
cascade, all of which support the dynamic equilibrium that maintains laminar blood 
flow and protects against the threat of fatal haemorrhage through breaches in vascular 
integrity2. The modern concept of coagulation presented in 1964 as the Cascade 
model3,4, unravelled the basic mechanism of one of the most remarkable 
characteristics of blood - its ability to clot. The coagulation cascade, forming the third 
arm of the haemostatic process, is a highly sophisticated amplifying series of enzymatic 
conversions culminating in fibrin deposition and formation of the definitive 
haemostatic plug (Figure 1.1). This model has since been further refined as the cell 
based model, describing the highly interwoven array of physical, cellular and 
biochemical processes that are primed to react, in an explosive manner, to vascular 
injury and stem blood loss5. The pathologic counterparts of haemostasis are 
thrombosis and bleeding.  
13 
 
 
 
 
 
 
 
 
 
The cell based theory divides coagulation into three phases. The initiation phase begins 
with the extrinsic pathway when contiguity of the vasculature is disturbed and 
Figure 1.1: Blood coagulation cascade. The coagulation cascade is divided into intrinsic, extrinsic and 
common pathways. The letter ‘a’ appended to a coagulation factor indicates that it is activated. 
Arrows symbolise proteolytic conversion. Cofactors are shown below the arrows. The following 
abbreviations are used: F, factor; HMW, high molecular weight; TF, tissue factor; PL, phospholipid; 
Ca
2+
, calcium. Coagulation is initiated by TF expressing cells released by damaged vascular 
endothelium and proceeds via the intrinsic pathway. Deficiency of proteins in the extrinsic pathway 
prolongs a prothrombin time assay. Initiation leads to generation of low levels of thrombin. FVIIa 
bound to TF activates both FX and FIX. FXa formed by TFFVIIa binds to FVa and converts small 
amounts of prothrombin to thrombin. Thrombin generation is then amplified, a major function of 
which is to activate platelets and convert FVIII into FVIIIa, which acts as a cofactor to FIXa on the 
platelet surface to support FXa generation. Coagulation is then propagated on the surface of 
activated platelets via the intrinsic pathway and results in the production of significant levels of 
thrombin. This leads to fibrin deposition and stabilisation of the platelet clot, forming the definitive 
haemostatic plug (secondary haemostasis). Deficiency of any intrinsic pathway factors prolongs an 
activated partial thromboplastin time assay.  
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subendothelial cells (such as smooth muscle cells and fibroblasts) become exposed to 
flowing blood. These cells expose tissue factor (TF), the principal initiator of 
coagulation. TF binds and activates coagulation factor VII (FVII), the resultant TFFVIIa 
complex proteolytically cleaves FIX and FX into FIXa and FXa, respectively. This allows 
FXa to associate with cofactor FVa to form the prothrombinase complex on TF 
expressing cells, which serves to convert prothrombin (FII) into thrombin (Figure 1.1). 
The slowly accumulating levels of thrombin on TF-bearing cells will further activate 
platelets that are localised to the site of vessel injury by the activities of von 
Willebrand factor (VWF). In parallel, thrombin will convert FV to FVa, thus amplifying 
prothrombinase activity, and convert FVIII to FVIIIa, which acts as a cofactor to FIX on 
the surface of activated platelets to support FXa generation (Figure 1.1). Additionally, 
thrombin converts FXI into FXIa. Following the amplification phase, the stage is set for 
propagation of thrombin generation; this final phase proceeds on the surface of 
activated platelets mediated by the intrinsic pathway. FIXa, activated during initiation, 
associates with thrombin-cleaved FVIIIa on the platelet surface (additional FIXa is 
supplied by platelet-bound FXIa), forming the tenase complex. FVIIIaFIXa catalyse the 
conversion of FX to FXa, which rapidly associates with FVa to assemble the 
prothrombinase complex (Figure 1.1), resulting in a burst of thrombin generation of 
sufficient magnitude to form an elastic, polymerised fibrin clot6,7.  
 
1.2 Von Willebrand factor 
Preservation of haemostatic integrity is secured by the activities of VWF, synthesised 
by endothelial cells. VWF is a multimeric plasma sialoglycoprotein that is crucial to 
primary haemostasis (formation of a platelet clot), particularly in the rapid flow of the 
arteriolar circulation, a process in which it plays dual roles. Upon vascular damage, 
VWF acts as a molecular bridge, enabling thrombus formation by facilitating the initial 
adhesion and aggregation of platelets to the denuded blood vessel wall8 (Figure 1.2). 
Furthermore, VWF is the protective carrier of procoagulant FVIII (intrinsic coagulation 
pathway) in plasma, thereby, prolonging its circulatory half-life and efficiently 
localising FVIII to the site of the incipient platelet plug, to initiate secondary 
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haemostasis, concluding in clot stabilisation by fibrin deposition9 (Figure 1.2). The 
arrest of bleeding and maintenance of haemodynamic equilibrium is critically 
dependent upon VWF, as exemplified by von Willebrand disease (VWD); the most 
common congenital bleeding disorder in man, resulting from defective (type 2) or 
deficient (type 1 and 3) VWF protein10,11 and affecting up to 1.3% of the population12. 
VWD is characterised by symptoms of excessive mucocutaneous bleeding such as 
epistaxis, menorrhagia and prolonged bleeding after trauma. This phenotype is 
consequent to the two-fold defect in haemostasis, that of impaired platelet adhesion 
and reduced FVIII concentration10,13. 
 
 
 
 
 
 
1.3 VWF gene 
Cloning of the VWF gene was achieved in 1985 using endothelial cell cDNA libraries by 
four independent groups14–17. VWF is located distally on the short arm of chromosome 
12, at the locus 12p13.317,18. It contains 52 exons, spans 178 kb in length and is 
transcribed into an 8.7 kb mRNA. Exon 28 is exceptionally large, comprising 1379 base 
Figure 1.2: Role of von Willebrand factor in thrombus formation. Schematic representation of the 
mechanisms of platelet aggregation (primary haemostasis) in flowing blood. At the site of vessel 
injury, VWF is first immobilised on exposed collagen fibrils. Immobilised VWF then binds flowing 
platelets and following stable platelet-VWF adhesion, platelets are activated and bind more plasma 
VWF, this forms the substrate onto which additional platelets are recruited and thrombus 
formation ensues. Upon which co-localised FVIII and tissue factor initiate secondary haemostasis, 
leading to enmeshment of the platelet plug by polymerised fibrin and formation of an impermeable 
platelet and fibrin clot. These mechanisms are discussed in detail in section 1.7. 
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pairs19 and is the most mutated region of VWF, encoding domains A1 and A2 that 
contain essential ligand-binding and cleavage sites, respectively10 (Figure 1.3).  
 
 
 
Furthermore, studies have also identified an unprocessed 21-29 kb VWF pseudogenic 
sequence (VWFP)20 located on chromosome 22q11.2. VWFP partially duplicates exons 
23 through 34 of the VWF gene, which encode important functional domains in VWF 
(domains A1-A2-A3). However, the accumulation of missense, nonsense and splice-site 
mutations in VWFP prevents it from generating a functional transcript. The 
pseudogene, VWFP, and VWF have diverged only 3.14% in nucleotide sequence 
(exons, 2.47%; introns, 3.25%), suggesting a recent evolutionary origin – approximately 
19-29 million years ago, that is before the separation of orangutan from humans and 
the African apes (10-15 million years ago), and near the time of divergence of humans 
and apes from monkeys (20-30 million years ago) by partial gene duplication21,22. This 
is consistent with the presence of VWFP in great apes (bonobo, chimpanzee, gorilla 
and orangutan) but not in more distantly related primates such as the rhesus or spider 
monkey23. The VWF pseudogene may occasionally serve as a reservoir of mutations 
that can subsequently be introduced into the VWF locus. Potentially pathogenic 
mutations have been identified in exons 27 and 28 of the VWF gene in VWD patients, 
and these sequence variations occur consecutively in VWFP, therefore it is likely they 
have been transferred to VWF by homologous gene conversion events24,25.  
 
 
Figure 1.3: Schematic of VWF gene and mRNA. Exons are shown as black vertical bars in the VWF 
gene. The lower panel shows the VWF mRNA with the large central exon 28, that is the most 
mutated region of VWF. 
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1.4 VWF expression and tissue distribution  
VWF is synthesised throughout the vascular tree, exclusively by endothelial cells26 and 
megakaryocytes27, with the former being the principal source of plasma VWF28. 
Endothelial cell VWF is either constitutively secreted into plasma or stored in 
cytoplasmic granules, termed Weibel-Palade bodies, that are specific for 
endothelium29,30. Megakaryocyte VWF is stored in the -granules of its platelet 
progeny31,32. Expression of VWF in the intact endothelium varies both spatially and 
temporally in different vascular beds. VWF mRNA levels are highest in the lung, spleen 
aorta and brain endothelial cells, with low levels in the kidney, skeletal muscle, gut and 
liver33. These differences are not accounted for by differences in vascularisation, as the 
kidney and liver are highly vascularised tissues with relatively low VWF expression, but 
rather reflect the differential expression of VWF mRNA from tissue to tissue. Thus, in a 
given tissue, VWF expression is generally greater in the venous side of the circulation 
than in arterial and arteriolar endothelial cells34, and greater in the large and small 
vessels than in the microvasculature33,34. This is surprising, as VWF is particularly 
important in the arterial vessels, which are most directly involved in haemostasis35. 
Furthermore, expression of VWF in the aorta is variable, with the gene product present 
in clusters of endothelial cells orientated parallel to the longitudinal axis of blood flow 
and is particularly concentrated in the endothelial cells lining the ostia of the 
intercostal arteries36. Thus, the heterogeneous expression of VWF in endothelial cells 
from different vessels is an example of vascular differentiation in an organ-specific 
manner and reflects the transcriptional control of VWF synthesis to maintain the 
microenvironment-specific haemostatic balance33,37. 
 
1.5 VWF primary translation product 
The primary translation product, preproVWF, is 2813 amino acids (aa) and contains a 
cleavable 22 aa signal peptide, an unusually large 741 aa propeptide and a mature 
2050 aa subunit protein38,39 (Figure 1.4). A consensus cleavage site for the 
endoprotease furin separates the propeptide from the remaining domains of mature 
VWF. The amino acid sequence of VWF is highly conserved. Human VWF is at least 78% 
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identical to VWF of other placental mammals; 73% identical to opossum VWF; 55-56% 
identical to bird, reptile and amphibian VWF; and 45-46% identical to fish VWF40. 
Random occurrence of the nucleic acid bases predicts that proteins would contain 
3.3% cysteine41. ProVWF however, has an extraordinarily high cysteine content, 
comprising 324 of the 2813 residues (8.3), with Cys being the most abundant amino 
acid. Interestingly, the Cys residues are found to be concentrated in the flanking N- and 
C-terminal regions, often in clusters of Cys-Cys, Cys-x-Cys or Cys-xx-Cys. The central 
triplicated A domains are notable for their relative scarcity of cysteines, with only six 
Cys among 603 residues. It was thought that secreted VWF multimers contain few or 
no reduced Cys residues, such that successful multimer assembly engages all VWF 
cysteines in intra- or inter-subunit disulphide bonding42. The N-termini at the free ends 
of the VWF multimer have not engaged in inter-subunit bonding and contain two 
reduced cysteines43. Recent data however, indicates that mature VWF contains 
unpaired cysteine thiol groups, that are both surface exposed on the protein and 
buried within the quaternary structure44–46. 
 
1.5.1 The modular architecture of proVWF 
A striking feature of the VWF sequence is its pattern of internal duplication. ProVWF is 
a highly repetitive protein that is classically thought to comprise four types of 
homologous domains (A-D), present in two to five copies and encompassing the 
greater proportion of the protein sequence15,39,47,48. A fifth element, ‘E’, had briefly 
been proposed47 based on examination of the mature peptide, however, upon 
determination of the complete precursor sequence, the ‘E’ sequences (‘E1’, aa 788-
833; ‘E2’, aa 2216-2261) were revised as the C-terminal fragments of D domains49. The 
classical D1 and D2 assemblies are tandemly duplicated in the propeptide sequence of 
the precursor, whereas D3 and D4 are separated by 755 residues: a 3+1 formation. A 
C-terminal D domain truncation, D’ (97 aa), immediately precedes the D3 region 
(Figure 1.4). Intricate analysis of the proVWF sequence, based on domain family 
alignments, was used to identify positionally conserved cysteine signatures and to 
delineate new VWF domain boundaries. This subsequently led to segmentation of the 
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classical D regions and reassignment of the modular architecture of VWF with respect 
to five homologous domain repeats: von Willebrand D (VWD), 8-cysteine (C8), trypsin 
inhibitor-like (TIL), E, and von Willebrand C (VWC) domains50 (Figure 1.4).  
 
 
 
 
 
 
 
1.5.2 Functional domains of VWF 
The functional versatility conferred by domain repeats, occurring in at least 14 of all 
proteins51, affords a protein enhanced evolutionary prospects due to the potential for 
multiple binding and structural roles52, and it follows that there is a greater abundance 
of domain repeats in organisms of higher complexity. Many domain families that form 
repeats are implicated in complex-assembly, cell-adhesion and signalling processes53. 
The VWF subunit contains numerous binding regions, to which specific functions have 
been ascribed. Binding sites for procoagulant FVIII54 and, controversially, heparin 
reside within the N-terminal 272 residues55,56, however, the indispensable heparin 
Figure 1.4: The modular architecture of VWF. Upper panel; VWF primary translation product 
showing the 22 aa signal peptide, a 741 aa propeptide and a 2050 aa mature protein. Middle panel; 
the classical VWF domain annotation is shown comprising the large VWF D regions (mean length, 
359 aa) in a 3+1 formation. Cleavage sites for furin, the metalloprotease ADAMTS13 and 
staphylococcal protease V8 are indicated with arrows. Binding sites for coagulation factor VIII, 
platelet glycoprotein Ib (GPIb) and platelet integrin receptor IIb3 are indicated. Bottom panel; 
reassigned VWF domains are shown, whereby each former D region is formed of an assembly or 
supradomain of VWD-C8-TIL-E domains. A TIL’E’ module defines the classical D’ region. The B/C 
regions are revealed to be a tandem arrangement of six VWC domains. An additional domain 
proximal to the former D4 region has been assigned as D4N
50
, and is part of the D4 assembly. 
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binding site57 is located 3’ upstream within the A1 domain58,59, localised to aa 1328-
135060. The A1 domain also contains the binding site for platelet GPIb (residues 1323-
1395)61–63. Additionally, the A1 domain binds collagen type VI64,65, which contains VWF 
type A domains in its noncollagenous regions that may become engaged in homotypic 
interactions with VWF A12. The principal binding region for fibrillar collagens I and III, 
however, is located within the A3 domain at aa 1740-178666,67. ADAMTS13 (a 
disintegrin-like and metalloprotease with thrombospondin type 1 motif, member 13)68 
docks at an exosite within the A2 domain between aa 1660 to 166869–71 where it 
cleaves the VWF Tyr1605-Met1606 peptide bond72. Platelet integrin receptor IIb3 
binds the VWF RGD tripeptide at aa 2507-2509 in domain VWC473,74. Further VWF 
binding regions include those for the integral membrane protein P-selectin (aa 776-
1241)75, sulphatides (aa 1392-1423)76–78 and the snake venom botrocetin (aa 1391 -
1431)79,80. Botrocetin from the viper Bothrops jararaca enhances the affinity of the A1 
domain for platelet receptor GPIb by increasing the life-time of the A1-GPIb bond 
two-fold. This leads to platelet consumption and haemorrhage in the envenomated 
host80. 
 
1.5.3 VWF domain evolution  
Domain repeats are thought to have evolved through internal gene duplication and 
recombination events52 and are most often created by duplication of several domains 
at a time53. In contrast to the evolution of other multidomain proteins that involve the 
addition of a single domain at either terminus53,81. The positions and phase of the 
intron-exon boundaries within the repeated units of VWF (a detailed analysis of which 
is given in Appendix 5.1) are consistent with the evolution of these domains by gene 
segment duplication rather than exon shuffling, for which the 5’ and 3’ splice junctions 
of the shuffled exon module are phase compatible with that of its new neighbour82–84. 
In VWF, repeated domains are spread over several exons, the borders of which do not 
delimit the structural domains and show only limited similarity in the corresponding 
gene segments that encode the homologous repeats (Figure 1.5). With the exception 
of the C8-to-TIL linkers that contains coincident phase 1 junctions C-terminal to Cys10 
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of domains C81 through C84. Overall however, a correlation between the modular 
architecture and the exon-intron structure is not observed in VWF, although the 
progression of time may have eroded and obscured the original genomic structure82, 
and therefore, the mosaic modularity of VWF alludes to a complex evolutionary 
history.  
 
 
 
 
 
The classical D regions (average length, 359 aa) of VWF constitute a supradomain 
formed by the assembly of a strongly conserved N- to C-terminal arrangement of 
VWD-C8-TIL-E domains; a TIL’E’ module defines the former D’ region. Domains 
combine in only a limited number of ways, and only a fraction of the possible domain 
combinations actually exist in genomes85, implying that this limited repertoire of 
supradomains that includes VWD-C8-TIL-E, have undergone strong evolutionary 
selection81. A number of proteins contain the VWD-C8-TIL triplet, often in repeats, and 
are segregated into two groups. VWF, otogelin, mucins and insect hemolectin are 
evolutionarily related by a triplicate of N-terminally placed VWD-C8-TIL supradomains, 
followed by a domain characteristic of the respective protein (VWF, triplicated A 
domains; otogelin, PTS and AbfB domains; mucins, PTS domain; hemolectin, F5/8 type 
Figure 1.5: Domain boundaries and splice junctions of VWF. ProVWF domain arrangement is shown 
aligned to the plot. The phase class of the splice junctions, on the y-axis, is plotted against the VWF 
amino acid sequence. Exon shuffling is governed by splice frame rules. Introns may interrupt the 
reading frame of a gene between two consecutive codons (phase 0 intro-exon boundary), or 
between the first and second nucleotide of a codon (phase 1), or between the second and third 
nucleotide (phase 2). Domains encoded by symmetric exons or symmetric sets of asymmetric exons 
are likely to have arisen by exon shuffling as their insertion or duplication would not disturb the 
reading frame
84
. 
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C domain), and often another VWD-C8-TIL module forming a D1-D2-D3-x-D4 motif 
(3+1 formation)86. They are phylogenetically distinct from other VWD-C8-TIL 
containing proteins, such as zonadhesin, SCO-spondin, tectorin and IgGFc-binding 
protein. A common denominator for VWF, hemolectin and the gel-forming mucins is 
their capacity to form oligomers.  
An arrangement of three N-terminally located VWD-C8-TIL modules is involved in the 
multimerisation of VWF87, insect hemolectin88 and mucins89,90. The VWF propeptide 
facilitates multimerisation in the acidic trans-Golgi compartments91 by an 
oxidoreductase mechanism92, to which the VWD1 and VWD2 CGLCG motifs are 
critical93. The importance of the triplicate VWD-C8-TIL module in multimerisation 
indicates that the tendency for the sequential order of the domains to be conserved94 
is likely due to a functional constraint that maintains inter-domain geometry; rather 
than simply a historical arrangement following a single ancestral recombination 
event53,81. Gel forming mucins appeared early in metazoan evolution, they are found in 
the starlet sea anemone (Nematostella vectensis) and are ancestors to VWF, that did 
not appear until the vertebrate lineage86. This is in alignment with a model of 
coagulation system evolution95. It is interesting that each TIL domain in VWF is 
followed by either a VWC domain truncation – the E domain repeat - or a VWC domain 
proper. Analysis of VWD-C8-TIL repeat proteins, reveals that the TIL associated E 
domain is common and not unique to VWF.  
Individual domains of the VWD-C8-TIL-E supradomain, however, are found in more 
basal species, such that the VWD alone is present in cyanobacteria. The subsequent 
addition of a C8 domain giving rise to the VWD-C8 doublet occurred in unicellular 
organisms such as choanoflagellates, the closest group to metazoan organisms, and 
the assembly of the VWD-C8-TIL triplet, as well as the VWD-C8-TIL-E supradomain 
appears to have emerged during the multicellularity of animals as a complete VWD-C8-
TIL-E sequence was found in the basal placozoan Trichoplax adhaerens and cnidarian 
Netamostella, (unpublished observations, Dr Romain Studer).  
Reconsideration of the classical VWF B/C domains, following the VWD4-C84-TIL4 
module (D4 assembly) indicates that it is formed of six VWC domains, occurring in 
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tandem and interrupted only by a unique orphan segment between VWC2 and VWC3 
(Figure 1.4). This segment may constitute a flexible linker due to the disorder 
suggested by its compositional bias to threonine, it does however, contain four Cys 
residues all of which have been chemically shown to form internal disulphide bonds42, 
thus hinting at structural order. VWC domains (also referred to as chordin-like cysteine 
rich repeats) are found in over 500 extracellular proteins, restricted to metazoan 
genomes. This promiscuous domain is one of the most commonly occurring motifs and 
is found in diverse protein architectures of variable functions, including the signalling 
CNN proteins, most isoforms of collagen, thrombospondin, mucins and neuralin96.  
Unlike the lone copy present in the CNN family of proteins, the VWC domain is 
typically found in multiple copies in other proteins. They are versatile binding units as 
evidenced by the diversity of processes they functionally support. In most proteins, the 
VWC repeat acts as an extracellular regulator of bone morphogenic proteins (BMPs) 
and transforming growth factor- (TGF-) signalling. BMPs are potent growth factors, 
with pleiomorphic functions during development including embryogenesis, skeletal 
formation, haematopoiesis and neurogenesis97. In proteins with multiple VWC 
domains, each unit can exhibit varying specificities and affinities, there may be silent 
VWC domains, as well as cooperativity in the function of multiple VWC domains 
generating higher binding affinities98,99, suggesting a complicated means of 
regulation96. This behaviour has led to speculation that the disulphide-rich core of 
VWC provides a scaffold for the attachment of a diversity of loops that can generate 
different binding specificities similar to an immunoglobulin – making the tandem VWF 
C domains highly interesting. In the conotoxin superfamily, comprising many hundreds 
of members with numerous disulphide bonds, a similar principle has been 
established100. The cellular role of most VWC domains however is as yet unknown101 
and the only functional role designated to the VWF C domains is platelet integrin 
IIb3 binding at VWC4102. 
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1.5.4 VWD-C8-TIL-E supradomain 
An alignment of the VWF VWD-C8-TIL-E supradomains, highlighting the conserved 
cysteines and motifs within the domains is shown in Figure 1.6. VWD-C8-TIL triplets in 
VWF assemblies D1 through D3 are followed by an E domain, whereas assembly D4 is 
followed by a full VWF C domain (VWC1), the first six cysteines of which align to the E 
domains. The VWD domain contains four conserved Cys residues; the first N-terminal 
pair of cysteines are disconnected by 21 amino acids, and flank a central TFDG motif. 
The second pair of conserved cysteines participate in the formation of the vicinal 
cysteine residue motif, CGLCG, found in VWD1, VWD2 and VWD3, which corresponds 
to the CGxC catalytic site of the thioredoxin superfamily (including protein disulphide 
isomerase)103. A truncated motif, GLCG, is present in the corresponding position in 
VWD4 (Figure 1.6). The C8 and TIL domains are enriched in positionally conserved 
cysteines; TIL units contain ten conserved Cys residues and participate in the formation 
of D assemblies, as observed in many extracellular proteins including VWF, or are 
found alone in serine protease inhibitors, such as potent nematode anticoagulants that 
are specific inhibitors of FXa and the TFFVIIa complex104,105. The nematode 
anticoagulant proteins, homologues of the VWF TIL units, are targets for 
antithrombotic drug development and are currently undergoing clinical and preclinical 
trials106. 
VWF TIL2 domain contains the tripeptide Arg-Gly-Asp (RGD) – a cell adhesion motif 
that is also present in domain VWC4 where it forms part of the binding region for 
platelet integrin receptor IIb373,74. However, the significance of the RGD motif in the 
prodomains is not known (Figure 1.6). The TIL unit belongs to the Ascaris protease 
inhibitor family (MEROPS clan IA, family l8); designated as a single evolutionary line of 
inhibitors defined by a conserved protein fold (VWF MEROPS ID: 108.950)107–109. The 
Ascaris family predominantly inhibit serine proteases of the S1 family, containing the 
catalytic triad His-Asp-Ser110,111, but also M4 family metalloproteases (that does not 
include ADAMTS13). S1 family inhibition by TIL units is achieved by the Laskowski 
(standard) mechanism111,112, whereby an extended solvent-exposed convex combining 
loop of canonical conformation, surrounds the reactive site P1-P1’ scissile bond 
forming a serine protease substrate analogue112,113.  
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The presence of the conserved TIL unit was alluded to early following the cloning of 
the VWF sequence. Sequences Cys3 to Cys10 of mature VWF TIL’ and TIL4 domains, 
were initially termed ‘E1’ and ‘E2’ domains, respectively47. This annotation was 
subsequently made obsolete by enveloping the ‘E’ domains within the C-terminal D 
regions49. PreproVWF contains five TIL domain units, separated by an average of 425 
residues. Interestingly, making it a potential homotypic compound serine protease 
inhibitor108. There are however, no published experimental data as to the possible 
inhibitory activity of VWF.  
The average pairwise sequence identity (and similarity)114 between the VWD-C8-TIL-E 
supradomains is 29.4% (42.3%). All pairwise sequence identities are above the twilight 
Figure 1.6: The classical D regions are formed of VWD-C8-TIL-E supradomains. Alignment of the 
VWF supradomains (VWD-C8-TIL-E) formed of the classical D1, D2, D3 and D4 assemblies is shown. 
Conserved cysteines are highlighted in black and numbered above the alignment according to the 
order in which they occur in the sequence, such that 1 represents Cys1. Cys1-Cys6 of domain VWF C1 
(aa 2257-2296) aligned to the E domains is also shown, to highlight sequence homology. Conserved 
motifs are highlighted in red; glycosylation sites are highlighted in grey; intron-exon boundaries are 
shown in bold and underlined. The VWD domain CGLCG motif is encompassed by Cys6 and Cys7. The 
TIL2 RGD motif is highlighted in green.  
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zone limit of 25%115, thereby allowing their evolutionary relatedness to be inferred. 
The VWD4-C84-TIL4 triplet was extended to encompass the first six conserved 
cysteines of VWF domain C1, residues 2257-2296 (Figure 1.6). Pairwise analysis of the 
sequences between each VWD-C8-TIL-E assembly indicates that VWD4-C84-TIL4-C1 
(D4 region) is the most remote module, whereas VWD1-C81-TIL1-E1 (D1) and VWD2-
C82-TIL2-E2 (D2) share the highest sequence identity and similarity. Furthermore, 
domains TIL’ and E’, forming the classical D’ region, are most similar to TIL1 and E1 of 
region D1, respectively (Figure 1.7).  
 
 
 
 
1.5.5 VWC and E domains 
By analysis of homologies to the CNN protein family and thrombospondin, there have 
been suggestions in the literature that the classical VWF B domains may actually be 
formed of VWC domains, and that there are a greater number of C domains in VWF 
than originally reported116,117. The VWC repeat is typically 70 amino acids in length 
and contains ten conserved Cys residues, forming five disulphide bonds, arranged in a 
distinctive pattern with the following consensus signature: C-C2xxC3xC4-C-C-C-C8C9xC10 
(connectivity 1-4, 2-8, 3-5, 6-9, 7-10)101,118. The motifs C2xxC3xC4 and C8C9xC10 are 
highly conserved, as are a glycine and an aromatic residue, often tryptophan, between 
Figure 1.7: Pattern of internal D assembly duplication in VWF. The D4 assembly includes the first six 
cysteines of domain C1. The intensity of the squares in the matrix reflects the percentage similarity, 
implementing the NEEDLE algorithm
114
, between the D regions (VWD-C8-TIL-E), with darker colour 
for higher scores. The regions aligned are shown on the x- and y-axes. It is clear that the D4 region is 
least similar to regions D1 to D3. With thanks to Micha Ben Achim Kunze for generating the matrix. 
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the first cysteine pair116, otherwise the intervening VWC domain sequences contain a 
high degree of variability (Figure 1.8), wherein the average sequence identity (and 
similarity) between the VWF C domains is 20.3% (29.0%).  
 
 
 
 
There are data to suggest that conserved Gly and Pro residues, of which there are 
clusters throughout the VWF C domains, may act to inhibit aggregation119–121 and this 
may be of importance to VWF. The tandem arrangement of six C domains presents a 
unique folding problem to VWF, as a high local homologous domain concentration 
makes proteins vulnerable to misfolding and aggregation122. In most multidomain 
proteins, domains are adjacent to non-homologous neighbours, such that misfolding 
events are unlikely81. However, for the VWC region of VWF, which has arisen due to 
internal duplication53, misfolding is potentially possible. Adjacent domains in a protein 
are less similar than non-adjacent domains, whereby, less than 10% of adjacent 
domain pairs have sequence identities greater than 40%, and the identity between 
adjacent domains peaks at 30% in eukaryotes122,123. Therefore, indicating that adjacent 
domains have sufficiently diverged in sequence to prevent interdomain misfolding and 
subsequent aggregation. In VWF, the pressure for divergence is seen in the overall low 
level of non-cysteine sequence conservation in the C domains; their pairwise identities 
range from 9.8% (VWC2-VWC3) to a maximum of 29.1% (VWC1-VWC2), which may 
serve to overcome the high local homologous domain concentration that would 
otherwise increase the aggregation propensity of VWF122 (Figure 1.9). Another 
distinctive evolutionary characteristic of tandem domain repeats is chunk duplication 
Figure 1.8: VWF C domains. The six tandem VWC domains are aligned below the schematic of the 
VWF domain arrangement, highlighting the VWC domain region, C1 to C6. In the alignment, 
conserved cysteines highlighted in black and conserved motifs in red. Glycosylation sites are 
highlighted in grey and intron-exon borders are shown in bold and underlined. The Arg-Gly-Asp 
(RGD) sequence in VWC4 that binds platelet integrin receptor IIb3 is highlighted in green. With 
the exception of positional cysteine conservation, the VWC domain sequence is highly variable.  
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of multiple domains at a time that prevents identical domains being placed 
immediately adjacent to one another81. Such is the case for the VWF D region 
supradomains (Figure 1.7) and C domains (Figure 1.9).  
 
 
 
 
VWF domain VWC1 has the highest sequence similarity with VWC2 (38.4%), VWC3 is 
most similar to VWC5 (46.5%) and VWC4 is most similar to VWC6 (38.6%). Therefore, it 
appears that a unit of two C domains has been duplicated twice in VWF, to give rise to 
the tandem arrangement of six VWC domains.  
The E domains are delineated by their conservation of the first six cysteines of a VWC 
domain, C1-C2xxC3xC4-C5-C6, and are divergently related to the VWC domains. The 
presence of a VWC truncation E domain in VWF was suggested soon after 
determination of the VWF primary sequence. This domain was termed Cx (aa 826-853) 
and was found to be highly similar to residues 2424-2455 and 2575-2607 of the 
classical C1 and C2 domains, respectively (Cys1 to Cys4 of VWC3 and VWC5)
47,116. The 
Figure 1.9: Pattern of internal C domain duplication in VWF. The intensity of the squares in the 
matrix reflects the percentage similarity between the six tandem VWF C domains, with darker colour 
for higher degrees of similarity. The regions aligned are shown on the x- and y-axes. With thanks to 
Micha Ben Achim Kunze for generating the matrix.  
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recently revised modular architecture of VWF (Figure 1.4) shows that the Cx fragment 
corresponds to the extreme C-terminus of TIL’ and the majority of E’ (Figure 1.6). The 
newly assigned VWF E domains are part of the fibronectin I-like superfamily, formed of 
disulphide-rich, all- domains. This domain family includes the FNI module of 
fibronectin, -microseminoprotein and subdomain 1 of a VWC module. Strong 
structural similarity is highly indicative of an evolutionary relationship124, and this 
conservation may be due to maintenance of function101. The E repeat likely represents 
an evolutionary isoform of a VWC domain, as a result of alternative splicing125–127; 
consistent with this theory is the intron-exon splice junction present between the sixth 
and seventh conserved cysteine residues of VWF domain C1 (Figure 1.8 and Appendix 
5.1), which immediately succeeds the D4 assembly. It would then simply follow that 
the E domains evolved by truncation of the random coil subdomain 2 of VWF C1 
through alternative splicing, an event without structural ramifications. Whether this is 
to introduce functional diversity is not clear. That the E domains are repeated within 
the VWF architecture and are part of the VWD-C8-TIL-E supradomain in the first three 
D regions, and the remote D4 module precedes a VWC domain true, persuasively 
suggests that domain VWC1 is the forefather of VWF E domains. 
 
1.5.6 Model of VWF D region evolution 
Thus, the ancient gene structure that gave rise to the current VWF D region 
architecture can be rationalised based on Occam’s razor: the remote ancestral gene of 
the present D assemblies (VWD-C8-TIL-E supradomains) was first duplicated to first 
give rise to VWD4-C84-TIL4-C1 (D4-C1) and the tandem arrangement of D1-D2; during 
the evolution of which subdomain 2 of VWF C1 domain was truncated giving rise to 
VWD1-C81-TIL1-E1 (D1) and VWD2-C82-TIL2-E2 (D2). The next event involved the 
imperfect duplication of the C-terminus of D1 (TIL1-E1) and the entire D2 region 
(VWD2-C82-TIL2-E2) to give the D’D3 (TIL’E’-VWD3-C83-TIL3-E3) arrangement. A 
corresponding tandem arrangement of three D regions is present in basal metazoa86, 
and multiple expansions of the VWD-C8-TIL-E supradomain were already present in 
the ancestor of multicellular animals, therefore the VWF D regions did not duplicate 
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independently in VWF, but rather are the result of evolutionary descent. This is a 
unifying model that would account for the sequence composition of the D regions; 
such that region D4 is the most divergent in sequence, the TIL’E’ domains are most 
similar to the homologous segment in region D1, and that the E domain is a splicing 
isoform of VWF C1 domain (Figure 1.10).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: Proposed model of D region evolution in VWF. The VWF D regions evolved by gene 
segment duplication. The ancestral sequence duplicated yielding one sequence that gave rise to 
region D4 and VWF domain C1, the second sequence evolved to lose subdomain 2 of domain C1 and 
underwent further duplication. The next such event gave rise to the present tandem arrangement of 
region D1D2. The most recent duplication involved the C-terminus of region D1 and the entirety of 
D2, yielding D’ (TIL’E’) and D3. This model of VWF D region evolution, corresponds to the early model 
proposed by Shelton et al
49
 and was further refined and confirmed by phylogenetic analysis under 
maximum likelihood (Dr Romain Studer, unpublished observations).  
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1.6 Biosynthesis of VWF 
Native VWF is a disulphide-bonded homopolymer, and the multimeric composition of 
VWF is a critical determinant of its haemostatic potency128. Multimer assembly is 
preceded by the formation of dimeric protomers (500 kDa)129 linked near their C-
termini, which through N-terminal disulphide-bonding assemble into a logarithmic 
distribution of multimers129,130, reaching sizes in excess of 20,000 kDa131,132. 
Polymerisation is facilitated by thioldisulphide oxidoreductase-like sequences in the 
propeptide93. During synthesis, VWF is extensively glycosylated with N- and O-linked 
oligosaccharides, whose side chains contribute approximately 20% of the mass of 
VWF133 and are believed to affect its functional and structural integrity134,135.  
Early metal-shadowing experiments visualised the gross VWF domain arrangement; 
VWF constitutively secreted into plasma usually appear as loosely coiled prolate 
ellipsoids136, with a modal diameter of 100-150 nm137, whereas globular VWF 
undergoes extension under shear flow138 to form active filamentous polymers that 
reveal a dimeric periodicity of 120-140 nm139,140, reaching lengths over 1 m, and up to 
the diameter of a platelet137–139. The protomer has a two-fold symmetry about a 
central axis (radius of gyration 30 nm)136 and the site of dimerisation is a small C-
terminal central node (3.4  6.4 nm), connected by long, flexible 34.0  2.0 nm fibrillar 
rods, joined to large globular 26.0  6.5 nm ends (N-termini)136,139. The large globular 
regions comprise amino-terminal 2128 residues (up to the D4 assembly) and the rod 
region is formed of aa 2129-2813 (VWC domains and domain CK). The rod region 
contains no -helices and is predominantly composed of -sheet structure56. 
Cooperativity between the VWD-C8-TIL-E supradomains would support the gross 
domain arrangement of N-terminal VWF; a large globular formation consisting of 
smaller rounded structures (Figure 1.11). VWF is the largest known soluble vertebrate 
protein, and its unusual size poses difficulties in biosynthesis, storage and secretion140. 
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1.6.1 Dimerisation in the endoplasmic reticulum 
Following translation of VWF mRNA and translocation into the endoplasmic reticulum 
(ER), the signal peptide is cleaved. In the ER, proVWF undergoes N-linked glycosylation 
and dimerisation141. Twelve N-linked oligosaccharide units are added to the proVWF 
molecule at the consensus sequence Asn-x-Ser/Thr (Asn857, Asn1231, Asn1515, 
Asn1574, Asn2223, Asn2290, Asn2357, Asn2400, Asn2546, Asn2585, Asn2635 and 
Asn2790)38, and an additional rare sequon, Asn-x-Cys (Asn1147) is also glycoslylated142. 
Mapping of the VWF N-glycome shows its great complexity as a population of 300 
distinct structures. Complex-type N-glycan chains, predominantly bi-antennary, 
constitute the dominant structures135,142,143 (Figure 1.12).  
 
 
 
These are highly unusual with respect to other plasma glycoproteins as 13% contain 
blood group A, B and O(H) antigenic structures143 (2-macroglobulin also expresses 
ABO(H) antigens144). The greater number of N-glycosylation sites are located in the 
Figure 1.12: Primary structure of the major N-linked glycans on VWF. Man, mannose; GlcNAc, N-
acetylglucosamine; Gal, galactose; NeuAc, N-acetylneuraminic (sialic) acid; Gal(β1→4)GlcNAc, N-
acetyllactosamine. 
 
Figure 1.11: Macromolecular structure of VWF. Schematic of the VWF dimeric protomer based on 
early metal shadowing electron microscopy and small-angle neutron scattering experiments
136,139
. 
The CK domain is dimeric and is the central axis of two-fold symmetry.  
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vicinity of, or within, a functional site and it is therefore unsurprising that they affect 
VWF property and function. Blocking the addition of N-linked glycans with tunicamycin 
abolished VWF dimerisation and subsequent processing and secretion91, of which 
Asn99, Asn857 and Asn2790 were of critical importance145. Further, it has been shown 
that glycosylation at site N857 (VWD3 domain) may be essential to formation of the 
correct disulphide bond topology in region D’D3 of VWF145 (Figure 1.13).  
One of the most striking effects of N-linked glycosylation is the correlation between 
ABO blood group and plasma VWF levels. There are significant differences in VWF 
levels between ABO blood groups, with 25% lower VWF levels in blood group O than in 
non-O individuals (ABABO)146,147. VWF plasma levels are further reduced in persons 
with the Bombay phenotype, who lack expression of ABO(H) antigens148. The precise 
mechanism by which ABO(H) antigens affect plasma levels remains unclear, however, 
the overriding evidence suggests an effect on accelerated VWF clearance142,147. ABO(H) 
antigens also alter VWF susceptibility to proteolysis by ADAMTS13, a specific protease 
regulating VWF multimeric size, with a cleavage rate in the rank order OBAAB149. 
VWF sialylation also specifically enhances its susceptibility to ADAMTS13 
cleavage142,150. Despite the demonstrated importance of N-linked glycosylation to 
VWF, only two naturally occurring N-linked glycan site mutations are reported, and 
neither causes VWD by a direct effect on glycosylation. Mutant Asn1231Thr represents 
a gene conversion event from the partial psuedogene sequence on chromosome 22151 
and is not thought to be causative for VWD, whereas in mutant Asn2546Tyr there was 
found to be an absence of mRNA containing this mutation, suggesting that another 
mutation was present in cis which completely prevented expression145.  
 
 
Figure 1.13: The VWF glycome. The mature VWF protein is shown. N- and O-glycosylation sites are 
represented by closed red and open lollipops, respectively.  
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ProVWF subunits dimerise through disulphide bonds near their C-termini (‘tail to tail’ 
bonding) forming the dimeric protomer. The cysteines involved in dimerisation have 
been localised to the last 90 residues of VWF that comprise the cysteine knot (CK) 
domain (aa 2724-2811)152. The CK superfamily of proteins, including TGF- and platelet 
derived growth factor, are always found at the C-terminus of extracellular proteins, but 
differ in the position of the cysteine that dimerises two monomers153. CK domains 
include six cysteines arranged in a knot-like topology. Disulphide bonds between the 
second and fifth cysteine, and between the third and sixth cysteine, form a macrocyclic 
ring that is penetrated by a disulphide bond between the first and fourth cysteines152 
(Figure 1.14). Chemical assignment resolved eight of the eleven cysteines in VWF CK 
domain leaving three potential dimerisation candidates: Cys2771, Cys2773 and 
Cys2811152. However, symmetry considerations and electron microscopy imaging 
support a VWF dimerisation model that is analogous to TGF-, in which the long axes 
of the two monomers are anti-parallel, and thus dimerisation through the cysteine that 
aligns with the TGF- dimerisation cysteine50, that is VWF Cys2773. This is further 
supported by the phenotype of Cys2773Arg/Ser mutants that results in aberrant C-
terminal linked dimers, the consequence of which is a qualitative multimerisation 
defect, VWD type 2A (IID)154,155. Exit from the ER is regulated by both glycosylation and 
dimerisation23. 
 
 
 
 
 
Figure 1.14: CK domain knot-like topology. Schematic of a representative CK domain, showing the 
knot-like disulphide bond topology. Cysteine residues are designated C and disulphide bonds are 
shown by gold connecting bars. 
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1.6.2 Multimer assembly in the Golgi 
The intracellular assembly of VWF presents a challenge to the cell, as enormous 
multimers are formed and these may exceed the capacity for vesicular transport from 
the ER to the Golgi, whereas, there seems to be no obvious size limit for transport 
form the late-Golgi to the cell surface156. Compatible with these size limitations, VWF 
has evolved a unique two-stage mechanism of assembly whereby, dimerisation occurs 
in the ER and the multimerisation event is postponed until the Golgi compartments 
(Figure 1.15). However, the ER has chaperones and a redox potential suitable for 
disulphide bond formation. In contrast, the Golgi lacks known chaperones and is 
relatively acidic, which generally prevents disulphide rearrangement. Therefore, VWF 
requires a specific mechanism to promote multimer formation in the Golgi 
apparatus156.  
 
 
 
 
 
Figure 1.15: Steps in VWF biosynthesis and their subcellular localisation. Following translation, the 
signal peptide directs VWF to the ER where the signal peptide is cleaved and initial N-linked 
glycosylation occurs and C-terminal dimers are formed. The molecule passes to the Golgi where 
there is the addition of O-linked glycans and sulphation of N-terminal N-linked glycans. In the trans-
Golgi network there is the addition of ABO(H) blood group sugars to N-linked glycans and VWF 
multimerisation by N-terminal disulphide bonding. The propeptide is cleaved and the molecule is 
either constitutively secreted or stored in Weibel-Palade bodies.  
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In the trans-Golgi network, further processing of correctly assembled proVWF 
protomers takes place, including proteolytic removal of the propeptide, tyrosine 
sulphation of certain N-linked glycans142,157 and the addition of ten O-linked 
oligosaccharides to serine or threonine residues (Figure 1.16). Two O-linked 
glycosylation sites are localised N-terminal to domain A3 and within VWC1 (Thr1679 
and Thr2298, respectively) while the remaining eight (Thr1248, Thr1255, Thr1256, 
Thr1263, Thr1468, Thr1477, Ser1486, Ser1487) are clustered in groups of four at either 
side of the A1 domain38,158 (Figure 1.13). 1% of the VWF O-glycome has recently been 
shown to harbour ABO(H) antigens and these glycans may also participate in 
determining plasma VWF levels and susceptibility to ADAMTS13 cleavage158.  
 
 
 
In the same compartments, multimerisation of proVWF occurs with the formation of 
additional ‘head to head’ disulphide bonds through cysteine residues in the D’D3 
region (N-terminal), yielding incredibly large polymers23. The VWF propeptide (D1D2 
region) is cleaved by the enzyme furin, at the P4Arg-P3x-P2Lys/Arg-P1Arg motif (where  
identifies the cleavage site)159, comprising substrate recognition residues 760 (P4) 
through 763 (P1), to generate mature VWF. The propeptide is essential to the correct 
assembly of VWF multimers. Following cleavage, the propeptide remains non-
covalently associated with VWF in an interaction promoted by the high calcium 
concentration and acidic pH of the trans-Golgi23. VWF multimerisation in the Golgi 
involves a unique oxidoreductase mechanism that relies on the propeptide to function 
as an endogenous chaperone that promotes disulphide bond formation specifically 
under acidic conditions91. Deletion of the VWF propeptide prevents multimerisation, 
and interestingly, the propeptide does not need to be a contiguous part of the primary 
structure, as isolated propeptide is able to act in trans to direct the assembly of 
disulphide-linked multimers160. Further, VWF propeptide cleavage is not necessary for 
multimerisation, as evidenced by the Arg763Gly mutation, that completely abolishes 
Figure 1.16: Primary structure of the major O-linked glycan. Gal, galactose; NeuAc, N-
acetylneuraminic (sialic) acid; GalNAc, N-acetylgalactosamine.  
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proteolytic cleavage but does not significantly affect the multimeric assembly of VWF, 
in which the multimers are composed of proVWF subunits161,162.  
The Golgi is a hostile environment for disulphide bond formation, as the low pH 
inhibits deprotonation of the cysteine thiol groups. Protein disulphide formation 
proceeds predominantly in the lumen of the ER and this is the site of polymerisation of 
most oligomeric proteins93,163. Nevertheless, VWF multimerisation is optimal at pH 5.8 
and in fact, an acidic trans-Golgi environment (pH 6.2) may be necessary because 
raising the pH with ammonium chloride or chloroquine inhibits multimerisation40,91,164. 
The decrease in pH between the ER and Golgi would facilitate the reversible 
protonation of a pH-sensing His residue. Histidine has a pKa of 6.0, a value suitable for 
detecting the difference in pH between the ER (pH 7.4) and trans-Golgi (pH 6.2)165, and 
is likely to perform this function during the assembly of VWF multimers. Several 
proteins employ His residues as pH sensors to regulate their function upon transport 
to the Golgi. His69 in the autoinhibitory propeptide of furin becomes protonated in the 
trans-Golgi, after which the propeptide dissociates and furin can cleave proVWF. There 
are at least two evolutionary conserved His residues in domain VWD2 (His395 and 
His460) that are critical for pH-dependant multimer assembly in the Golgi, as 
demonstrated by the profound defect in intersubunit disulphide bond formation upon 
mutation to alanine40. This is consistent with the observation that the VWF propeptide 
forms non-covalent homodimers, which bind tightly to multimeric VWF at pH 6.4 but 
dissociate at neutral pH. This would facilitate the juxtaposition of two VWF D3 regions, 
and in this manner correctly orientate dimeric VWF for multimerisation upon arrival at 
the Golgi166. 
Intriguingly, to overcome the impediment of an acidic environment, VWF employs its 
own propeptide as an oxidoreductase131. The VWD1 and VWD2 domains contain CxxC 
sequences, Cys159-Gly-Leu-Cys162 and Cys521-Gly-Leu-Cys524, which is the signature 
motif of the functional sites of the thiol:disulphide oxidoreductase family. This 
conserved motif is characterised by a pair of vicinal cysteine residues that shuffle 
between the disulphide and dithiol form163. When spacing of this sequence is altered 
by insertion of a glycine residue, into either VWD1 or VWD2, thus changing it to CxGxC, 
dimers were secreted without multimer assembly, therefore the propeptide catalyses 
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multimerisation by its intrinsic pH-dependant disulphide isomerase activity93. The role 
of the CGLC motif in domain VWD3, at the N-terminus of the mature protein, is 
unknown. Mutation of the corresponding VWD3 motif in mucins permits multimer 
formation in the presence of monensin, suggesting that an intact VWD3 CGLC motif 
acts to prevent multimerisation in the non-acidic ER, cis- and medial-Golgi 
compartments89, the mechanism by which this may be accomplished is not clear.  
The thiol:disulphide oxidoreductase model for VWF propeptide function predicts that 
rearrangements would proceed through a covalent disulphide-linked intermediate 
between a catalytic Cys residue on the oxidoreductase and a Cys residue to be 
modified on the substrate. Indeed, it has been shown that the propeptide and the D3 
region of VWF subunit form an intra-chain disulphide-bonded intermediate in the ER 
that rearranges in the Golgi to yield VWF multimers, linked by inter-dimer disulphide 
bonds92 (Figure 1.17). The D’D3 region of VWF was sufficient to form this intermediate 
with the propeptide, thereby confining the mechanistically important thiols 
participating in multimerisation to the N-terminus. These cysteine residues have been 
localised to Cys1099 and Cys1142 in domains C83 and TIL3, respectively43.  
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1.6.3 Storage and secretion 
VWF is partitioned between two pathways in the Golgi of endothelial cells. The 
majority, up to 95%, is secreted constitutively towards both the lumen (apical 
secretion) and the subendothelial matrix (basolateral secretion)167. The remainder is 
directed to storage by the propeptide, for later inducible release, into Weibel-Palade 
bodies (WPBs). VWF multimers released through the constitutive pathway are smaller, 
and hence, less thrombogenic than those stored in WPBs, which are unique to vascular 
endothelial cells and enriched in ultra large VWF (ULVWF) forms. VWF produced by 
megakaryocytes is stored in -granules that are later partitioned into platelets. VWF 
Figure 1.17: Biosynthesis of VWF. The VWF propeptide (D1D2 region) is shown in red and the 
mature protein is shown in grey. VWF is synthesised in the ER as a 2813 aa prepro-protein. In the ER 
VWF forms tail-to-tail dimers between C-terminal cysteine knot (CK) domains. Disulphide bonds are 
represented by black lines. Later in the ER, a transient disulphide-linked intermediate is predicted to 
form between the propeptide and the D3 region of VWF, the mechanism of which is represented by 
balls. In the Golgi the disulphide-linked intermediate rearranges to yield head-to-head linked 
multimers. Disulphide bonds form between the D3 regions. In the trans-Golgi furin cleaves the 
propeptide. 
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circulates in plasma at a concentration of 10 g/mL, has a half-life of approximately 
twelve hours and is cleared from the circulation by hepatic and splenic 
macrophages168. 
VWF undergoes extraordinary structural changes during its synthesis and storage and 
one of the enduring mysteries of VWF biology is how incredibly large multimers are 
condensed and packaged into the cigar-shaped WPBs. The details by which VWF 
achieves this remarkable feat are beginning to emerge. VWF multimers are stored as 
paracrystalline helical tubules with a precise parallel alignment169 that extends the 
entire length of the WPB, 1-5 m30. In contrast to DNA, with two molecules per helix, 
the VWF helices are one start, that is, there is one VWF multimeric molecule per 
helix166, hence a single helical VWF multimer may extend up to 5 m. The tubules 
consist of a right-handed helix with 4.2 repeating units (dimers) per turn and a pitch of 
12 nm166,169. Indicating that every 1 m of VWF tubule length, might correspond to a 
disulphide-linked multimer of 700 subunits (350 dimers), having a mass of 175 million 
Da and an extended length of 49 m (average extension per monomer of 70 nm140).  
The organisation of VWF multimers into helical tubules nucleates in the trans-Golgi 
and relies solely on the propeptide and the D’D3 region, requiring Ca2+ and a low pH as 
found in the trans-Golgi and WPB environments. The D1D2 propeptide and the D’D3 
regions form the core of the helix, with the remainder of the VWF subunits (domains 
A1 to CK) extend from the helix core and may interdigitate to account for the regular 
spacing seen between VWF tubules in a WPB166,169,170. The A2 to CK domains of each 
subunit of a dimer assemble into a stem-like extended conformation (termed the 
dimeric bouquet) at acidic pH representative of the trans-Golgi (pH 6.2) and WPB 
environments (pH 5.45)140,171. In each dimer pair, these C-terminal domains are 
brought into very close association, and in conjunction with the propeptide-VWF dimer 
association, they ensure co-linear multimerisation of VWF protomers and are thus, 
crucial for the arrangement of VWF into tubules. This arrangement facilitates 
disulphide bond formation between the D3 region of VWF dimers in neighbouring 
positions in the assembling helical tubule, rather than within VWF dimers, between 
monomers on different tubules or in non-neighbouring positions in the same tubule. 
Covalent addition of a new VWF dimer to the end of the growing helix, catalysed by 
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the propeptide, provides a strategy for packaging the long VWF multimers without 
entanglement169. This mechanism, unbelievably, enables a 50-fold compaction in the 
length of tubules compared with extended secreted VWF166, and compaction is likely 
to be assisted by the reduction in pH in mature WPBs, which approaches the isoelectric 
point of VWF171. Furthermore, compaction is particularly extreme at the C-terminal, 51 
nm long, dimeric bouquet region of VWF that extends out from the core of the 
helix140,172, as the 25 nm diameter tubules pack with a centre-to-centre spacing of 28.4 
nm169. Tubule formation enables orderly unravelling of VWF from the ends of helices 
when secreted into plasma140.  
At the trans-Golgi level, disorganised tubules are packed into vesicles that bud off, 
leading to the formation of immature WPBs. Those containing lower molecular weight 
VWF tubules are destined for constitutive release173. During maturation, WPBs 
undergo homotypic fusion thereby increasing their VWF tubule content and 
subsequently a dense paracrystalline core is formed by the alignment and 
condensation of VWF tubules. An event characterised by a reduction in the WPB 
diameter from 222 nm to 151 nm169,170,173. Once they have entered the regulated 
secretory pathway, mature WPBs lie dormant in the endothelial cell awaiting a signal 
to undergo exocytosis and release VWF into circulation. A myriad secretagogues can 
induce the release of VWF from WPBs and these are divided into two groups: Ca2+-
raising agonists and cyclic AMP (cAMP) raising agonists174. 1-deamino-8-D-arginine 
vasopressin (DDAVP), a pharmaceutical analogue of vasopressin (antidiuretic 
hormone), binds to endothelial V2 receptors leading to production of cAMP and 
activation of protein kinase A, consequently stimulating WPB exocytosis175. This results 
in a transient increase in VWF and FVIII plasma levels and has led to the widespread 
use of DDAVP in the treatment of patients with VWD and mild haemophilia A175. 
The first step in secretion is the formation of a narrow constriction between the 
endothelial cell plasma membrane and the WPB. This results in WPB swelling, as a 
consequence of the rise in pH, where alkalinisation rapidly propagates from one end of 
the WPB to the other, and partial hydration of the granule core171. The WPB 
morphology change is associated with loss of alignment in the VWF paracrystal169. 
Secretion proceeds with the rapid unfurling of VWF helices172 into long strings at the 
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luminal endothelial cell surface. Plasma VWF is disorganised and globular in solution 
and when extended in high shear flow can have lengths of up to 4 m139. In dramatic 
comparison, following secretion from endothelial cells, ULVWF strings often reach 
extraordinary lengths of 100-1000 m and they remain anchored to the surface of the 
endothelial cell176,177. As each monomer in an extended configuration spans 70 
nm140,172, an unravelled 5 m VWF helical tubule would be expected to measure 245 
m. Thus, the exceptionally long VWF strings, observed at lengths of up to 1 mm, are 
thought to arise following WPB secretion through end-to-end self-association, as well 
as lateral staggered association that stacks the multimers into thick fibrillar structures 
in shear flow. The mechanism appears to involve cysteine thiol:disulphide exchange of 
unpaired thiols in mature VWF44–46, of which the VWC3 Cys2431-Cys2453 bond is 
believed to be involved178 and the process modulated by ADAMTS13179.  
 
1.6.4 Remodelling VWF multimer distribution 
Whereas globular plasma VWF is functionally quiescent in the absence of shear, due to 
shielding of binding sites, ULVWF released by the inducible pathway at sites of vascular 
injury is highly thrombogenic and hyperactive in its capacity to bind platelets and 
subendothelial matrix128. This difference relates to both the multivalent nature of VWF 
binding, with multiplicity of available collagen and platelet binding sites, and the 
propensity of ULVWF to adopt an elongated, active conformation in the normal 
circulating shear forces of flowing blood; as the forces acting on proteins in shear flow 
scale with protein size and length180–182. Consequently, their release may result in 
spontaneous platelet adhesion, aggregation and systemic thrombosis181. This is the 
pathophysiology underlying the catastrophic arterial thrombotic disorder, thrombotic 
thrombocytopenic purpura (TTP)183, that is characterised by extensive microvascular 
occlusion with thrombi composed almost entirely of VWF and platelets. The clinical 
consequence of which, is microangiopathic haemolytic anaemia and 
thrombocytopenia leading to renal failure, neurologic dysfunction and fever as signs of 
end organ damage. Without treatment, TTP undertakes a rapid course of deterioration 
and death, in most cases184,185. TTP is caused by severe deficiency in ADAMTS13, which 
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is responsible for the processing of ULVWF to less reactive plasma forms186 and is the 
only known mechanism that governs VWF multimer size. Hereditary TTP is caused by 
homozygous or compound heterozygous mutations in the ADAMTS13 gene186, 
although ADAMTS13 deficiency more commonly arises through acquired TTP involving 
the formation of inhibitory anti-ADAMTS13 autoantibodies184.  
To prevent this disastrous consequence, ULVWF is subject to rapid but limited 
proteolysis by ADAMTS13 through cleavage at the Tyr1605-Met1606 peptide bond in 
the A2 domain72. Within two hours, following WPB exocytosis from endothelial cells, 
ULVWF is remodelled into smaller, haemostatically active, but no longer 
prothrombotic forms, of variable size that are characteristic of the circulating pool of 
globular VWF187 (Figure 1.18). ADAMTS13 is constitutively active in plasma, unusually 
therefore, VWF proteolysis is regulated by conformational change188,189. The 
ADAMTS13 cleavage site is normally hidden within the core of the folded A2 domain, 
and when plasma VWF is circulating in its inactive globular conformation it is resistant 
to proteolysis190. However, shear-induced unfolding and elongation not only exposes 
the scissile bond but also cryptic exosites for ADAMTS1371,182. ULVWF freshly released 
from endothelial cells spontaneously adopts an elongated configuration enabling 
ADAMTS13 to both access and cleave the exposed A2 domains180,182. Thrombospondin-
1 (TSP-1) also appears to regulate cleavage of VWF strings by ADAMTS13. The 
inhibitory effect of TSP-1 may be explained by competition between TSP-1 and 
ADAMTS13 for the same binding sites in VWF A2 and A3 domains191.  
Conversely, excess ADAMTS13 mediated proteolysis would severely impair the 
haemostatic function of aberrantly short VWF multimers, leading to bleeding, as found 
in patients with type 2A (IIA) VWD192 who harbour mutations that destabilise the A2 
domain - resulting in enhanced cleavage193.  
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1.7 VWF in haemostasis and structure-function relationships 
The three significant interactions of VWF in haemostasis are with collagens, platelets 
and procoagulant FVIII, to which the multidomain, multimeric configuration of VWF is 
fundamental. Much of the function of VWF has been revealed, however detailed 
insight into the molecular structure that enables VWF to orchestrate haemostatic 
processes, in particular FVIII stabilisation in plasma, is lacking. In addition, high 
resolution structure determinations of the topologically complex disulphide-bonded 
VWF domains have not been possible, with the exception of the cassette of A domains 
containing only a pair of cysteines each, for which there are X-ray crystal 
structures62,63,190,194–197.  
 
1.7.1 Shear and VWF activation 
A remarkable feature of VWF is that it is the key shear-sensing protein in haemostasis, 
and is especially important in arterial bleeding where shear is high23. ULVWF and 
plasma VWF adopt different conformations that make the former constitutively active 
and the latter inactive, but can be activated by shear induced elongation138. Once 
Figure 1.18: ADAMTS13 remodelling of VWF multimers. VWF multimers are assembled in the trans-
Golgi as an initial distribution (Initial) and secreted into the blood constitutively or from WPBs. This 
multimer distribution is modified by rate of ADAMTS13 proteolysis and clearance by hepatic and 
splenic macrophages (). The distribution of plasma VWF reflects the sum of these effects.  
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released into circulation, the overall shape of VWF is dynamic and dependent on the 
type of flow encountered (Figure 1.19). 
 
 
 
 
As blood flows through a vessel, velocity is maximal in the centre and falls to zero at 
the wall. Conversely, the gradient of velocity, or shear rate,  (expressed in units of 
cm/s per cm or s-1), is maximal at the vessel wall and zero at the centre. Part of the 
effect of shear is to increase the transport of platelets to the vessel wall, but more 
importantly to increase the reactivity of VWF by increasing the number of accessible 
binding sites23. The circulatory system is exposed to an amazingly wide span of shear 
rates (Table 1.1).  
 
                          Table 1.1: Shear rates within the human vasculature
198
. 
Vessel Diameter (mm) Shear Rate  (s
-1
) 
Ascending aorta 23.0-45.0 50-300 
Femoral artery 5.0 300 
Common carotid 5.9 250 
Internal carotid 6.1 220 
Left main coronary 4.0 460 
Right coronary 3.4 440 
Small arteries 0.3 1500 
Arterioles 0.03 1900 
Large veins 5.0-10.0 200 
Inferior vena cava 20.0 40-60 
Figure 1.19: Events associated with shear-induced conformational changes in VWF. VWF circulates 
in a globular conformation in which the platelet GPIb binding site in the A1 domain and ADAMTS13 
cleavage sites are inaccessible. Both parameters protect VWF from premature platelet interactions 
and ADAMTS13-mediated degradation. Exposure to high shear flow unfolds the protein, allowing 
platelet binding and ADAMTS13 cleavage.  
46 
 
The hydrodynamic drag that opposes platelet adhesion and aggregation on the luminal 
surface exposed to rapidly flowing blood, increases with shear rate. Consequently, its 
effects on VWF and thrombus formation are more relevant in arteries, where platelet 
adhesion is dependent on VWF, than in veins2,35. Above a critical shear rate of 1000 s-
1, VWF in free flow is overcome by hydrodynamic drag and the molecules elongate, 
becoming functionally multivalent172,199–201. In vivo, shear rates in this range occur in 
small arterioles of 10-50 m diameter, where the shear rates are estimated to vary 
between 470 s-1 and 4,700 s-1 (median, 1,900 s-1). Above atherosclerotic plaques, in 
partially occluded arteries, shear rates of up to 11,000 s-1 have been recorded23,202. 
VWF acts as a molecular bridge, and is central to the initiation of platelet adhesion and 
sustaining platelet aggregation under conditions of elevated shear2. Thus, the two-fold 
consequence of elevated shear, causing a near vessel wall platelet excess and 
activating VWF are of utmost strategic importance to VWF in haemostasis (Figure 
1.20). Conversely, that same capacity to promote platelet adhesion in high shear rates, 
conditions found in stenosed arteries, also makes VWF a crucial component of 
atherothrombosis in cardiovascular disease and ischaemic stroke203–206.  
 
     
                
 
 
 
 
 
Figure 1.20: Blood flow in a vessel. Normal endothelial cells are nonreactive for platelets, but 
exposed subendothelial structures such as collagen, induce rapid platelet adhesion and aggregation. 
Blood flow is laminar, with each layer moving at a different velocity. The laminae near the centre of 
the vessel have greater velocity than those near the wall (depicted by arrows). The shear rate is the 
rate of change of velocity with respect to distance measured perpendicularly to the direction of 
flow. The negative sign indicates that the gradient is defined from the centre (where velocity is 
maximal) to the wall (where velocity is minimal). Because of these rheological properties, 
erythrocytes occupy the greatest part of the lumen, pushing leucocytes and platelets to the sides 
creating a near-wall platelet excess
2
.  
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1.7.2 VWF A1 and A3 domains – collagen binding 
The subendothelial matrix, of which fibrillar collagens are a major component, is 
exposed when the continuity of the vascular tree is interrupted by traumatic injury to 
tissues. In the wounded vessel, VWF rapidly binds to collagens type I and III in the 
deeper layers of the vessel (tunica media and tunica adventitia), as well as 
microfibrillar collagen type VI in the subendothelium2. This is substantially contributed 
to by subendothelial VWF, as a pool distinct from plasma VWF207,208. The transition 
from soluble plasma VWF to immobilised VWF marks the initiating event in 
thrombogenesis. The VWF A1 domain preferentially interacts with collagen type VI, 
whereas VWF binds to collagens type I and III through the A3 domain. The A1 domain 
also contains the binding site for platelet GPIb of the GPIb-IX-V complex. The latter, 
A3 mediated collagen interaction is apparently both necessary and sufficient to 
support VWF binding to collagens57,209,210. It is of note however, that the extensive 
investigation of the interaction between VWF A1 and A3 domains and fibrillar 
collagens has been primarily undertaken in static conditions using recombinant soluble 
VWF with deleted A3, which demonstrates antithrombotic activity. In contrast stands 
the in vivo evidence that mutations in domain A3 (Ser1731Thr, Ile1741The, Gln1743H, 
Trp1745Cys, Gln1762Arg, Ser1783Ala, His1786Asp) inhibiting collagen binding (type 
2M VWD; classified by decreased VWF-dependant platelet adhesion) are still capable 
of sustaining haemostasis211–214. Therefore, fluid dynamic conditions and mechanical 
forces may modulate these interactions, with a complex interplay between domains 
A1 and A3 in effecting immobilisation of VWF, which is contingent on the nature of the 
lesion2. Such that binding of domain A1 to collagen type VI may be particularly relevant 
in A3 defective mutants, and may account for the lack of severe bleeding in these 
patients214.  
VWF is also able to interact with the subendothelial matrix independently of collagen. 
The A1 domain contains a heparin-binding site, Tyr1328-Ala1350 that may reflect the 
ability of VWF to interact with matrix proteoglycans that contain sulphated 
carbohydrates2,215. In addition, VWF binds to sulphated glycosphingolipids 
(sulphatides) that are present on various cellular membranes and are likely to serve an 
accessory role in promoting localisation on wounded tissue78. Sulphatides are 
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constituents of erythrocytes, but are not normally exposed; however, in sickle cell 
anaemia reversible sickling and oxidant damage to the membrane could expose these 
molecules to the surface. The subsequent interaction between VWF and exposed 
sulphatide may cause periodic vaso-occlusion in the affected patient, the severest 
manifestation of sickle cell anaemia2,182.  
As the principal activator of thrombosis, a mechanistic understanding of the VWF-
collagen interaction is vital. The structure of the A3 domain has been determined by X-
ray crystallography195,196. The VWF A domains are the prototype for the von Willebrand 
factor type A domain (VWA) superfamily, that are found in many proteins including 
collagens, complement proteins and integrins66. The A3 domain adopts the 
dinucleotide-binding fold, consisting of a central hydrophobic parallel -sheet 
containing six strands that is enclaved by seven -helices. A single disulphide bridge 
between residues Cys1688 and Cys1872 connects the N- and C-terminal regions and 
denotes the domain boundaries. The VWA domains contain a metal ion dependant 
adhesion site (MIDAS) motif at the top of the -sheet that is critical for its adhesive 
function, however, the VWF A3 domain is notable for its absence of the MIDAS motif, 
indicating that metal ions are not required for collagen binding195,196.  
The collagen binding site was localised by transferred cross-saturation, a nuclear 
magnetic resonance (NMR) method enabling rigorous identification of contact residues 
in a protein complex67 and it was subsequently structurally characterised by 
crystallisation of the VWF A3-collagen complex197. Collagen is formed of three tightly 
interwoven polypeptide chains (-chains) in a right-handed triple helix with a one 
residue stagger. These -chains have the repeating sequence G-x-x’, where x is 
frequently proline (P) and x’ is frequently 4-hydroxyproline (O). The VWF binding site 
on collagen III is located on residues 572-580 with the sequence: RGQOGVMGF216. In 
collagen III, these residues form a unique VWF interaction surface to which all three -
chains contribute. The A3 domain binds collagen at its front face, across strand 3 and 
helices 2 and 3; the binding site can be divided into three regions (Figure 1.21). First, 
a small hydrophobic patch on A3 interacts with the N-terminus of the collagen III 
recognition sequence. Second, interacting with the central portion of the collagen 
sequence is an A3 acidic region. Third, the hydrophobic C-terminus of the collagen 
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recognition sequence interacts with a large hydrophobic patch on A3 including a 
shallow hydrophobic pocket that binds collagen sequence Phe (F-pocket). Comparison 
of free and collagen-bound VWF A3 domains shows that collagen binding occurs 
through the conformational selection model of ligand binding. In this model, the 34 
loop of domain A3 adopts a conformation that facilitates formation of the hydrophobic 
F-pocket, which is stabilised by a network of hydrogen bonds between His1786, 
Ser1783 and the Met residue (M) in the collagen binding sequence. This hydrogen-
bonding network is crucial to collagen binding as evidenced by the type 2M VWD 
mutant Ser1783Ala that completely abolishes VWF binding to collagen212.  
 
 
 
 
 
Platelets have no measurable interaction with soluble VWF and the obligatory 
perquisite to platelet adhesion is VWF immobilisation onto collagen. Inhibition of VWF 
binding to collagens by targeting the nonapeptide collagen sequence may be a useful 
therapeutic strategy. In vivo studies have demonstrated that targeting VWF-collagen 
binding can prevent platelet thrombosis on an otherwise highly thrombogenic injured 
artery. This antithrombotic approach may provide a valuable alternative to the 
antiplatelet therapies in current clinical practice217,218. 
 
Figure 1.21: Structure of the VWF A3-collagen peptide complex. The left panel shows the VWF A3 
domain in red by ribbon representation, with the 2, 3, 3 secondary structure elements labelled. 
The 3 to 4 loop is indicated. The triple helical collagen peptide in complex with A3 is shown in 
grey (pdb: 4DMU)
197
. The one residue stagger in collagen results in a leading, middle and trailing 
chain. The core VWF binding sequence on collagen is shown and it is flanked by glycine-proline-
hydroxyproline (GPO) repeats. The right panel shows the surface representation of VWF A3 domain 
in white and the residues interacting with collagen are highlighted in grey. The residues are denoted 
by single-letter amino acid codes.  
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1.7.3 VWF A1 domain - platelet GPIb tethering 
In a blood vessel with normal cell counts, erythrocytes represent the greatest cellular 
mass, and as a consequence of their erratic motion and lateral migration, they occupy 
the greatest part of the lumen. This pushes leucocytes and platelets to the vessel sides, 
creating a near-wall platelet excess, where platelets are flawlessly placed to facilitate 
adhesive interaction with immobilised VWF (Figure 1.20). The clinical observation that 
bleeding, particularly spontaneous, is usually not of consequence until the platelet 
count drops below 10,000/L, is explained by the near-wall platelet excess. While 
formation of the large platelet aggregates required to seal post-traumatic wounds in 
vessels may be affected by even a relatively small reduction in platelet number, the 
platelet monolayer that maintains vascular permeability (and thus, prevents 
spontaneous haemorrhage) is largely undepleted until the platelet count drops 
significantly (1% of normal). Furthermore, since the near-wall platelet excess is 
consequent to the presence of erythrocyte mass, it is then clear why anaemia may 
predispose to excessive bleeding2. 
Above a threshold shear rate of 500-800 s-1, only the interaction between immobilised 
VWF domain A1 and platelet GPIb has a sufficiently fast on-rate to initiate platelet 
adhesion2,219, as the intrinsic association rate of the platelet receptor with its ligand 
must be faster than the relative velocity at which the molecules move relative to each 
other. Remarkably, VWF will be most extended in just those environments where its 
haemostatic functions are needed most. Shear rate is greatest at the vessel wall, and 
when immobilised onto collagen, VWF cannot tumble and thus, the hydrodynamic 
forces acting on vessel-bound VWF are greater than on plasma VWF, and these forces 
are purely elongational172,220. This phenomenon serves to induce a conformational 
change in VWF that exposes A1 domain sequences for initial interaction with platelet 
GPIb receptors221,222. An additional level of regulation utilises the N-terminus flanking 
region of the A1 domain to stabilise the quaternary association of the A1-A2-A3 
domains, which in turn regulates VWF A1-GPIb binding223,224. Circulating VWF 
propeptide has also been implicated in the partial regulation of VWF A1-platelet GPIb 
complex formation225. 
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Platelets bind specifically to immobilised VWF in a two-stage process that involves 
sequentially, GPIb and integrin IIb3. Initial tethering is mediated by GPIb-VWF A1 
domain bonds that form extremely rapidly but have a limited lifetime and hence, 
cannot support stable adhesion219. Rather, these bonds support a slow rolling 
movement along the adhesive VWF surface in the direction of blood flow, and platelet 
translocation is associated with platelet activation. Interestingly, the bond between 
GPIb and VWF has two states; distinct, flexed low affinity and extended, high affinity 
states226. Increasing shear exponentiates the GPIb-VWF bond lifetime causing platelet 
rolling velocity to decrease and facilitates platelet activation and subsequent integrin 
mediated attachment219,226,227. The mechanochemical force-resistant properties of the 
GPIb-VWF bond226 requires high shear rates to achieve functionally efficient lifetimes, 
and as such, a property that may prevent VWF A1 domains from agglutinating platelets 
in the circulation227. The inherently stickier ULVWF released by stimulated endothelial 
cells may enhance the efficiency of the process, as these molecules spontaneously 
form high strength bonds with GPIb181.  
The unusual variant, type 2B VWD, is due to gain-of-function mutations in the VWF A1 
domain that lead to constitutive VWF A1-GPIb complex formation, and can explain 
the ability of type 2B VWF to agglutinate platelets in circulating blood2. Type 2B 
mutations in the VWF A1 domain, eliminate the shear threshold requirement for 
platelet rolling, and result in an enhanced A1-GPIb association rate with relatively 
long bond lifetimes, even when exposed to low shear rates172,227,228. This is consistent 
with the significantly slower rolling, with near zero velocity of platelets interacting with 
immobilised type 2B VWF A1 domains2,228. Paradoxically, the enhanced GPIb-VWF A1 
bonding in these patients is associated with excessive bleeding. This is due to depletion 
of the large, haemostatically most active VWF multimers from plasma, relapsing 
thrombocytopenia due to platelet consumption, and the occupancy of GPIb receptors 
that interferes with the tethering of platelets to VWF at the site of vascular injury229. 
This phenotype is additionally contributed to by excessive ADAMTS13-mediated 
proteolysis229,230. Conversely, the Bernard-Soulier syndrome and type 2M VWD result 
in defective VWF A1-GPIb binding secondary to loss-of-function mutations in the 
GPIb-IX-V complex and VWF A1, respectively231.  
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Crystal structures of GPIb-VWF A1 complex62,63 have provided important insight into 
the molecular details of their interaction. Crystallisation of the complex, in one 
instance, required use of gain-of-function mutations; type 2B mutant Arg1306Gln in A1 
and platelet-type VWD mutant Met239Val in GPIb62. As expected the overall VWF A1 
domain structure is very similar to the A3 domain with a disulphide bridge linking the 
N- and C-proximal sequences (Cys1272-Cys1458). GPIb is the central component of 
the unique GPIb-IX-V receptor complex consisting of transmembrane glycoproteins 
Ib, I, IX and V, each of which, is a member of the leucine-rich repeat protein 
superfamily. GPIb anchors the complex to the platelet cytoskeleton and harbours the 
VWF binding site in its 282 N-terminal residues. The VWF binding site on GPIb is 
formed of the N-terminal eight tandem leucine-rich repeats that are exposed well 
above the platelet surface by a connecting 45 nm long highly O-glycosylated stalk, 
which is anchored to the transmembrane domain, and followed by the cytoplasmic 
tail232.  
Crystallographic studies reveal that the leucine-rich repeats wrap around one side of 
the VWF A1 domain, but only the N-terminal -finger region and the C-terminal -
switch region make contact with A162,63 (Figure 1.22). 
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In unliganded A1 domain however, the lower region of GPIb contact is shielded by 
the N- and C-terminal arms of A1, creating an interface that is stabilised by salt-bridges 
and hydrophobic contacts, thereby making the -finger binding site on A1 inaccessible 
to platelets in plasma194. Type 2B VWD mutations are clustered at the lower face of 
domain A1, in a single disulphide loop between residues Cys1272 and Cys1458, 
encompassing the GPIb -finger interaction site, and map to buried positions in 
domain A1 62,63,194 (Figure 1.22). These mutations are likely to destabilise the interface 
created by the folded conformation of the A1 N- and C-terminal arms, which protects 
the -finger interaction site. In the crystal structure of the complex, indeed a 
displacement of the A1 N- and C-termini away from the interaction site was 
observed62. Furthermore, the 1-to-1 loop acts as a conformational switch, that in 
unliganded A1 adopts a conformation that creates a steric clash with GPIb and would 
therefore, be incompatible with platelet binding. In wild-type A1 complexed with 
Figure 1.22: Structure of the complex between VWF A1 domain and platelet GPIb A ribbon 
representation of the complex is shown (pdb:1M10). VWF A1 domain is coloured red and the N-
terminal VWF binding region of GPIb is coloured grey. This region is formed, centrally, of eight 
short leucine-rich repeats. The N-terminus of GPIb is formed of a -hairpin, termed the -finger. 
The C-terminus of GPIb contains a disordered loop termed -switch. The positions of type 2B VWD 
mutations are shown as carbon- spheres in black.  
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GPIb the 1-to-1 loop is more open and shifted away from GPIb allowing faster 
dissociation, whereas the loop adopts a more closed and extended conformation that 
is shifted towards GPIb in type 2B mutants, which would stabilise a tighter 
association with GPIb63 (Figure 1.23). These conformational transitions illustrate the 
manner in which the GPIb-A1 interaction may be modulated by remote type 2B 
amino acid substitutions, through allosteric changes at the binding face and 
conformational rearrangements induced by shear, to facilitate VWF-platelet 
tethering63.  
 
 
 
 
 
 
 
 
Figure 1.23: A1 1-to-2 loop: a conformational switch in GPIb binding. Superposition of 
unliganded A1 (pdb: 1AUQ)
194
, wild-type A1-GPIb complex (pdb: 1SQ0)
63
 and mutant Arg1306Gln 
A1-Met239Val GPIb complex (pdb: 1M10)
62
. Unliganded A1 (black) adopts an intermediate 
conformation, between the closed conformation in the mutant complex (red) and the open 1 to 2 
loop conformation in the wild-type complex (blue).  
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1.7.4 VWC4 domain – platelet integrin IIb3 aggregation  
Following the initial platelet tethering, intracellular signalling through the GPIb-IX-V 
complex induces pulses of increased cytoplasmic Ca2+ concentration, indicating 
platelet activation2. Plasma VWF is then able to bind to the surface of adherent and 
activated platelets. Activated platelet integrin IIb3 receptors irreversibly bind to the 
RGD sequence of VWC4 domains leading to stabilisation of the initial GPIb-VWF A1 
bond and definitive platelet arrest. This new layer of VWF forms the substrate onto 
which more flowing platelets attach through their GPIb receptors. Accrual of 
additional platelets in successive layers is secured by the binding and activation of 
newly recruited platelets. A process that continues until the thrombus mass grows 
sufficiently to stem bleeding (haemostasis) or in pathological conditions, until the 
vascular lumen is occluded (thrombosis)233. In addition to VWF binding, activated 
IIb3 receptors also bind to fibrinogen, an interaction that strengthens the adhesion 
and stability of aggregating platelets234. Congenital absence the IIb3 as in 
Glanzmann’s thrombasthenia results in a severe bleeding phenotype, thereby 
underscoring its importance as an adhesive receptor in platelet aggregation235. 
Missense mutations in VWF VWC4 domain are associated with type 1 VWD (type 1, 
partial quantitative deficiency representing 80% of VWD cases) and there are no 
reported mutations affecting the RGD tripeptide sequence (aa 2507-2509)236. 
Structural characterisation of these mutations or detailed insight into the mechanism 
of VWC4-IIb3 binding is as yet not possible, due to the paucity of structural data for 
this region of VWF. 
Vascular damage-induced exposure of subendothelial tissue factor (extrinsic pathway) 
and co-localised FVIII (intrinsic pathway) by its carrier protein VWF, initiate secondary 
haemostasis at the site of the growing thrombus. Propagation of the coagulation 
cascade occurs by localised enzymatic complexes assembled on the activated-platelet 
plasma membrane exposing negatively charged phospholipids. The thrombin thus 
generated, further activates platelets and leads to fibrin deposition resulting in a stable 
impermeable haemostatic plug6,7. Platelet adhesion, activation and aggregation, 
together with concurrent thrombin generation are central events in this process.  
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1.7.5 VWF region D’D3 – FVIII complex formation 
The FVIII binding site on VWF has been localised to the N-terminal 272 residues 
comprising domains TIL’E’VWD3 (aa 764-1035, V8 protease and tryptic digest fragment 
SPIII-T4)54,237, of which the first 106 residues (aa 764-869) encompassing domains TIL’E’ 
may be of particular importance238. The interaction of VWF with FVIII is of direct and 
great clinical significance, and the importance of VWFFVIII complex formation is 
illustrated by patients with severe VWD (type 3), who have undetectable VWF levels. 
Not only do these patients have a concomitant deficiency in procoagulant FVIII, but 
they also have a considerably reduced half-life of intravenously administered 
FVIII239,240. This phenotype, that which mimics mild haemophilia A, is also observed in 
patients with type 2N VWD, harbouring VWF mutations that lead to decreased FVIII 
binding affinity10,241. This behaviour reflects the dependence of FVIII survival on the 
formation of VWFFVIII complexes, and demonstrates the biological significance of this 
interaction. 
Whereas VWF is synthesised throughout the vascular endothelium, the liver is likely to 
constitute the primary source of FVIII synthesis242. Synthesis has been localised to the 
cells lining the microvasculature of the liver, most likely sinusoidal endothelial cells and 
Kupffer cells243. It is of interest to note, that compared to FVIII, the liver is not a 
significant site of VWF synthesis, at least at the mRNA level243. Despite the association 
of VWF with FVIII in the peripheral circulation, there is no direct evidence to suggest 
that VWF and FVIII are synthesised together in any particular cell type in vivo9. 
Nevertheless, numerous indicators suggest that limited co-expression may exist. It is 
well recognised that the administration of DDAVP results in a transient increase in 
VWF and FVIII levels. Interestingly, recent studies have demonstrated that whilst liver 
transplantation cures haemophilia A, subsequent infusion of DDAVP in these patients 
produced a transient increase in plasma VWF levels, but did not further increase 
plasma FVIII levels244. Whereas non-haemophilic liver transplant recipients 
demonstrate responses in both VWF and FVIII following DDAVP. Furthermore, DDAVP 
administration does not significantly increase plasma FVIII levels in patients with type 3 
VWD10,245. Cumulatively, these data support the hypothesis that a co-synthesised, 
releasable pool of VWF-FVIII may indeed exist in vivo245.  
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FVIII circulates in blood as a heterodimer composed of two non-covalently associated 
polypeptide chains, a light chain with a molecular weight of 80 kDa and a 
heterogeneous heavy chain with a molecular weight varying between 90 and 210 
kDa239,246. Immediately following release into the circulation, FVIII forms a tight non-
covalent complex with VWF; each monomer in multimeric VWF is able to bind one 
FVIII molecule247,248 with high affinity, the KD of the interaction is in the sub-nanomolar 
range (0.2-0.5 nM)247,249. It is of note that high affinity binding is dependent upon the 
multimeric structure of VWF and assembly of heterodimeric FVIII, and it not known if 
all exposed FVIII binding sites on multimeric VWF must be occupied before binding to 
another VWF molecule. Kinetic analysis of VWFFVIII complex formation reveals that it 
is characterised by very fast association and dissociation rate constants (kon  7 x 10
6 
mol-1 s-1 and koff 4 x 10
-3 s-1)250–252. 50% of FVIII is bound to VWF in approximately two 
seconds and more than 95% will be bound within 12 seconds following FVIII cellular 
release250,251. This is extremely rapid in comparison to the half-life of a few hours 
observed for FVIII in the absence of VWF in plasma240,250,253. The relatively low stability 
of the VWFFVIII complex, highlighted by the fast dissociation rate constant (Table 1.2), 
may be important for the regulation of FVIII activity; indeed, a high stability of the 
complex could hamper dissociation of FVIII from VWF following thrombin cleavage at 
sites of vascular injury252. An additional consequence of the high association and 
dissociation rates is that a small but significant proportion of FVIII molecules (5-8%) is 
unprotected by VWF147,254. 
The molar concentrations in plasma of the two molecules differ greatly. The typical 
plasma concentration of FVIII is 100-250 ng/mL (1 nM, assuming an average 
molecular mass of 240 kDa), whereas that of VWF is 10 g/mL (50 nM, in 
monomers). Therefore, in vivo, the stoichiometry is limited by the amount of FVIII, 
resulting in approximately a 1:50 ratio, such that not all VWF monomers are 
complexed with FVIII247,250. Even amongst normal individuals, plasma concentrations of 
VWF and FVIII vary with age, race, gender and ABO blood group. FVIII:Ag and VWF:Ag 
levels are significantly higher in African-Americans (approximately 20%) as compared 
with similar Caucasian populations, although the effect of ABO blood group is 
maintained. In addition, plasma FVIII and VWF levels rise with increasing age in 
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adults255. Importantly, elevated VWF and FVIII levels are independent risk factors for 
venous thromboembolism204,205,256, thus the probability of deep vein thrombosis and 
pulmonary embolism is greater in non-O blood type patients and African-Americans257. 
FVIII is synthesised as a single polypeptide chain of 2351 aa that includes a 19 residue 
signal peptide and a 2332 residue mature protein (Figure 1.24). The FVIII protein also 
has a discrete domain organisation as follows: A1-a1-A2-a2-B-a3-A3-C1-C2258,259. The A 
domains are bordered by linkers (a1, a2 and a3) that contain clusters of Asp and Glu 
residues and hence are termed the acidic regions239. In the a3 region, residues 1649-
1689 (41 amino acids), acidic residues comprise 37% of all amino acids. Within the 
Golgi apparatus, FVIII undergoes intracellular proteolysis. The middle and C-terminal 
regions of the B domain comprise a Arg-xx-Arg motif, that is similar to the motif 
recognised by intracellular proteases of the subtilisin-like family246. Consequently, the 
FVIII polypeptide chain is cleaved at Arg1313 and Arg1648 in the B domain, an event 
that disrupts the covalent linkage of the FVIII heavy chain (heavy chain, A1-a1-A2-a2-B) 
and light chain (light chain, a3-A3-C1-C2), giving rise to the heterodimeric molecule 
that circulates in plasma239 (Figure 1.24). The heavy and light chains of FVIII remain 
non-covalently associated through the A1 and A3 domains in a divalent metal ion-
dependant manner260.  
Mutations in the FVIII gene that cause aberrant biosynthesis or secretion result in 
haemophilia A, an X-linked bleeding disorder with an incidence of 1 in 5000 males. It is 
characterised by frequent and spontaneous bleeding into joints and soft tissues due to 
unstable clot formation261. In haemophiliacs, platelet surface FX activation by the 
FVIIIaFIXa tenase complex (during propagation phase) is abolished and therefore, 
platelet surface thrombin generation fails. The TFFVIIa complex cannot effectively 
substitute for FVIIIaFIXa, as it produces FXa on TF-bearing cells, although it is possible 
for some FXa to diffuse through the fluid phase onto the platelet surface. In addition, 
platelet adhesion and aggregation at the site of injury occurs over the site of TF 
expression, resulting in an essentially insurmountable barrier to the movement of FXa 
(and other activated factors). Thus, fibrin production mediated by the extrinsic arm of 
coagulation alone is inadequate in both amount and distribution, to support 
haemostasis6.  
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Although the assembly of the FVIII heterodimer increases the affinity of FVIII and VWF 
interaction, the VWF binding site on FVIII is entirely located within the light 
chain248,249,262,263. Two residue stretches on FVIII are implicated in binding VWF: the 
amino-terminal a3 acidic region of intact FVIII light chain and the C-terminal C1 and C2 
domains. These regions are in close proximity and act synergistically in capturing VWF 
in plasma, with subsequent formation of the VWFFVIII complex (KD FVIII light chain 
binding to VWF, 3.8 nM)247,264. Independently, a3 and C2 present with affinities of 72 
nM and 564 nM, respectively264 (Table 1.2). However, it is the acidic a3 region that is 
critical to high affinity binding and this is dependent upon tyrosine sulphation at 
Figure 1.24: Factor VIII domain structure and arrangement of heavy and light chains. FVIII is a 
glycoprotein that acts as an initiator and regulator of the intrinsic pathway of coagulation. The N- to 
C linear arrangement of the heavy and light chains in shown in the top panel, the mature protein 
consists of 2332 residues which are arranged in a discrete domain structure. The A domains are 
bordered by acidic regions: a1 (aa 337-372), a2 (aa 711-740) and a3 (aa 1649-1689). FVIII is secreted 
as a heterodimer formed of a heavy and light chain (middle panel) due to intracellular proteolysis at 
Arg1313 and Arg1648, the latter event disrupts the covalent linkage between the heavy and light 
chains giving rise to heterodimeric FVIII. The heavy and light chains remain non-covalently 
associated through the A1 and A3 domains in a metal ion dependent manner. Immediately 
following release into circulation, FVIII interacts with its carrier protein VWF to form a tight, non-
covalent complex. Two FVIII peptide regions are implicated in VWF binding, the light chain acidic a3 
and C2 domains. Proteolytic activation of FVIII by thrombin (FIIa) proceeds by cleavage of the heavy 
chain at Arg372 and Arg740, and at Arg1689 in the light chain to yield the FVIIIa heterotrimer. FVIIIa 
dissociates from VWF, associates with the FIXa serine protease (via domains A2 and A3; FVIII light 
chain contributes most of the binding energy) and directs localisation of the resulting tenase 
complex to the membrane surface of activated platelets via an interaction with its C-terminal C2 
domain. Membrane bound FVIIIaFIXa activates FX, which then activates thrombin. 
60 
 
residue 1680 of a3265. Mutation of this site (Tyr1680Cys/Phe) reduces the affinity for 
VWF by 5-fold and is associated with mild to moderate haemophilia A266. In these 
patients, FVIII:C is fully functional but FVIII:Ag content is reduced to 10-20% of normal 
levels267. Furthermore, loss of acidic a3 from the FVIII heterodimer (heavy chain/A3-
C1-C3) results in a 1000-fold decreased KD for VWF (Table 1.2); this would predict a 
similar reduction for VWF affinity upon thrombin a activation264.  
Table 1.2: Kinetics of the interaction between VWF and FVIII 
251,252,262,264,268–270
. LCh, light chain; HCh, 
heavy chain; SPIII-T4, VWF V8 protease and tryptic digest fragment. 
Interaction KD kon koff 
VWFFVIII 0.2-0.5 nM 8.56 x 10
6
 M
-1
 s
-1
 
 
6.89 x 10
-3
 s
-1 
 
VWFFVIII LCh 3.0-4.1 nM 9.2 x 10
5
 M
-1
 s
-1 
 3.2 x 10
-3
 s
-1 
VWFA3C1C2  625 nM 6.4 x 10
4
 M
-1
 s
-1
  4.0 x 10
-2
 s
-1
 
VWFC2 564 nM 6.2 x 10
4
 M
-1
 s
-1
  3.5 x 10
-2
 s
-1
 
VWFa3 fragment 72 nM 3.3 x 10
4
 M
-1
 s
-1
 2.4 x 10
-3
 s
-1
 
VWFHCh/A3C1C2 640 nM 5.93 x 10
4
 M
-1
 s
-1
  3.8 x 10
-2
 s
-1
 
Dimeric VWFFVIII 4.95-6.37 nM - - 
SPIII-T4FVIII 48.5 nM - - 
SPIII-T4FVIII LCh 102 nM 0.81 x 10
5
 M
-1
 s
-1
  8.2 x 10
-3
 s
-1
 
 
Thrombin activates FVIII (FVIIIa) by cleavage at one site in the light chain, Arg1689, and 
at two sites in the heavy chain: Arg372 and Arg740. Cleavage at Arg1689 bisects the 
acidic a3 domain from the remainder of the light chain (Figure 1.24). Removal of 
domain a3 significantly reduces the affinity of FVIIIa for VWF, thereby releasing FVIIIa 
from the VWFFVIII complex. Dissociation exposes FVIII surfaces that are important for 
efficient FVIIIa association with FIXa, and binding to phospholipid on the surface of 
activated platelets264,271. Mutation of Arg1689, as found in haemophilia A, predisposes 
to a haemorrhagic diathesis due to the inability of thrombin to cleave and dissociate 
FVIIIa, to assemble the FVIIIaFIXa (tenase) complex239. Interestingly, in the crystal 
structures of B domain-less FVIII, the acidic a3 domain of the FVIII light chain could not 
be resolved and remained disordered, suggesting that the interaction with VWF may 
be important in stabilising this region272,273.  
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In addition to the high affinity acidic a3 binding site on FVIII, the C2 domain, and to 
some extent the C1 domain, have also been shown to be important in determining 
interaction with the N-terminus of VWF. Interestingly, structural analysis of the FVIII 
light chain structure reveals that the C1 domain forms an extensive hydrophobic 
interface with domain A3 and is thus fixed, whereas domain C2 is only loosely tethered 
to the C1 domain and is capable of significant motion, thereby, possessing a greater 
degree of conformational flexibility272,273. Contributory regions to VWF binding within 
the FVIII C2 domain have been identified following characterisation of various 
recombinant C2 variants274–276, including some haemophilia A associated mutations. In 
particular, the hydrophobic doublets Met2199/Phe2200 and Leu2251/Leu2252 have 
been shown to directly interact with VWF275,277, as well as to phospholipid membrane, 
whereby cluster mutation of these residues resulted in a more than 50-fold reduction 
in VWF binding affinity275 (Figure 1.25).  
 
 
 
A role for the C1 domain in mediating the interaction between FVIII and VWF has also 
been described, a naturally occurring inhibitory antibody directed towards an epitope 
Figure 1.25: Hydrophobic spikes of FVIIII C2 domain. The VWF and membrane interactive 
hydrophobic amino acids in -hairpin turns of FVIII light chain C2 domain are shown as red carbon- 
spheres
275,277
. Residue numbers relate to the full length mature FVIII protein.  
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within the C1 domain has been shown to inhibit VWFFVIII complex formation and the 
mutations Ser2119Tyr and Arg2159Cys resulted in an 80- and 50-fold loss of affinity for 
VWF, respectively278–281 (Figure 1.26). However, given the dramatic loss of affinity of 
the FVIII light chain for VWF following thrombin cleavage at Arg1689 and loss of the N-
terminal acidic a3 sequence, the importance of the C1 and C2 domains seems 
somewhat incongruous. Nevertheless, specific residues within C1 and C2 may 
contribute to the avidity, rather than affinity, of VWFFVIII complex formation.  
Convergent lines of evidence suggest that VWFFVIII complex formation is principally 
mediated by electrostatic forces252. First, the putative binding sites for VWF on the 
FVIII molecule are strongly and oppositely charged; the acidic a3 region is negatively 
charged, whereas the C2 domain bears an overall positive charge. Second, VWD and 
haemophilia A disease-causing mutations of charged residues in VWF and FVIII, 
respectively, have been shown to abolish binding236,274,276,281,282. Furthermore, 
perturbation of the electrostatic properties of charged C2 domain residues, underlies 
the inhibition mechanism of the VWFFVIII interaction by pathogenic FVIII inhibitors276. 
Third, the presence of sulphated Tyr1680 on FVIII a3, which is able to establish 
electrostatic interactions, is indispensable for the binding of FVIII to VWF265. Lastly, it is 
well established that exposure to high salt concentrations leads to dissociation of the 
VWFFVIII complex252,283,284, and this is solely due to a decrease in the second-order 
association rate constant; the dissociation rate constant of the interaction is not 
significantly influenced by ionic strength252. Therefore, coupled with the high VWFFVIII 
association rate constant at physiological ionic strengths (Table 1.2) that exceeds 105 
M-1 s-1 (a value suggested as a start of the diffusion controlled regime of protein-
protein interactions285), this implies that the formation of the VWFFVIII complex 
depends on long-range electrostatic steering effects252. VWFFVIII complex formation is 
also inhibited by acidic pH, with negligible interaction at pH values less than 5; this 
behaviour reflects the decisive role ionisation of charged residues in FVIII play in VWF 
interaction and attest to a predominately electrostatic interaction252. 
Type 2N VWD represents a relatively rare form of VWD, estimated to affect 1-5 
people per million population, and accounting for approximately 1-2% of all identified 
VWD cases (13% of all type 2 VWD)286,287. Recessive inheritance of two mutations is 
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necessary for type 2N VWD. Affected individuals are either homozygous for a single 
type 2N mutations, compound heterozygous for two different 2N missense mutations 
or compound heterozygous for a type 2N mutation and a silent VWF allele. The N-
terminal 272 residues of VWF, containing the FVIII binding site, is encoded by exons 
18-23; however, 87% of all type 2N missense mutations reported occur in exons 18-20 
encoding domains TIL’E’ (D’ region)10,236. Type 2N mutations usually occur within 
hypermutable (CpG dinucleotide sequence) arginine codons, and the missense 
mutation Arg854Gln (c.2561G>A) occurs with polymorphic frequency in Caucasian 
populations10,288.  
 
 
 
 
 
 
Consequent to the intrinsic defect in VWF that results in impaired FVIII binding and 
complex formation, plasma FVIII is labile, prone to early proteolysis and levels are 
usually lower than those of plasma VWF287. It is well established that interaction of 
Figure 1.26: Haemophilia A mutations in the FVIII light chain that decrease VWF binding. The acidic 
a3 domain (red) is an all loop region and this disorder prevented its assignment in the reported FVIII 
crystal structures. Thus the full length FVIII light chain was modelled as a chimera using crystal 
structures of FVIII (pdb: 3CDZ)
272
 to model domains A3-C1-C2 and an Escherichia coli kinase (pdb: 
1OJ4) for the a3 region, in Modeller9v8. A ribbon representation of the full length FVIII light chain is 
shown, with the a3 region coloured red and the A3-C1-C2 domains in progressively darker shades of 
grey. Reported mutations
9,274,276,281
 that have been shown to decrease VWF binding are represented 
by carbon- spheres in black. a3: Y1680C/F. C1: Q2087E, R2090C, I2098S, S2119Y, N2129S, 
R2150C/H, P2153Q, and R2159C. C2: S2173I, A2201P, V2232A, P2300L, R2304C/G/H/L, R2307Q. 
Interestingly, two mutations in domain C2 show enhanced VWF binding: D2288A and R2320T.  
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FVIII with VWF increases survival of FVIII in plasma. The half-life of infused FVIII 
concentrate in patients with type 3 VWD is only 1-2.5 hours, as compared to 12 hours 
in patients with haemophilia A9,240,253. Thus, VWFFVIII complex formation is critical to 
the survival of FVIII in circulation; free FVIII is rapidly cleared from the circulation 
whereas, complexed FVIII decays with the half-life of VWF289. The mechanism for 
maintaining FVIII circulatory residence time includes stabilisation of the FVIII structure 
and the prevention of cleavage, and removal by cellular interactions. When FVIII is 
bound to VWF, a stable association of its heavy chain and light chain is maintained290; 
interaction of the FVIII light chain with VWF enhances the rate of light and heavy chain 
association and may function as a surface upon which the FVIII heterodimer 
assembles262,291. VWF protects FVIII from proteolytic degradation by phospholipid-
binding serine proteases such as activated protein C (a potent anticoagulant) and 
activated FXa289,292–294. Furthermore, VWF bound FVIII cannot bind to FIXa, thereby 
denying FVIII the capacity to assemble the FX-activating tenase (FVIIIaFIXa) 
complex295–297. The protection of FVIII by VWF is mediated by two mechanisms. First, 
VWF-bound FVIII is competitively inhibited from binding to phospholipids or 
platelets269,298, second, direct protease-binding sites within the FVIII light chain are 
cryptic whilst FVIII is in complex with VWF297,299. Furthermore, rapid VWFFVIII complex 
formation, may prevent FVIII from interacting with components that bind with lower 
affinity250, such as FIXa (KD 15 nM)
295 and phospholipids (KD 2 to 4 nM)
300. This 
protection from proteolysis serves to increase the FVIII circulatory residence time.  
As well as concealing binding sites on FVIII essential to its procoagulant activity, VWF 
interaction modulates clearance of FVIII from the circulation by macrophage low-
density lipoprotein receptor-related protein-1 (LRP1). VWF inhibits uptake of FVIII by 
macrophage LRP1 by shielding the LRP1 binding site on the FVIII light chain301,302. VWF 
does not interact with LRP1 in the absence of shear301–303, and due to the higher 
affinity of FVIII for VWF (KD FVIII interaction with LRP1 60 nM)
301, VWF prevents 
binding of complexed FVIII to the macrophage receptor9. Intriguingly however, VWF 
does not protect FVIII from LRP1-dependent endocytosis under conditions of high 
shear, which converts sheared VWF into its active platelet-binding conformation and a 
65 
 
ligand for LRP1, and thus, shear flow drives the catabolism of the VWFFVIII complex by 
macrophages303,304.  
Moreover, complex formation with VWF has a direct effect on the immunogenicity of 
FVIII, and may protect FVIII against inhibitor formation in haemophilia patients. 
Inhibitor formation against infused FVIII is among the most serious complications of 
haemophilia treatment, occurring in 25% of patients305. It is a T-cell-dependent 
immune response to foreign infused FVIII, rendering it ineffective and leads to poorly 
controlled bleeding and severe morbidity. The light chain C2 domain is a significant 
antigenic target of anti-FVIII antibodies and a frequent epitope has been localised to 
residues 2248 through 2312306. Antibodies to this epitope have been shown to inhibit 
FVIII binding to both VWF and phospholipid, but are less reactive to FVIII in complex 
with VWF. In addition to masking epitopes on FVIII, complex formation also prevents 
FVIII interaction with antigen presenting cells such as macrophages and dendritic cells 
and thereby blocking subsequent activation of CD4+ T-cells9,305. 
The molecular structure of the FVIII binding region on VWF is not known, and the 
importance of its elucidation is two-fold. First, it would provide important and detailed 
insights into the mechanism of FVIII docking onto VWF, and the minimal unit required 
to stabilise FVIII in vivo. This would allow for the improvement of haemophilia A 
treatment that relies on FVIII replacement therapy, as well as the development of 
novel approaches to treat both haemophilia A and VWD. Plasma-derived and 
recombinant human FVIII products are used for the treatment of haemophilia A. 
Following intravenous infusion, the primary determinant of FVIII residence time in 
plasma is its non-covalent association with VWF. However, haemostatic protection 
with current FVIII products is temporally limited as a consequence of a short FVIII half-
life of 8-12 hours, requiring frequent prophylactic injection to maintain FVIII at a level 
that is protective against spontaneous bleeding episodes (above 1%)307,308. Thus, 
targeting FVIII half-life extension would have the greatest impact in achieving long 
therapeutic windows with protective plasma levels in haemophilia A patients. Second, 
analysis of VWD patient mutations against a backdrop of both structural and functional 
perturbations will provide the link between genetic pathology and clinical phenotype, 
thereby enabling improved and targeted management of VWD patients.  
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1.8 NMR for protein structure determination 
NMR spectroscopy, first described by Felix Bloch and Edward Mills Purcell in 1956, is 
the phenomenon of atoms absorbing radio frequency electromagnetic radiation (RF) 
under the influence of a magnetic field. For NMR spectroscopy of biomolecules, the 
detection of this absorption requires the use of isotopes of hydrogen, nitrogen and 
carbon that possess odd mass numbers and a spin ½. 
 
1.8.1 Chemical shift 
Spin is a quantum mechanical property attributed to protons, neutrons and electrons, 
measured in multiples of ½ and can be positive or negative. The most important nuclei 
with a ground state (I) spin ½ are 1H, 13C and 15N. A nuclear state with spin I is (2I  1)-
fold degenerate, thus a nucleus with spin ½ will have two possible states - a low or 
high energy state. In the absence of a magnetic field the two states are of equal 
energy, however, in an applied magnetic field the energies of the spin states are split 
into two nuclear spin levels: nuclear Zeeman splitting (Figure 1.27). 
 
 
At equilibrium, transitions from one spin state to another occur infrequently. However, 
the application of RF energy equal to the difference between the two nuclear states 
(the Larmor frequency) will promote the oscillation between the two states. Following 
a pulse of RF energy, the spin states of the majority nuclei will relax to their ground 
state. This relaxation is known as free induction decay (FID). The energy required to flip 
nuclear states is dependent upon the strength of the magnetic field, the type of 
Figure 1.27: Energy levels for a nucleus with spin ½. The nuclear Zeeman sublevels of a spin ½ 
nucleus are shown. Each level is given a magnetic quantum number, m.  
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nucleus and the surrounding chemical environment, and this gives rise to a range of 
resonance frequencies for each nucleus, an effect termed the chemical shift. The 
chemical shift mechanism is due to the applied magnetic field inducing currents in the 
electron clouds of the molecule, these circulating molecular currents, in turn, generate 
an induced magnetic field. The nuclear spins experience the total effect of the applied 
magnetic field as well as the induced field generated by molecular electrons, and 
hence give rise to measurable shifts in nuclear resonance frequencies.  
Chemical shift is an extremely important concept in NMR as it permits the 
identification of individual nuclei and their subsequent characterisation. Because 
chemical shift reflects the local electronic environment of the nucleus, it contains 
information about protein structure, wherein secondary structure elements are 
associated with specific chemical environments of the spin. As a result, the secondary 
structure of folded proteins can be identified from their chemical shifts. A near 
complete chemical shift assignment is a prerequisite for structural studies by NMR.  
 
1.8.2 J-couplings 
When nuclei are bonded to one another, the magnetisation may be transferred 
through the bonding electrons. This type of spin-spin coupling is termed scalar or J-
coupling and it provides a direct spectral manifestation of the chemical bond; unlike 
the chemical shift, the J-coupling independent of the applied magnetic field. Two spins 
have a measurable J-coupling only if they are linked together through a small number 
of chemical bonds, including hydrogen bonds. The J-coupling is exclusively 
intramolecular. Protein structure determination relies on J-couplings to identify the 
sets of resonances of individual amino acid residues in the NMR spectra and to 
subsequently establish the sequential connectivity of amino acids in the protein 
sequence. 
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1.8.3 Nuclear Overhauser enhancement 
Whereas J-coupling is a through-bond transfer of magnetisation, nuclear Overhauser 
enhancement (NOE) is a measurement of through-space transfer. The NOE is a 
manifestation of the prediction that dipolar-coupled spins do not relax independently 
and is one of the most important effects in NMR spectroscopy.  As each nuclear spin is 
a magnetic dipole, it generates a magnetic field around itself (Figure 1.28, spin I). A 
second nuclear spin (spin S) in spatial proximity may interact with the magnetic field of 
spin I. The corollary is that spin I will also experience the effect of the magnetic field 
generated by spin S. Such an interaction is a direct dipole-dipole coupling and thus 
leads to the NOE.  
 
 
 
The NOE is currently the most significant NMR parameter in protein structure 
determination, as it provides a measurement of through space interactions between 
atoms that are spatially close ( 6 Å). An NOE occurs when magnetisation is 
transferred between two protons through saturation of absorption intensity of the 
spins followed by dipolar cross relaxation. The dipolar cross relaxation rate constant is 
proportional to the inverse sixth power of the distance between the two interacting 
protons as given by the following equation: 
               (  ) 
Figure 1.28: Magnetic fields generated by nuclear spins I and S. This through space magnetisation 
transfer allows distance information to be obtained for both intra- and inter-residue interactions 
between protons that are typically less than 6 Å apart.  
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Where σIS is the rate constant of magnetisation transfer, rIS is the distance between 
the two interacting nuclei, γI and γS are gyromagnetic ratios of the two nuclei and τC is 
the correlation time for molecular tumbling. A majority of the restraints used to 
calculate the three dimensional structure of a protein come from many hundreds of 
NOE cross-peaks, and are represented as bounds on the separation of pairs of 1H 
atoms. Thus, NOEs are used to restrain the molecular structure and conformation 
unambiguously.  
 
1.8.4 Residual dipolar couplings 
The r-6 dependence of NOEs stipulates that the distance-dependent information 
provided is both short-range and local; the presence of two pairs of NOEs does not 
provide insight into how they are related to one another. In contrast, the effect of 
dipole-dipole coupling may be used to obtain distance-independent orientational 
restraints, termed residual dipolar couplings (RDCs). RDCs provide additional structural 
information regarding the orientation of inter-atomic vectors with respect to a 
molecular coordinate frame.  
In isotropic solutions the dipolar coupling between two spins averages to zero due to 
molecular motion; however, to extract dipolar coupling data the molecule must 
behave anisotropically. When molecular tumbling is anisotropic, such as when a 
protein is partially aligned in a liquid crystal, the orientational distribution is not 
equiprobable and the molecule has a preferential orientation, thus the dipolar 
coupling does not average to zero. This non-zero coupling is called the RDC.  
There are several types of alignment media used to generate partial alignment of 
biological molecules for RDC measurements. They include bicelles, filamentous 
bacteriophage Pf1 and poly(ethyleneglycol)/hexanol mixtures. These co-solutes, 
restrict free molecular tumbling and induce alignment by steric (bicelles and 
poly(ethyleneglycol)/hexanol mixtures) or electrostatic (Pf1) interactions.  
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Although partial structure determination can be performed with RDC data alone, they 
are most often used as restraints to refine existing structures, as well as to determine 
the relative orientation of domains in multi-domain proteins.  
 
1.9 Summary 
VWF is a Janus-faced protein that is critical to the processes of both haemostasis and 
its pathologic extensions bleeding and thrombosis (Figure 1.29). The cysteine-rich N- 
and C-terminal regions of VWF have been the subject of significant efforts aimed at 
characterising the structure and plasticity of function of this unique protein, 
particularly in view of the involvement of VWF in pathological processes that transcend 
haemostasis. The primary aim of this work is to determine a high-resolution structure 
of the FVIII binding region on VWF that would reveal insights into the mechanism of 
VWFFVIII complex formation and the molecular basis of the bleeding diathesis type 2N 
VWD.  
 
 
 
 
 
 
 
 
Figure 1.29: VWF: a Janus protein in bleeding and thrombosis. The haemostatic system is designed 
to react rapidly upon vascular damage to minimise blood loss, a process that requires tight 
regulation to prevent thrombotic occlusion of the vessels. VWF is a key player in the haemostatic 
system, as illustrated by its liaison with both haemorrhagic and thrombotic conditions.  
71 
 
2.   Results and Discussion 
Electron microscopy studies have given a first and fascinating glimpse into the domain 
arrangement and overall structure of the multi-domain VWF protein. The limited 
resolution of this technique, however, has precluded the elucidation of vital atomic 
details needed to examine the molecular recognition and binding of FVIII to VWF. 
Therefore, detailed analysis of the VWF molecular structure that facilitates binding to 
FVIII, which would reveal crucial mechanistic insight into their intimately intertwined 
activities, has until now, remained elusive.  
Solving the three-dimensional structure of the biological macromolecule under 
investigation is essential for the complete understanding of its function and of the 
structure-function correlation. Unlike X-ray crystallography, NMR spectroscopy permits 
the determination of not only an atomic resolution molecular structure in solution, but 
also of time-dependent phenomena such as protein dynamics. Function in biological 
systems is exquisitely dependent upon spatial and temporal changes in the protein 
structure, and these dynamics contribute to the stability of functional states and play 
an important role in catalysis, where conformational rearrangements can juxtapose 
key residues; in ligand binding, which may require structural rearrangements; in 
molecular recognition processes, which are often fine-tuned by disorder-to-order 
transitions; and in allostery, where coupled structural fluctuations can transmit 
information between distant sites in a protein309. Hence, NMR is uniquely suited to the 
study of both protein structure and site-specific dynamic processes.  
The FVIII binding region on VWF is contained within the amino-terminal 272 residues 
(exons 20-23)54,237 comprising domains, TIL’ (aa 767-827), E’ (aa 829-863) and VWD3 
(aa 867-1031). Several lines of evidence, however, suggest that of these regions, 
domains TIL’ and E’ (the classical D’ region) are essential for FVIII binding. First, 72% of 
unique missense mutations that directly affect FVIII binding to VWF (type 2N VWD) are 
found in domains TIL’E’. The majority of the remaining type 2N mutations are in 
domains VWD3 and C83. Importantly, type 2N mutations that result in the most severe 
phenotypes and the lowest circulating FVIII levels, are found in the TIL’ domain236,310–
312. Second, the epitopes of the most potent FVIII binding-blocking monoclonal 
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antibodies (mAb) map to the TIL’ domain; the epitopes of mAb 418 and mAb 32B12 
encompass residues 765-816 and 814-823 in TIL’, respectively313–315. Third, the 
interaction between VWF and the FVIII light chain is disrupted in high ionic strength 
solutions and by low pH (< pH 5), indicating that VWFFVIII complex formation is 
mediated by electrostatic interactions252,283. Domains TIL’E’ contain numerous charged 
residues that likely contribute to this interaction; there is an over-representation of 
charge-change inducing type 2N mutations in TIL’E’.    
Despite the importance of the interaction of VWF with FVIII under physiological and 
pathological conditions, the molecular mechanisms that govern VWFFVIII complex 
formation remain incompletely defined. The regions of VWF and FVIII involved in 
binding, as well as the affinity and kinetics of the interaction have been investigated. 
However, the absence of structural information has precluded the understanding of 
the detailed topology and mechanism of VWFFVIII complex formation. The results 
discussed herein, are of the successful expression of the VWF TIL’E’ (D’) region in 
Escherichia coli (E. coli) and the determination of its high resolution NMR structure and 
dynamic characteristics. The TIL’ domain lacks extensive secondary structure, is 
strikingly dynamic and is coincident with the clustering of pathological mutations 
leading to decreased FVIII binding affinity (type 2N VWD). The major FVIII binding site 
is localised to a specific and flexible pocket in domain TIL’, that is supported by the 
structured regions of TIL’ and the rigid E’ domain.  
 
2.1. Determination of TIL’E’ domain boundaries by sequence analysis  
The application of NMR spectroscopy to structure determination requires the correct 
assignment of VWF domain boundaries to ensure that the structure of an 
autonomously folded TIL’E’ region is solved. The TIL’ and E’ domains were delineated 
by positionally conserved TIL (Ascaris) and fibronectin I-like domain family cysteines. 
The TIL’E’ fragment spans VWF residues 767 through 863 (97 aa), encompassing 
sixteen cysteines that form eight disulphide bonds (Figure 2.1). Three of five cysteine 
linkages in domain TIL’ have been biochemically characterised42; the remainder, 
together with the three disulphide bonds in E’, were assigned by the positional 
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conservation of cysteine residues in a multiple sequence alignment of homologous 
domain sequences.  
 
 
 
 
 
The disulphide bond topology is well preserved in the Ascaris family, their Cys residue 
connectivity is as follows: Cys1-Cys7, Cys4-Cys10, Cys3-Cys5, Cys2-Cys6, Cys8-Cys9 (Figure 
2.2, panel A); and correspond to VWF TIL’ disulphide bridges Cys767-Cys808 (1-7), 
Cys776-Cys804 (2-6), Cys788-Cys799 (3-5), Cys792-Cys827 (4-10) and Cys810-Cys821 
(8-9). Disulphide bond linkages of the TIL domains, determined initially by chemical 
methods alone (1-9, 3-7, 2-5, 4-6, 8-10)110, were revealed to support neither the 
structure determined by crystallography105,316, nor assignments derived from NMR 
spectra104,317–319, highlighting the difficulty in unambiguously pairing such closely 
spaced Cys residues. A multiple sequence alignment of the conserved ten-cysteine 
core of the TIL domain family (60 aa) was generated, which enhanced the reliability of 
domain boundary assignments, and facilitated the alignment of VWF TIL’ with its 
structural homologues for subsequent comparative modelling (Figure 2.2, panel A). 
Figure 2.1: FVIII binding sequence on VWF. The FVIII binding region on VWF, identified within a 
tryptic fragment termed SPIII-T4 (aa 764-1035)
54
, is formed of three conserved domains, TIL’, E’ and 
VWD3, the sequence of which is shown. Conserved Cys residues are highlighted in black and their 
connectivity is shown by gold bars. Biochemically determined disulphide bridges
42
 are indicated by a 
* and these are, TIL’: Cys767-Cys808 (1-7), Cys776-Cys804 (2-6) and Cys810-Cys821 (8-9); VWD3: 
Cys867-Cys996 (1-7), Cys889-Cys1031 (2-8), Cys898-Cys993 (3-6) and Cys914-Cys921 (4-5). 
74 
 
The Apis mellifera chymotrypsin/cathepsin G inhibitor-1 NMR structure317 (AMCI-1; 
pdb: 1CCV) displays significant sequence identity with VWF TIL’ (32.3% identity and 
37.1% similarity); modelling based on this template required the least number of 
insertions and deletions in a pairwise alignment (Figure 2.2, panel B). Regions of 
sequence insertion or deletion corresponded to accessible loop regions of structure 
1CCV, as is desired for optimal modelling.  
The E’ domain was assigned based on sequence conservation of the VWC subdomain 1 
cysteine signature Cys1-Cys2xxCys3xCys4-Cys5-Cys6 (Figure 2.2, panel C). The fibronectin 
I-like family comprises small 35 residue domains, and scanning by means of fold 
recognition algorithms320, against all structures deposited in the protein data bank, 
ascertains their structural homology to the N-terminal VWC domain fold118. In the ten-
cysteine full VWC domains, conserved residues Cys2 and Cys6 participate in 2-8 and 6-9 
linkages, respectively, in which the Cys2-Cys8 linkage couples subdomain 1 to 
subdomain 2. Free thiol groups are rare and the reported pKa values of Cys thiols are in 
the region of 8-9, thus their low abundance is likely to be linked with the risk of 
aberrant polymerisation an ionised cysteine may present at extracellular basic pH 
values321,322. As such, homology modelling of E’ was based on the reasonable 
hypothesis that Cys2 and Cys6 would not remain unbound but rather, form a Cys2-Cys6 
disulphide bridge in agreement with the close proximity of the corresponding residues 
in fibronectin I domains323, resulting in the following linkage pattern: Cys829-Cys851 
(1-4), Cys846-Cys863 (2-6) and Cys849-Cys858 (3-5) (Figure 2.2 panel C). The VWF E’ 
domain was modelled against the NMR structure of VWC subdomain 1 of human 
collagen IIA (pdb: 1U5M)118, sharing 30.6% and 38.9% sequence identity and similarity, 
respectively (Figure 2.2, panel D). Therefore, based on sequence homology, these 
comparative models provide a reliable prediction of the overall structure of the VWF 
TIL’ and E’ modules, and of the complete TIL’E’ disulphide bond topology (Figure 2.2).  
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The correct formation of disulphide bonds is of critical importance to the maintenance 
of structure and function, as well as to protein stability by reducing the entropy of the 
unfolded state324,325. It has long been noted that disulphide bonds are highly conserved 
in evolution322,326, and interestingly, in almost all cases conservation of half-cysteines 
even surpasses that of tryptophan, which is usually the most conserved amino acid326. 
It is striking that instances where the bond is not conserved, pairs of half-cysteines are 
replaced in concert in 99% of cases327; such is the case for the Cys3-Cys5 bond in VWF C 
domains VWC2, VWC4 and VWC6 (Introduction, Figure 1.8). Similarly, a novel single 
VWC domain family has recently been characterised in arthropods328 that is also 
distinguished by its selective loss of disulphide bridge 3-5, which is arguably the least 
Figure 2.2: Sequence and structural modules of TIL’E’. Sequence alignments of VWF TIL’ and E’ with 
their structural homologues are shown (pdb codes are given). Conserved cysteines are highlighted in 
black, regions of -strands are shown in grey. -strand positions are based on the high resolution 
structures of TIL and fibronectin I-like family domains, whereas those of VWF TIL’ and E’ are derived 
from secondary structure assignment (DSSP) of the homology models. Positions of non-cysteine type 
2N von Willebrand disease mutations are shown in red and underlined in the sequence. Panel A 
shows an alignment of the Ascaris protease inhibitor family whose disulphide bond connectivity is 
shown in gold and residues that would constitute the reactive site P1 and P1’ scissile bond in this 
family are in bold. In panel B is shown the TIL’ homology model based on structure 1CCV
317
. Panel C 
shows an alignment of members of the fibronectin 1-like family and modelling of domain E’ on 
subdomain 1 of VWC structure 1U5M
118
 is shown in panel D - the induced Cys2-Cys6 disulphide bond 
is indicated.  
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important bond as it connects two -strands within a sheet. Importantly, the Cys2-Cys6 
(Cys846-Cys863) linkage predicted in domain E’ is thus, corroborated by its specific 
absence in domain E2 (Introduction, Figure 1.6). The disulphide bonding pattern of 
both the TIL’ and E’ domains cannot be separated it into two discrete subpatterns of 
independently cross-linked regions (Figure 2.3, panels A and B). This connectivity 
formation is far more frequent than an independent disulphide bonding topology329 
(Figure 2.3, panel C), and it is thought to confer evolutionary advantage, as entropic 
stabilisation is greater for inseparable patterns whose complexity may be essential for 
maintaining the protein fold330; in support of the conservation of TIL’ and E’ disulphide 
bond topology. 
 
 
 
 
 
Similar disulphide connectivity patterns place similar spatial geometric constraints on 
the protein backbone, and consequently on the overall three-dimensional 
structure327,331,332, and this facilitated prediction of the discrete TIL’ and E’ domain 
structures by virtue of homology (Figure 2.2 panels B and D). Protein structures diverge 
linearly, although at a much lower rate, with the sequence variability in homologous 
proteins. Hence, structure is more conserved than sequence333,334. However, when the 
protein core is stabilised by disulphide bonds, as is the case for small domains ( 70 
Figure 2.3: Disulphide bonding patterns of domains TIL’E’. Connectivities are composed of 
disulphide cross-linked loops. In the relative arrangement of disulphide bonds, there are three 
relationships that may occur between any two cross-linked loops; overlap, enclosure and 
independence
330
. Panel A shows the disulphide connectivity of domain TIL’, in which there is overlap 
and disulphide bridge 8-9 is enclosed within the loop of disulphide bridge 4-10. Panel B shows the 
overlapping disulphide bonding pattern of domain E’. Panel C shows an example of an independent 
disulphide bonding pattern which can be divided into discrete cross-linked regions.  
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residues) such as TIL’ (61 residues) and E’ (35 residues), disulphide bond conservation 
with sequence divergence can be reasoned to selection pressure preserving 
geometrical restraints333,335. Even in the case of extremely low sequence similarity 
(sequence identify < 25%)331, there exists an intimate relationship between disulphide 
connectivity patterns and protein structure. Based on this premise, together with the 
knowledge that disulphide bonds very rarely occur between protein domains322, the 
reliability of using cysteine signatures to delineate VWF domain boundaries and build 
comparative models is greatly increased. The TIL’ and E’ domain boundaries form the 
basis for biochemical and structural characterisation of the FVIII binding region.  
 
2.2. Rational design of TIL’E’ expression constructs 
A preliminary assessment of the TIL’ and E’ multiple sequence alignments and 
homology structures guided the choice of N- and C-termini end residues chosen for 
expression. This prevented both the inadvertent truncation of conserved regions and 
disruption of predicted secondary structural elements in TIL’E’. Additionally, this 
approach limited the addition of excess flexible N- and C-termini loop residues that 
give rise to poorly resolved cross peaks in NMR spectra and do not contribute 
structural information. Initially, numerous expression constructs and expression 
conditions were tested. Ultimately, the thioredoxin (TRX)-tagged VWF TIL’E’ fragment, 
comprising residues 766-864 was chosen for expression and subsequent structural 
assignment by NMR.  
The production of correctly folded protein in sufficient quantity and purity is essential 
for advancement to structural studies; the enteric bacterium E. coli remains the most 
popular host for heterologous expression of recombinant proteins. However, the 
cytoplasm of wild type E. coli, is a reducing environment and is therefore, unable to 
sustain disulphide bond formation, which requires the pairwise oxidation of free thiol 
groups present on Cys residues; indeed cysteine is the most abundant amino acid in 
proVWF, comprising 8.3% of all residues and 16% of the TIL’E’ domains. Given 2n 
cysteines that form n disulphide bonds, the number of possible connectivity patterns 
of all 2n cysteines is: (2n)!  (2nn!), thus as the number of cysteines increases, the 
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number of potential pairings increases factorially327,336. For the 16 cysteines of TIL’E’, 
there are 2,027,025 possible combinatorial disulphide patterns. To circumvent this 
problem, an E. coli mutant strain with a cytoplasmic redox potential comparable to 
that of the mammalian endoplasmic reticulum has been developed by disruption of 
the thioredoxin and glutathione reductase genes. This trxB-/gor- double mutant is 
conducive to the formation of disulphide bonds in the cytoplasm337. Nevertheless, 
protein overexpression remains particularly arduous when disulphide bonding is both 
abundant and topologically complex, such is the case for TIL’E’, and this poses a 
significant challenge to recombinant production by E. coli.  
When proteins with more than two cysteines are oxidised, non-native disulphide 
bonds inevitably form, which results in a randomly scrambled set of protein isomers. 
Proteins that are mis-oxidised and therefore mis-folded may be isomerised back to 
their native disulphide-bonded state during in vivo folding by the E. coli periplasmic 
oxidoreductase chaperone DsbC. The isomerase activity of DsbC is of critical 
importance to the non-consecutive, multi-disulphide bonded VWF TIL’E’ fragment, 
hence, the oxidative E. coli strain SHuffle337, engineered to co-expresses active 
cytoplasmic DsbC was used for the expression of thioredoxin tagged TIL’E’ (VWF 
residues 766-864).  
Fusion of TIL’E’ to an N-terminal thioredoxin tag was essential for successful expression 
of the protein in E. coli. Notably, the thioredoxin tag resembles the native VWF 
prodomains that contain thioredoxin-like sequences93. Although, TIL’E’ (residues 766-
864) in the absence of an N-terminal thioredoxin tag (Figure 2.4, panel A) could be 
expressed and purified from E. coli, incorrect disulphide bonds were formed. The 
purified TIL’E’ domain (lacking a thioredoxin tag) migrated as a doublet when analysed 
by non-reducing SDS-PAGE (Figure 2.4, panel B lanes 6-10 and panel C). As this protein 
migrated as a single band under reducing conditions (Figure 2.4, panel B lanes 1-2 and 
panel C), this indicates that multiple disulphide-bonded species (isomers) were 
present.  
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Figure 2.4: Purification of His6-TIL’E’. A schematic of the His6-TIL’E’ construct is shown in panel A. 
The linker between the His6 tag and TIL’E’ encompasses the TEV cleavage site (ENLYFQ
G). This 
purification is of uncleaved His6-TIL’E’. Panel B shows the SDS-PAGE of fractions taken from the initial 
Ni-NTA (Nickel, Ni
2+
) affinity column purification. The lysate, binding flow-through and washing 
fractions are run under non-reducing conditions and are shown in lanes 3-5. Ni-NTA elution fractions 
(lanes 6-10) show the bound His6-TIL’E’ protein (13.2 kDa) that migrates as a doublet under non-
reducing conditions. His6-TIL’E’ elution fractions in lane 6 and 9 (*), are also run under reducing 
conditions in lanes 1 and 2, in which the doublet collapses and migrates as a single band, indicating 
the presence of disulphide isomers. Fractions containing His6-TIL’E’ (lanes 6-10) are then applied 
over a size exclusion chromatography column (16/60 Superdex 75), the elution fractions of which are 
shown in panel C under reducing and non-reducing conditions. The lane numbering corresponds to 
peaks 1 to 4 of the chromatogram shown in panel D. Under non-reducing conditions, purified His6-
TIL’E’ migrates as a doublet. 
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Details of the final VWF TIL’E’ construct are given in Materials and Methods (section 
4.3) in brief however, the TIL’E’ coding sequence (Ser766-Asp864, 99 residues) was 
cloned into a pET32b(+) vector containing an N-terminal thioredoxin and His6 tag. The 
TRX-His6 tag is separated from the TIL’E’ coding sequence by a 31 residue linker 
containing the Tobacco Etch Virus (TEV) cleavage sequence (ENLYFQG) to allow 
removal of the tag from purified TIL’E’ (Figure 2.5). 
 
 
 
 
 
Once suitable domain boundaries that define a folded TIL’E’ region were established 
and the expression construct and conditions optimised, uniformly isotopically labelled 
TIL’E’ was successfully obtained by over-expression of TIL’E’ in M9 minimal medium 
containing 15N-ammonium chloride (15NH4Cl) and 
13C6-D-glucose. TIL’E’ was 
subsequently purified to homogeneity by a two-step Ni-NTA (nickel) affinity 
Figure 2.5: Arrangement of construct TRX-His6-TIL’E’. The nucleotide sequence of the TRX-His6-
TIL’E’ construct and its amino acid translation is shown. The 107 residue thioredoxin tag (dark grey, 
bold) is followed by a six histidine tag (light grey, bold) and the TEV protease cleavage site 
(ENLYFQG, in black bold). VWF residues Ser766 through Asp864 (cDNA bp 2296-2592) were cloned 
using restriction sites 5’ NcoI (ccatgg) and 3’ XhoI (ctcgag), these are underlined in the sequence. 
Cleavage by TEV leaves four residues (GAMG, boxed) N-terminal to VWF Ser766 as cloning artefacts. 
Highlighted in grey are single base pair mutation sites in TIL’ to remove an NcoI (c.2310C>G) and an 
XhoI (c.2358C>G) restriction site within TIL’. The stop codon TAA follows VWF residue Asp864.  
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chromatography purification protocol. TRX-His6-TIL’E’ is eluted from the first Ni-NTA 
column application following binding of the His6 tag (Figure 2.6, panel A lanes 3-6), the 
TRX-His6 tag is subsequently cleaved by TEV and the cleavage reaction (Figure 2.6, 
panel B lane 1) reapplied to the Ni-NTA column, from which cleaved TIL’E’ is collected 
in the flow-through. Soluble monomeric TIL’E’ is then applied to a size exclusion 
chromatographic column as a final purification step, from which pure TIL’E’ 
reproducibly elutes at 73 mL, in a single symmetrical peak (Figure 2.6 panel C). Its 
subsequent migration as a single band, under non-reducing SDS-PAGE, indicates that 
the recombinantly produced TIL’E’ is homogenous and monomeric (Figure 2.6, panel B 
lane 7). The calculated polypeptide masses for tagged (TRX-His6-TIL’E’) and untagged 
TIL’E’ are 28.6 kDa and 11.3 kDa, respectively. The final TIL’E’ protein contains 103 
residues of which the N-terminal four amino acids (GAMG) constitute cloning artefacts 
(Figure 2.5).  
Of interest, mutation of the N-linked glycosylation site Asn857, in domain TIL’ and 
adjacent to Cys858, results in increased levels of free thiol groups in VWF when 
expressed in mammalian cell lines and hence, is not compatible with formation of the 
correct VWF disulphide bond architecture145. However, unglycosylated TIL’E’ expressed 
in an oxidising cytoplasm in E. coli, was able to form the correct disulphide bonded 
structure. This may be reasoned to the continual exposure of TIL’E’ to an oxidative 
DsbC-enhanced folding environment, that does not rely on an N-glycan dependent 
calnexin/calreticulin folding cycle338 or glycan chain mediated interaction with 
endoplasmic reticulum protein disulphide isomerase ERp57, which has been shown to 
be involved in VWF synthesis145,339. 
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Figure 2.6: Purification of TRX-His6-TIL’E’. Shown in panel A is a non-reducing (NR) SDS-PAGE of the 
first Ni-NTA affinity purification step. Above the SDS-PAGE is a schematic of the construct at this 
stage of the purification. Lane 1 shows the unbound material from the filtered E. coli cell cytoplasm 
(binding flow-through) and lane 2 shows the washing flow-through. Lanes 3 to 10 are successive 
elution fractions of bound TRX-His6TIL’E’. Monomeric TRX-His6-TIL’E’ migrates as a single well-
defined band and elutes as expected for a 29 kDa protein. It is clearly seen that fractions containing 
higher molecular weight TRX-His6-TIL’E’ forms (lanes 7-10) with incorrectly formed disulphide bonds 
are segregated from predominantly monomeric TRX-His6-TIL’E’ fractions. Monomeric TRX-His6-TIL’E’ 
fractions (lanes 3-6) are collected and subjected to Tobacco Etch Virus (TEV) protease for proteolytic 
cleavage of the TRX-His6 tag, the reaction of which is shown in lane 1 of panel B, where TEV appears 
as a doublet of 21 kDa and the cleaved TRX-His6 tag obscures the TIL’E’ domain (11.3 kDa). A 
schematic of the cleaved construct is shown above the SDS-PAGE in panel B. Cleaved TIL’E’ does not 
bind to the second Ni-NTA column as it does not contain a His6 tag and is retrieved in the flow 
through, concentrated and subsequently applied to a 16/60 Superdex 75 size exclusion column. The 
peak fractions eluting from the size exclusion chromatography (SEC) step are shown in panel B lanes 
3-7 and are numbered in the order in which they elute from the column, as shown in the 
chromatogram in panel C. Pure, monomeric TIL’E’ (11.3 kDa) consistently elutes at 73 mL in a single 
symmetrical peak (peak 7) and migrates as a single band under non-reducing SDS-PAGE as shown in 
panel B lane 7. 
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2.3. TIL’E’ expressed in E. coli is correctly folded and disulphide bonded 
Following purification of monomeric TIL’E’, Ellman’s assay and nanoelectrospray 
ionisation mass spectroscopy (nanoESI-MS) were used to show that TIL’E’ is correctly 
folded and contains no free thiol groups. A compact folded protein is expected to have 
a significantly smaller projected area compared to unstructured protein molecules, 
and would therefore accommodate fewer charges on the protein surface during the 
ion evaporation stage. This phenomenon is reflected in the native nanoESI-MS profile 
of TIL’E’ (Figure 2.7), in which compelling evidence that the TIL’E’ protein is well-folded 
is clearly provided by the very narrow charge-state distribution, centred on the 
[M6H]6+ state. 
 
 
 
 
 
 
 
Figure 2.7: Native nanoESI-MS of recombinantly produced 
1
H
12
C
14
N TIL’E’. The ESI-MS profile of 
TIL’E’ shows a very narrow charge-state distribution as expected for a well-folded protein molecule. 
An unfolded protein would display a far broader charge-state distribution than that shown above, 
due to the accommodation of more positive charges during the ion evaporation stage. The 
experimental mass obtained from this MS is 11318.90  0.12 Da. The calculated mass with eight 
disulphide bonds formed is 11320.19 Da, while with no disulphide bonds the calculated mass would 
be 11336.32 Da. The ESI-MS profile reveals a significantly narrow projected area, as expected for a 
well-folded protein molecule. Mass spectrometry and generation of this figure were kindly 
undertaken by Dr Konstantinos Thalassinos.  
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In addition, a 1D 1H NMR experiment was used to further evaluate the conformational 
properties of TIL’E’; the folded or unfolded (unstructured) state of a protein may be 
rapidly deduced from a 1D 1H NMR spectrum. Within the 1D profile, very sharp methyl 
peaks coupled with a lack of dispersion of the backbone amides (HN) clustered in the 
region of 7-8.5 ppm, suggesting that all HN protons are in a similar (averaged) chemical 
environment, is strongly indicative of an unstructured protein. The 1D spectrum of 
TIL’E’, however, exhibits a broad 1HN chemical shift dispersion, especially downfield of 
8.5 ppm, in addition to isolated methyl group signals below 0.5 ppm, together these 
are sensitive and reliable probes for a folded protein structure (Figure 2.8).    
 
 
 
 
 
To evaluate the conformation of TIL’E’ at a residue level, a 2D 15N-HSQC (heteronuclear 
single quantum coherence) spectrum was recorded of 15N-labelled TIL’E’. An HSQC 
Figure 2.8: 1D 
1
H NMR spectrum of TIL’E’. The spectrum was recorded in 20 mM sodium phosphate, 
100 mM NaCl, pH 7.4, 25C and at 500 MHz. The x-axis represents the chemical shift, a frequency 
scale expressed in parts per million (ppm). Shown are the chemical shift ranges observed for various 
types of 
1
H resonances. An enhanced view of the backbone amide region is shown in the upper left 
and a broad chemical shift dispersion is seen, an area highlighted in grey between 7 ppm and 8.5 
ppm indicates the region in which backbone amide peaks would cluster if TIL’E’ had been 
unstructured. The upper left corner shows the methyl group region, highlighting the distinct methyl 
peaks below 0.5 ppm indicative of a folded protein.  
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experiment correlates each nitrogen atom of an amide to the attached proton, and 
thus the spectrum contains a cross peak for each backbone amide group (1H-15N), 
except proline, for a well behaved protein. Also visible in the HSQC spectrum are the 
NH2 side chain groups of Asn (N2-H2), Gln (N2-H2) and the Trp indole side chains 
(N-H). In essence, a 15N-HSQC spectrum provides an excellent high-resolution 
fingerprint of TIL’E’ (Figure 2.9).  
 
 
 
 
 
In corroboration of the 1D TIL’E’ spectrum (Figure 2.8), the many discrete and 
dispersed peaks of the 15N-HSQC spectrum are indicative of a stable tertiary structure 
(Figure 2.9). Of the 99 residues in TIL’E’, seven are proline, therefore, including a 
Figure 2.9: 2D 
15
N-HSQC NMR spectrum of 
13
C
15
N TIL’E’. The TIL’E’ 
15
N-HSQC spectrum, showing all 
1
H-
15
N (amide group) correlations, was recorded at 600 MHz in 20 mM sodium phosphate, 100 mM 
NaCl, pH 7.4, 25C. A schematic of the magnetisation transfer is shown in the top right corner of the 
spectrum. Most of the peaks are well dispersed, indicating the TIL’E’ protein is well folded. The 
expected single tryptophan side chain N-H group is circled and the asparagine/glutamine side 
chain N-H2/N-H2 groups are boxed in the top right corner. The C-terminus of the protein usually 
gives an intense peak in the bottom left of the spectrum. 79 of the expected 93 peaks (excluding 
seven prolines and including the indole of Trp856) are seen. The absence of a peak may be due 
spectral overlap, loop dynamics or conformational exchange.  
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resonance for the indole 1H-15N of Trp856, 93 1H-15N peaks are expected in the 15N-
HSQC spectrum; however, only 79 peaks are observed. Considered collectively, with 
the inhomogeneous peak intensities observed at inspection of the HSQC spectrum, the 
decreased number of 1H-15N peaks are an initial indication that the folded TIL’E’ 
domains contain flexible and dynamic regions. Furthermore, when all cysteine residues 
are reduced, a starkly different HSQC spectrum is obtained, in which there was 
complete unfolding of TIL’E’ as demonstrated by the significantly reduced 1H-15N peak 
dispersion, ranging between 8 and 8.5 ppm (Figure 2.10, black spectrum); thereby, 
highlighting the folded configuration of the native TIL’E’ molecule (Figure 2.10, red 
spectrum) and the structural importance of the TIL’E’ disulphide bonds in maintaining 
the fold. 
 
 
 
 
Figure 2.10: 2D 
15
N-HSQC spectrum of reduced 
15
N TIL’E’. In red is shown the native spectrum of 
TIL’E’ over which lays the HSQC spectrum of reduced TIL’E’ (black) in 20 mM sodium phosphate, 100 
mM NaCl, 10 mM DTT, pH 7.4. The spectra were recorded at 600 MHz and 25C. Reduction of TIL’E’ 
with 10 mM DTT results in the collapse of the amide signals into the centre of the spectrum 
between 8 and 8.5 ppm. A classic spectrum of an unfolded protein. 
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It is noteworthy, that in contrast to the TIL’E’ molecule (VWF residues 766-864), 
expression and purification of thioredoxin-tagged TIL’ domain alone (residues 766-828) 
revealed that in the absence of E’, it is unstable and cannot achieve a natively folded 
configuration; forming an intermediate that is reminiscent of a molten-globule. In the 
HSQC spectrum of 15N-labelled TIL’, the non-native, but not unfolded state is 
evidenced by the extremely broad and overlapped peaks with an agglomeration of 
signals in a narrow range between 7.8-8.8 ppm (Figure 2.11). This suggests that there is 
substantial conformational exchange and complex dynamic behaviour. A number of 
sharper, dispersed peaks are present at chemical shift values above 8.6 ppm, indicating 
that TIL’ is, to a certain extent, folded (Figure 2.11); unlike the unfolded HSQC 
spectrum of reduced TIL’E’ in which peak dispersion in the 1H dimension are not 
present (Figure 2.10). The dispersed TIL’ peaks do not overlay with any peaks of the 
native folded TIL’E’ HSQC spectrum (Figure 2.9) and therefore, it is not known which 
regions of TIL’ are likely to be folded. The inability of TIL’ to achieve a stable, native 
configuration suggests that the final TIL’ structure cannot be assembled in the absence 
of domain E’, such that there may be cooperativity in folding between the domains.  
 
 
 
Figure 2.11: 2D 
15
N-HSQC spectrum of 
15
N TIL’. The TIL’ 
15
N-HSQC spectrum was recorded at 600 
MHz in 20 mM sodium phosphate, 100 mM NaCl, pH 7.4, 25C. TRX-His6-TIL’ was successfully 
expressed and domain TIL’ (residues 766-828) purified following cleavage of TRX-His6 tags. The 
fingerprint resonances from the amide protons in domain TIL’ are not well dispersed, range 
predominantly from 7.8-8.8 ppm and display significant broadening and overlap. There are a few 
very sharp dispersed peaks, indicating that TIL’ is in a non-native conformation. 
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In summary, recombinantly expressed TIL’E’ is homogeneous, monomeric and contains 
no free thiol groups. It is of the expected molecular mass for an eight-disulphide 
bonded molecule and forms a stable tertiary structure. Furthermore, the formation of 
disulphide isomers when TIL’E’ is expressed in the absence of a thioredoxin tag, 
together with the instability of domain TIL’ when expressed alone, emphasise the 
importance of the continuity of the N-terminal proVWF domains in the correct folding 
and stability of TIL’E’.  
 
2.4. TIL’E’ binds to FVIII and mAb 418 
The paragon of TIL’E’ function is binding to FVIII. This is dependent upon the folded 
TIL’E’ adopting its biologically active conformation. Proteolytic digestion of full length 
VWF with staphylococcus aureus V8 protease and trypsin yields a monomeric, N-
terminal 272 residue fragment, termed SPIII-T4 (VWF residues 764-1035)54,237. The 
FVIII binding site on VWF has been shown to be contained within fragment SPIII-T4, 
comprising domains TIL’E’VWD3. The epitopes of extensively characterised anti-VWF 
antibodies, which block FVIII binding to VWF, have been mapped to residues Leu765-
Arg816237,313 (mAb 418, TIL’), Met814-Ala823314 (mAb 32B12, TIL’) and Cys829-
Gly839314 (mAb 31H3, E’), as shown in Table 2.1.  
Table 2.1: FVIII binding-blocking anti-VWF antibodies  
Monoclonal 
antibody 
Epitope Domain VWF recognition 
mAb 418 765-816 TIL’ Potent inhibitor of VWFFVIII 
interaction, conformation-dependent 
(does not bind reduced VWF)
237,313
 
mAb 32B12 814-823 TIL’ Potent inhibitor of VWFFVIII 
interaction and recognises reduced 
VWF (conformation-independent)
314
 
mAb 522
313
 798-844 TIL’-E’ - 
mAb 31H3 829-839 E’ Moderate (partial) inhibitor of 
VWFFVIII interaction, conformation-
dependent, only recognises non-
reduced VWF
314
. 
MAb W5-6A 841-859 E’ Moderate (partial) inhibitor
340
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The most potent inhibitors of the VWFFVIII interaction, however, localise to domain 
TIL’ (mAb 418 and mAb 32B12), with partial inhibition of FVIII binding achieved by mAb 
31H3 binding to domain E’. This suggests that VWF domain TIL’ forms the principal 
FVIII binding face.   
Dot blot analyses of TIL’E’ with recombinant FVIII were undertaken to validate 
retention of biological activity. Recombinant FVIII was spotted onto a nitrocellulose 
membrane in increasing amounts, from 125 ng to 1 g, and incubated with TRX-His6-
TIL’E’ (0.79 mg/mL); binding of TIL’E’ to immobilised FVIII was subsequently detected 
with anti-His antibodies (Figure 2.12).  
 
 
 
 
 
 
 
Binding of TIL’E’ to the potent FVIII binding-blocking mAb 418313 was also evaluated by 
dot blotting. The epitope of mouse anti-VWF mAb 418 (residues 765-816) 
encompasses the greater majority of domain TIL’ and recognition of TIL’ is sensitive to 
the reduction of VWF cysteines; mAb 418 is thus, a native VWF conformation-
dependent antibody237,313,314,341. TIL’E’ (0.45 mg/mL) was reduced with dithiothreitol 
Figure 2.12: Dot blot analysis of TIL’E’ functionality – binding to FVIII. The experimental blot is 
shown in panel A. Reconstituted, recombinant FVIII (Helixate NextGen 0.25 g/IU) was spotted onto 
a nitrocellulose membrane in increasing amounts of 125 ng, 250 ng, 500 ng and 1 g. The membrane 
was subsequently incubated with blocking buffer containing 0.79 mg/mL TRX-His6-TIL’E’. Binding of 
TRX-His6-TIL’E’ to immobilised FVIII was revealed by ECL chemiluminescence detection of horse 
radish peroxidase (HRP)-conjugated anti-(penta)His antibodies. It is clear that TIL’E’ binds to FVIII. A 
control blot was generated, shown in panel B, which confirms that there is no erroneous binding of 
anti-His5 antibodies to immobilised FVIII. Spotted onto the control blot are a negative BSA control 
(250 ng), FVIII (62.5 ng to 1 g) and FV (29 ng to 230 ng), a structural homologue of FVIII but does 
not bind to VWF. Surprisingly, FV binds directly to anti-His antibody at 57.5 ng, 115 ng and 230 ng, 
although the FV amino acid sequence does not contain three or more consecutive His residues. A 
positive TRX-His6-TIL’E’ control is shown in the bottom left corner of the control blot. 
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and alkylated with an excess of iodoacetamide. Both native TIL’E’, and reduced and 
alkylated TIL’E’ were blotted onto a nitrocellulose membrane in increasing amounts 
from 56.25 ng to 450 ng. The membrane was subsequently incubated with mAb 418 
and binding of mAb 418 to TIL’E’ was detected with a secondary anti-mouse antibody 
(Figure 2.13); mAb 418 binds only to native TIL’E’. 
 
 
 
 
 
 
That TIL’E’ binds to both FVIII and mAb 418 is clearly attested to by dot blotting 
studies, and importantly, reduced and alkylated TIL’E’ does not bind mAb 418 (Figure 
2.13). Together, these results reveal a specific TIL’E’FVIII interaction that is not 
dependent upon glycosylation, and affirms that the recombinantly expressed TIL’E’ is a 
faithful facsimile of these domains in full-length VWF - adopting a biologically active 
native fold, complete with the correct pattern of disulphide bridges. Importantly, 
binding of TIL’E’ to FVIII identifies the minimal VWF domains that form the major FVIII 
binding region and indicate that TIL’E’ may be sufficient to stabilise FVIII survival in 
vivo.  
  
Figure 2.13: Dot blot analysis of TIL’E’ functionality – binding to mAb 418. Cleaved TIL’E’ (0.45 
mg/mL) was reduced with 10 mM dithiothreitol and the TIL’E’ thiol groups were subsequently 
blocked with 30 mM iodoacetamide to prevent their re-oxidation. Native, and reduced and alkylated 
TIL’E’ were spotted onto the nitrocellulose membrane in increasing amounts of 56.25 ng, 112.5 ng, 
225 ng and 450 ng. The membrane was incubated with mAb 418 in blocking buffer and binding of 
mAb 418 to TIL’E’ was revealed by ECL detection of secondary HRP-conjugated anti-mouse antibody. 
mAb 418 binds to native TIL’E’ but not to reduced and alkylated TIL’E’.  
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2.5. Resonance assignment of TIL’E’ backbone atoms 
Once it had been established that the recombinantly produced TIL’E’ is both correctly 
folded and functional, the chemical shifts of the TIL’E’ nuclei were assigned by 
standard triple-resonance experiments (Table 2.2).  
Table 2.2: Triple resonance experiments used for sequential backbone assignment
342
. 
Experiment Correlations observed Magnetisation transfer 
HNCO 1H
N
i  
15
Ni  
13
COi1 
 
 
 
HN(CA)CO 1H
N
i  
15
Ni  
13
COi 
1
H
N
i  
15
Ni  
13
COi1 
 
 
HN(CO)CA 1H
N
i  
15
Ni  
13
Ci1 
 
 
 
HNCA 1H
N
i  
15
Ni  
13
Ci 
1
H
N
i  
15
Ni  
13
Ci1 
 
 
HNCACB 13Ci/
13
Ci  
15
Ni  
1
H
N
i 
13
Ci1/
13
Ci1  
15
Ni  
1
H
N
i 
 
 
The experiments outlined in Table 2.2 are used in the initial stage of any protein 
investigation by NMR spectroscopy, to make connections between 1H, 13C and 15N 
nuclei. The patterns of connections are then mapped onto the protein sequence to 
assign all resonances belonging to each amino acid residue. The nuclear spins attached 
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to each of the TIL’E’ 1H-15N resonances observed in the 15N-HSQC (Figure 2.9) were 
subsequently identified in the HNCO, HN(CA)CO, HN(CO)CA, HNCA and HNCACB 
spectra, to obtain an assignment of TIL’E’ backbone atoms (Table 2.2). These standard 
triple-resonance experiments correlate each 1H-15N amide group with the 13CO, 13C 
and 13C of its own residue (i), and with that of the preceding residue (i1), thereby 
permitting the assignment of individual spin systems (nuclear spins from a single 
residue), which are then correlated to a specific amino acid in the TIL’E’ sequence 
(Figure 2.14). 
 
 
 
 
Identification of the nuclear spins attached to each 1H-15N resonance in the 15N-HSQC 
spectrum facilitates their sequential connectivity, such that the carboni (
13CO, 13C and 
13C) chemical shift of one residue is aligned to the carboni1 (
13CO, 13C and 13C) shift 
of the following residue in the TIL’E’ sequence, and henceforth (Figure 2.15). These 
Figure 2.14: Correlation of a single spin system. Cys792 
1
H-
15
N (designated i) resonance from the 
assigned 
15
N-HSQC spectrum is linked to its i-1 (Thr791) 
13
CO resonance in the HNCO and then to its 
own CO shift in the HN(CA)CO spectrum. The Cys792 C and Thr791 C are similarly linked in the 
HN(CO)CA and HNCA spectra as shown. Thus, the COi, COi-1, Ci and Ci-1 resonances of Cys792 are 
known. The intra-residue peak is often of greater intensity than the inter-residue peak, aiding 
assignment. 
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patterns of connections were subsequently mapped onto the TIL’E’ amino acid 
sequence to specifically assign a spin system to each residue. This procedure is greatly 
assisted by the distinct C and C chemical shifts of glycine (C45.38), isoleucine 
(C61.62 ppm), proline (C63.32 ppm), valine (C62.53 ppm), alanine (C19.07 
ppm), serine (C63.72 ppm) and threonine (C69.61 ppm)343.  
 
   
 
In this manner, 78% of the TIL’E’ 1HN, 13C and 15N backbone nuclei were assigned, 
whereby the missing resonances are contributed to by seven proline residues (Pro769, 
Pro770, Pro777, Pro811, Pro812, Pro828 and Pro838), and the remaining unassigned 
nuclei reside predominantly in the TIL’ region between residues 781 and 805 (Figure 
2.16).  
Figure 2.15: Sequential TIL’E’ backbone walk. Shown are strips from the 3D HNCACB spectrum, 
illustrating the sequential linkage of 
13
C atoms. The connectivity from Ci to Ci-1 to Ci in the 
preceding residue’s strip are indicated to sequentially link spin systems.  
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The assigned 15N-HSQC spectrum (Figure 2.17, upper panel) enabled a more detailed 
analysis of the peak intensity inhomogeneity that was observed on initial inspection 
following TIL’E’ HSQC spectral acquisition. It appears that the effect of peak 
broadening is primarily confined to resonances assigned to domain TIL’, in particular at 
positions Cys767, Ala778, Asn780, Ala783, Cys810, Asn819, Gly833 and Cys846 (Figure 
2.17, lower panel). This indicates that TIL’ is undergoing chemical exchange between 
different conformations, and is consistent with missing resonances in the 15N-HSQC 
spectrum (79 peaks observed of the 93 expected) and the location of unassigned 
backbone residues in the TIL’E’ sequence (Figure 2.16).  
Figure 2.16: Assigned TIL’E’ 
1
H, 
13
C and 
15
N backbone nuclei. The TIL’E’ construct is composed of 103 
residues, of which the N-terminal four amino acids, shown boxed, constitute cloning artefacts 
(GAMG). The VWF sequence begins at the fifth residue corresponding to Ser766 and ends at Asp864. 
The backbone 
1
H
N
, 
13
C (CO, C C) and 
15
N chemical shifts of VWF residues that have been assigned 
are highlighted in red. Proline residues are highlighted in grey. Unassigned residues are 
predominantly found between residues 781 and 805 of domain TIL’.  
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Figure 2.17: Assigned 
15
N-HSQC NMR spectrum of 
13
C
15
N TIL’E’ and peak intensity analysis. The 
assigned 
15
N-HSQC spectrum recorded at 600 MHz in 20 mM sodium phosphate, 100 mM NaCl, pH 
7.4, 25C is shown in the upper panel. A near complete backbone assignment of 
1
H-
15
N resonances is 
achieved. Of the 79 peaks observed, 77 backbone amides and the indole of Trp856 are assigned. A 
single unassigned peak in the centre of the spectrum is indicated by *. Side chain NH2 groups of Asn 
and Gln residues are assigned and connected with grey bars. There are broad peaks with lower 
intensity seen in the spectrum, the plot in the lower panel confines the peak intensity heterogeneity 
to domain TIL’, in particular to residues Cys767, Ala778, Asn780, Ala783, Cys810, Asn819, Gly833 and 
Cys846 (circled) and this is highly suggestive of conformational exchange in at least one region of 
TIL’. The intense C-terminal peak of Asp864 has been omitted from the plot for clarity.  
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2.6. TIL’E’ backbone chemical shifts predict secondary structure, dynamics and 
oxidation state of cysteine residues 
Assignment of TIL’E’ backbone atoms permitted a preliminary assessment of the 
secondary structure elements and conformational flexibility of TIL’E’. NMR chemical 
shifts of backbone nuclei depend on the secondary structure of the individual residues. 
This allows accurate mapping of protein backbone order based on the observation that 
random coil chemical shifts are characteristic of highly flexible regions, whereas non-
random coil shifts are commonly found in rigid areas of protein structures. Therefore, 
the TIL’E’ backbone shifts were used to provide an initial indication of TIL’E’ secondary 
structure and of backbone flexibility, as given by the random coil index (RCI) derived 
order parameter, S2, which describes the amount of local mobility. Extreme RCI-S2 
values of 1 and 0 correspond to fully restricted and unconstrained internal motion of 
the backbone, respectively344–346 (Figure 2.18).  
TIL’ is less structured and more dynamic than domain E’. The unassigned TIL’E’ 
backbone nuclei (residues 781 to 805) cluster in unstructured loop regions, to the 
greatest extent between predicted strands 1 and 2 of domain TIL’ (Figure 2.18, 
upper panel). This region is coincident with low RCI-derived order parameters 
indicating a dynamically disordered loop, that is significantly more flexible than the 
remainder of TIL’E’ (Figure 2.18). The peak broadening, observed for residues Cys767, 
Ala778, Asn780, Ala783, Cys810, Asn818 in TIL’ and Gly833 and Cys846 in E’ (Figure 
2.17), is accounted for by their position in predicted loop regions, of which Ala778, 
Asn780 and Ala783, occur in the 1-to-2 loop of domain TIL’ (Figure 2.18, lower 
panel). Furthermore, broader peaks were largely found in domain TIL’ and this is 
consistent with this domain exhibiting a greater degree of backbone flexibility. 
97 
 
 
 
 
 
 
 
 
In addition to secondary structure and backbone flexibility predictions, the backbone 
chemical shifts were used to ascertain the redox state of cysteine residues. C 
chemical shifts of the assigned Cys residues provided further evidence that the sixteen 
cysteine residues of TIL’E’ are oxidised and engaged in disulphide bonds. A database of 
cysteine 13C C and C shifts, constructed from published NMR structures, revealed 
Figure 2.18: Secondary structure and order parameter predictions of TIL’E’. The backbone 
1
H, 
13
C 
and 
15
N chemical shifts that have been assigned are highlighted in red. Proline residues are 
highlighted in grey. The secondary structure of TIL’E’ is shown above the sequence; in grey are the 
predicted secondary structure elements (arrow, -strand; wave, -helix) from the backbone 
chemical shifts, and in black are shown the experimentally derived secondary structure elements 
from the high resolution solution structure of TIL’E’. Unassigned residues and residues that exhibit 
peak broadening are found in loop regions. The bottom panel shows the random coil index (RCI) 
derived order parameter (S
2
) prediction
345
, and in the plot is shown the TIL’E’ predicted secondary 
structure for clarity. An RCI-S
2
 value of 0 indicates completely unrestricted motion, whereas an RCI-
S
2
 value of 1 indicates rigidity. Dynamic residues are taken to be those with an order parameter 
value less than 0.6. The loop between predicted strands 1 and 2 of the TIL’ domain is significantly 
more dynamic than the remainder of the molecule.  
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that reduced and oxidised cysteines have characteristic chemical shifts347. The 13C 
chemical shifts of reduced and oxidised cysteine range narrowly from 50.5 ppm to 65.6 
ppm, and hence, exhibit considerable overlap; whereas, the 13C shifts of reduced and 
oxidised cysteine span a wider range (23.8 to 50.9 ppm), and clearly fall into two 
distinct clusters347 (Figure 2.19). Therefore, 13C chemical shifts are diagnostic of 
disulphide bond formation and can discriminate between cysteine residues in the 
reduced and oxidised state. The observed C shift for oxidised cysteine is 40.7  3.8 
ppm, and for reduced cysteine is 28.4  2.4 ppm, and is thus, capable of defining the 
Cys residue redox state (Reduced  32.0 ppm; oxidised  35.0 ppm)347.  
The C shifts of all cysteines assigned in TIL’E’ (Cys776, 40.1 ppm; Cys792, 36.3 ppm; 
Cys804, 38.6 ppm; Cys808, 41.3 ppm; Cys810, 36.6 ppm; Cys821, 40.9 ppm; Cys827, 
37.2 ppm; Cys829, 42.4 ppm; Cys846, 37.8 ppm; Cys849, 50.5 ppm; Cys851, 36.9 ppm; 
Cys858, 47.9 ppm; Cys863, 37.6 ppm) are indicative of oxidised Cys residues (Figure 
2.19). Of the remaining three cysteines, the signal from N-terminally placed Cys767 is 
very weak, which prevented assignment of its C/C shifts; Cys788 and Cys799 are 
predicted to participate in a 3-5 linkage in an unstructured region, and remain 
unassigned (Figure 2.18). The C shifts of cysteine residues may also be correlated with 
secondary structure, such that the mean chemical shift for an oxidised cysteine in a -
strand is 43.0 ppm (range: 35.9-50.9 ppm; median: 43.2 ppm)347; the chemical shifts of 
cysteines Cys808, Cys821, Cys829, Cys849, Cys851 and Cys858, support their predicted 
secondary structure assignment to -strands (Figure 2.18, upper panel).  
In summary, 78% of TIL’E’ backbone atoms have been assigned. Unassigned residues 
and residues exhibiting peak broadening are predominately localised to flexible loop 
regions in domain TIL’. Importantly, the full formation of eight disulphide bonds in 
TIL’E’ is further supported by their Cys residue 13C chemical shifts.   
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2.7. Assignment of TIL’E’ side chain atoms 
The accuracy of the calculated NMR structure is dependent upon a near complete 
assignment of all atoms in the TIL’E’ molecule; this ensures that the subsequently 
derived structural restraints reflect maximal coverage of the molecule. Accordingly, 
the resonances of aliphatic and aromatic side chain 1H and 13C nuclei were assigned 
using TOCSY (total correlation)-based experiments, CC(CO)NH-TOCSY, HCC(CO)NH-
TOCSY, HCCH-TOCSY, which correlate every intra-residue 1H or 13C distal to the  
position down the amino acid chain (Figure 2.20).   
Figure 2.19: Distribution of cysteine C chemical shifts as a function of redox state. Shown is the 
distribution plot of C chemical shifts, as derived by Sharma et al
347
. The C chemical shifts of 
reduced (grey bars) and oxidised (red bars) cysteine fall in two distinct domains, but overlap in a 
narrow range of 33.0 ppm to 34.0 ppm
347
. These shifts however, are also clustered as a function of 
secondary structure. The mean C shifts of oxidised and reduced cysteine in a -sheet are 43.0 ppm 
and 29.7 ppm, respectively. The positions of TIL’E’ cysteine C shifts, in relation to this distribution 
plot, are shown. They are strongly indicative of oxidised cysteine residues.  
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The amide side chains of Asn and Gln residues, methyl groups of Met and the 
diastereotopic methyl groups of Val and Leu, were also assigned. Assignment of Val 
and Leu methyl groups greatly improves the precision and accuracy of structure 
determination, as these groups are involved in numerous identifiable inter-residue and 
long range contacts348, and were used as restraints in the subsequent structure 
calculation of TIL’E’. The unambiguous assignment of prochiral methyl groups in valine 
and leucine, by the elegant method of fractional labelling349, is based on the premise 
that biosynthesis of these residues from glucose is stereoselective. Biosynthetic 
fractionally labelled TIL’E’ was obtained by growing E. coli in minimal media containing 
10% 13C-D-glucose and 90% unlabelled glucose as the sole carbon source. The carbon 
positions in these preparations are 13C labelled to an extent of 10%. Disregarding the 
natural 13C abundance of 1.1% in the unlabelled glucose, the probability that two 
adjacent carbon positions are labelled in the same molecule is then 1%, unless the two 
carbon atoms originate from the same carbon source molecule so that this probability 
becomes 10%349. These two distinct situations prevail for the isopropyl group of valine 
and leucine (Figure 2.21). 
Figure 2.20: 3D HCCH-TOCSY assignment of Ile844 side chain protons. In the HCCH-TOCSY 
experiment magnetisation is transferred from the side chain hydrogen nuclei to their attached 
13
C 
nuclei. This is followed by isotropic 
13
C mixing and finally transfer back to the side chain hydrogen 
atoms for detection. This spectrum yields strips at each carbon frequency in the side chain in which 
all side chain hydrogen (proton) resonances are visible. Thus, in each CH strip, all the hydrogen 
atoms attached to all other carbon atoms in the same chain are observed, as shown for Ile844. 
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The Pro-R methyl carbon (C1 in Val and C1 in Leu) derives from the same pyruvate as 
the adjacent branching methine carbon (-CH) and are, in the absence of isotope 
scrambling, labelled with 13C in the same molecule, while the Pro-S methyl carbon (C2 
in Val and the C2 in Leu) and the adjacent carbon originate from two different 
pyruvate molecules (Figure 2.21). Therefore, if the pro-S methyl group is enriched with 
13C, there is a probability of only 1% that the adjacent –CH group in the same molecule 
is also labelled. Consequently, the valine and leucine methyl groups of fractionally 
labelled TIL’E’ were readily identified in a constant time 13C-HSQC spectrum, in which 
Figure 2.21: Stereoselective biosynthesis of valine and leucine. Reaction pathways for the 
biosynthesis of valine and leucine from a mixture of fully 
13
C-labelled and unlabelled glucose 
showing the stereochemistry and the principal labelling patterns
349
. This methyl migration is 
stereoselective, and the migrating methyl group becomes the Pro-S in valine and leucine, 
2
CH3 and 

2
CH3, respectively
349
. A red carbon indicates a 
13
C label, and a black carbon indicates the natural 
13
C 
abundance of 1.1%.  
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the C1 and C1 methyl group (pro-R) peaks appear with opposite sign (-ve), as they 
have an even number of directly bonded 13C atoms, to the C2 and C2 methyl groups 
(pro-S).  
A total TIL’E’ atom assignment of 88.9% was achieved (Figure 2.22). Unassigned atoms 
correspond to residues in unstructured regions of TIL’E’, with the exception of Lys773 
in domain TIL’, and Phe830, Tyr836 and Cys858 in E’ that are in -strands (Table 2.3). 
 
 
 
Figure 2.22: CT 
13
C-HSQC spectrum showing the 
13
C-
1
H chemical shift assignments of TIL’E’. This 
spectrum is the carbon equivalent of the 
15
N-HSQC spectrum. In the constant time (CT) 
13
C-HSQC all 
13
C-
1
H correlations are observed. The assigned C region is shown and 88.9% of all TIL’E’ resonances 
have been assigned. Peaks appear with opposite sign to the 
13
C-
1
H peaks if they have an even 
number of directly bonded aliphatic carbons.  
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Table 2.3: Unassigned TIL’E’ protons. Q denotes diastereotopic groups. 
Amino acid Unassigned protons 
Ser766 HN H Q 
Cys767 H Q 
Arg768 HN H Q Q Q 
Pro769 Q 
Lys773 Q Q 
Leu781 HN H 
Gly785 HN Q 
Leu786 HN 
Glu787 H Q Q 
Cys788 HN H Q 
Thr789 HN H Q 
Lys790 Q 
Tyr795 H2 H2 
Cys799 HN H Q 
Met800 HN Q 
Met802 HN Q Q 
Val805 HN 
Pro811 H Q Q Q 
Pro812 H Q Q Q 
Gly813 HN 
Phe830 H2 H2 
Gln832 HN 
Tyr836 H2 H2 
Gly845 HN 
Cys858 HN 
 
 
2.8. NOE distance restraints 
Following extensive assignment of nearly all backbone and side chain resonances in 
TIL’E’ (Appendix 5.2), 108 backbone dihedral angle restraints ( and ) were calculated 
from 15N, 1HN, 13CO, 13C, and 13C backbone chemical shifts using the programme 
TALOS+345 and NOE (nuclear Overhauser enhancement)-based experiments for the 
extraction of distance restraints were analysed. The most important NMR-observable 
parameter used in determining protein structure is the NOE. Unlike the triple-
resonance experiments used to assign the TIL’E’ backbone chemical shifts, whereby 
magnetisation is transferred from one nucleus to another directly through bonds 
connecting atoms, the NOE is a measurement of ‘through-space’ interactions between 
atoms that are spatially close. The NOE peak intensity is proportional to the inverse 
sixth power of the distance between two interacting 1H nuclei, hence the r-6 
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dependence permits the detection of NOEs only between protons within a 6 Å 
distance342. 13C- and 15N-edited NOESY experiments were used for the measurement of 
NOEs, which are correlated with inter-nuclear 1H-1H distances of assigned resonances, 
and in turn, used as distance constraints in structural calculations to determine the 
TIL’E’ fold (Figure 2.23). 
 
 
 
 
A total of 954 unique inter-residue distance restraints were unambiguously identified 
using an iterative strategy, in which successive cycles of structure calculations included 
an increasing number of inter-residue NOE restraints; this method permitted the 
resolution of NOE ambiguities and assignment of additional NOEs by reference to a 
preliminary TIL’E’ structure model. NOE restraints that were not collaterally supported 
by other NOEs to residues in proximal vicinity, were discarded to avoid propagating 
errors that may influence assignment of other NOEs, or worse, restrain an incorrect 
fold. The steps from assignment to structure and error analysis were performed in a 
repetitious manner until an optimised data set was obtained, from which the final 
Figure 2.23: NOEs as structural restraints. Shown are NOESY spectra strips from 
15
N-edited NOESY 
and 
13
C-edited NOESY experiments. Each strip in a 
15
N-edited NOESY contains NOEs from one 
1
H-
15
N 
amide group to all other hydrogen atoms in its proximity, whereas in the 
13
C-edited NOESY, each 
strip contains NOEs from one –CH group to all other hydrogens nearby. Examples of assigned NOE 
peaks to a neighbouring residue (Gly833 to Lys844; E’), across a -sheet (Thr841 to Val850; E’ 3 to 
4) and across disulphide bond NOE (Cys849 H to Cys858 H; E’ 3-5 linkage) are given. 
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TIL’E’ structure models were calculated. Of the unique NOE distance restraints used in 
the final structure calculation, all of which were assigned in all three dimensions, 353 
are long-range, distances between hydrogen nuclei that are more than five residues 
apart in the primary sequence; 97 are medium range, sequence separation of four to 
five residues; 121 are short-range, sequence separation of two to three residues; and 
383 NOE restraints are between sequential residues. NOEs obtained for each residue 
are summarised in Figure 2.24. Overall there is good NOE coverage of the TIL’E’ 
molecule; however, there is a greater degree of NOE density in domain E’ that is most 
likely due to both the localisation of unassigned residues to TIL’ and its predicted 
flexibility, giving rise to broader and weaker signals that cannot be unambiguously 
assigned.  
 
 
 
 
 
 
Figure 2.24: Assigned NOEs per residue of TIL’E’. The number of sequential NOEs (black), short-
range NOEs (brown; sequence separation of two to three residues), medium range NOEs (grey; 
sequence separation of four to five residues) and long range NOEs (red; sequence separation of 
more than five residues) are plotted against TIL’E’ residues. There is a greater degree of NOE density 
in domain E’ (aa 829-863) than in TIL’ (aa 767-827).  
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2.9. NOE-based confirmation of TIL’E’ disulphide bond topology 
Formation of a disulphide bond demands the close proximity of sulphur atoms (2.03 
Å), an angle between the disulphide and the -carbon (C-S) that is close to 103, and 
that the two -carbons are orientated to correspond to a rotation close to either 90 
or 90 about the disulphide bond336,350. A disulphide bond is the only molecular 
interaction that imposes such stringent stereochemical requirements on a protein, and 
with respect to structure determination in solution state NMR spectroscopy, the 
correct identification of disulphide bonds constitutes a powerful conformational 
constraint, that considerably restricts the structural space available336. The NMR active 
isotope of sulphur (33S) has highly unfavourable magnetic properties351, making the 
unequivocal establishment of disulphide bond connectivity by NMR alone difficult, 
particularly in unstructured regions of a protein; however, the multipronged approach 
used here, supported by biochemical data, has obviated this difficulty.  
The designations of NOESY cross peaks between side chain -protons of two Cys 
residues were used to infer that they are covalently connected by a disulphide linkage. 
This is a reasonable assumption, since the distance between the C atoms of a bonded 
Cys pair ranges from 3.5 Å to 4.3 Å, with a mean of 3.8 Å352–354, and consequently the 
inter-residue distance between the pair of -protons in a disulphide bond will always 
be less than the NOE upper limit (6 Å)351. The mean distance between the C atoms 
of Cys residues in a disulphide bond is 5.63 Å321,354,355, and approaches the limit for 
NOE detection, however some NOEs are seen between the -protons of Cys residues 
in a disulphide bond, such as between Cys849-Cys858 (Figure 2.23 and Table 2.4). Up 
to four -proton NOE peaks may be observed between the two Cys residues in a pair, 
and up to four NOEs between the -proton of one Cys and the -proton of its partner 
Cys residue (for both  carbons). Five disulphide bonded cysteines were investigated 
and at least four NOE cross peaks were found across each linkage; furthermore, there 
were no ‘antidiagnostic’ NOEs between Cys HN and Cys H of its partner residue, which 
would strongly indicate the absence of a disulphide bond356 (Figure 2.25 and Table 
2.4).  
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            Table 2.4: Summary of NOEs observed between coupled cysteines.  indicates a unique NOE. 
Disulphide bond Domain connectivity H-H H-H H-H H
N
-H 
767-808 TIL’: 1-7 - - - - 
776-804 TIL’: 2-6     
788-799 TIL’: 3-5 - - - - 
792-827 TIL’: 4-10     
810-821 TIL’: 8-9 - - - - 
829-581 E’: 1-4     
846-863 E’: 2-6     
849-858 E’: 3-5     
 
Of the three remaining TIL’ Cys pairings (Cys767-Cys808, Cys788-Cys799 and Cys810-
Cys821): the N-terminal Cys767 (1-7 linkage) and cysteines 788 and 799 (3-5 linkage) 
are unassigned (Table 2.3). Lastly, no observable NOEs were found across the assigned 
Cys810-Cys821 residues (8-9 linkage). A disulphide bonding pattern other than that 
which was predicted, is excluded by the absence of NOEs between non-paired cysteine 
residues, supporting the unequivocal inference that the TIL’E’ model is of the correct 
fold. It is important to note, that six NOE peaks across the homology-predicted Cys846-
Cys863 disulphide bond in domain E’ confirms their covalent linkage in a 2-6 
configuration (Figure 2.25). A disulphide bond is composed of six atoms linking the two 
-carbon atoms of the cysteine residues; C-C-S-S’-C’-C’. These atoms define five 
 angles that can be either positive or negative, resulting in twenty possible disulphide 
bond configurations355. However, because disulphide bonds exist in different 
conformations in the various NMR models357, this precluded their finer 
characterisation in TIL’E’, based upon bond geometry355,358. 
Further confirmation of the validity of the Cys pairings was afforded by the observation 
that structure calculations performed with inclusion and exclusion of the eight 
disulphide bond constraints was achieved without perturbation to the global TIL’E’ 
fold. In particular, when disulphide bond constraints were excluded, all predicted 
cysteine pairs lay in close proximity in the TIL’E’ structure, with the exception of bond 
Cys788-Cys799 (3-5 linkage) and to some extent bond Cys776-Cys804 (2-6 linkage) in 
domain TIL’ 1-to-2 loop, that were heterogeneous and poorly defined. Furthermore, 
all C atoms were closer to the C atom of a partner Cys residue than to another Cys 
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C in spatial proximity, thereby eliminating connectivity ambiguities for disulphide 
bonds Cys792-Cys827 (linkage 4-10 of TIL’) and all three Cys-Cys pairings in E’, that 
have been predicted but not biochemically assigned. In accordance with the preceding 
observations, all disulphide bonds were included as constraints in subsequent 
structure calculations.  
 
 
 
 
2.10. RDC orientational restraints 
In complement to NOEs, 361 vector-orientation restraints were also collected by 
means of residual dipolar couplings (RDCs). Orientation-dependent magnetic 
interactions (dipolar couplings) between atomic nuclei in isotropic solution conditions 
average to exactly zero as a result of Brownian rotational diffusion, where the inter-
nuclear vector samples all possible orientations with equal probability. However, 
under anisotropic conditions, when a very slight deviation from the random 
distribution of macromolecules in solution is imposed (such as in a liquid crystal), not 
all molecular orientations are equiprobable, the molecule will thus have a preferential 
Figure 2.25: Across disulphide bond NOEs. Stick representation of the disulphide bonded TIL’E’ 
cysteine pairs, showing across disulphide bond NOEs. The  carbons and sulphur atoms are coloured 
in gold. NOEs between H and H atoms are depicted by dotted lines for Cys776-Cys804 (TIL’), 
Cys792-Cys827 (TIL’), Cys829-Cys851 (E’), Cys849-Cys858 (E’) and Cys846-Cys863 (E’).  
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orientation. In this case, the dipolar coupling does not average to zero and a residual 
fraction of the coupling survives (Figure 2.26). RDC interactions are very sensitive 
measures of the orientation of the corresponding inter-nuclear vectors, and thereby 
offer highly precise structural information359,360. In contrast to the short-range, local 
distance restraints derived from NOEs, RDCs provide global distance-independent 
orientational restraints361.  
 
 
 
 
 
 
 
 
Although RDCs, impose tight restrictions on the orientation of the corresponding inter-
nuclear vector, there results degeneracy in orientation, that is the inability to 
distinguish an isolated vector orientation from its inverse. Thus, multiple RDCs were 
measured within the peptide plane and in different alignment media to alleviate 
degeneracy360,362. Seven sets of RDCs were measured in a poly(ethyleneglycol)/hexanol 
mixture (that orientates the TIL’E’ molecules by steric interactions); 1HNi-
15Ni, 
15Ni-
13COi-
Figure 2.26: Extracting residual dipolar couplings. On the left is shown a schematic of a procedure 
for extracting 
1
H
N
i-
15
Ni couplings (J) under isotropic conditions from an IPAP (In phase/anti phase) 
15
N-HSQC experiment, in which the dipolar couplings (D) average to zero. The 
1
H-
15
N coupling is 
allowed to evolve during the 
15
N indirect chemical shift evolution period, leading to doublets for 
each backbone amide in the resulting spectrum. To prevent the increased spectral crowding due to 
doubling of peaks, two subspectra are recorded in which the splitting is either in phase or anti phase. 
Subsequent addition and subtraction of the subspectra gives rise to two further subspectra 
containing only the upfield or downfield component. The J coupling is then simply extracted by 
measuring the chemical shift difference between the upfield and downfield components for each 
amide. Subsequent repeat measurement under aligned conditions yields splittings that are the sum 
of the coupling constant (J) and the dipolar coupling (D), J+D. The RDC is then calculated by taking 
the difference between the isotropic coupling (J) and the partially aligned anisotropic splittings (J+D), 
to give the magnitude of the RDC (D). Beside the peptide backbone are shown the coupling 
constants (J) from which the effect of the residual dipolar coupling is calculated.  
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1, 
1HNi-
13COi-1, 
13COi-
13Ci, 
1HNi-
13Ci-1, in the TIL’E’ backbone peptide plane; and 
13Ci-
1Hi and 
13Ci-
13Ci, at the junction of the peptide plane. 
1HNi-
15Ni RDC measurements 
were also repeated in filamentous phage, Pf1, that induces alignment of TIL’E’ 
molecules by electrostatic interactions. It is of interest to note that Pf1 phage has a 
negatively charged surface and preparation of a weakly Pf1 aligned TIL’E’ sample 
proved difficult due to a strong interaction of TIL’E’ with the bacteriophage molecules; 
suggesting the presence of a positively charged region on TIL’E’.  
RDC restraints were used to refine the orientations of the individual bond vectors, this 
improved both the -sheet arrangement and precision of the overall TIL’E’ structure. 
The orientational dependence of RDCs was also exploited to determine the relative 
orientation of domain TIL’ with respect to E’, as knowledge of the geometry of subunit 
assembly is critical to understanding the interface formed by TIL’E’ in VWFFVIII 
complex formation. Amino acid residues undergoing significant internal dynamics (as 
distinguished by their heteronuclear 1[H]-15N-NOE value; section 2.13) were excluded 
from the analysis. The quality of the RDC-refined TIL’E’ structure was evaluated by 
comparison of back calculated RDCs from the lowest energy model against the 
experimentally derived RDC data, using the programme Module 1.0363. The resulting 
fits are of good quality for the greater proportion of RDCs measured; the high 
correlation is also graphically visible in Figure 2.27. Of note, where an increased scatter 
is observed in the plots (Figure 2.27), this is reflective of an increased relative error in 
the experimentally derived RDCs, due to the decreased magnitude of the measured 
RDC. The plots indicate that all RDC restraints are very close to being fulfilled and the 
RDC-refined TIL’E’ model is an excellent representation of the molecule in solution. 
The correlation between the back-calculated RDCs and experimentally derived 1HNi-
13Ci-1 RDCs, however, is very poor. This can be reasoned to the very small dipolar 
couplings of only 0-1 Hz, from which it is difficult to derive an accurate RDC 
measurement (Figure 2.26), and is not the result of an incorrect TIL’E’ model, as a 
single template was used for the back-calculation of all RDC measurements (Figure 
2.27).  
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Figure 2.27: Correlation between experimental RDCs and back-calculated RDCs. Shown are 
correlation plots of the experimentally derived RDCs against those obtained from the RDC-refined 
final solution structure of TIL’E’. A single template TIL’E’ structure was used for all calculations. The 
agreement is quite good, for most RDCs measured, with the exception of 
1
H
N
-
13
C RDCs. The 
squared of the correlation coefficient (R
2
), a measure of the goodness of fit of the trend line, is 
shown in the corner of each plot. Data for Pf1 aligned TIL’E’ is not shown.  
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2.11. High resolution structure of VWF TIL’E’ 
The final high resolution solution structure of TIL’E’ was calculated based upon the 
following experimental NMR restraints; 954 NOEs, 361 RDCs, 108 backbone dihedral 
angles and eight disulphide bonds, using the programme CYANA 3.0364. From the final 
set of calculations a family of the ten lowest energy structures was chosen to 
represent the solution conformation of VWF TIL’E’. The lowest energy solution 
structure of VWF TIL’E’ (D’ region) is shown in Figure 2.28.  
The global fold of TIL’E’ is crescent-shaped; this is consistent with the overall domain 
shape seen in low resolution electron microscopy imaging140. The structure clearly 
shows that TIL’ and E’ form independently folding domains and the domain assignment 
separating D’ into two distinct domains is demonstrably correct.  
Salient features of domain TIL’ (aa 767-827) are the restricted regions of secondary 
structure ( 84% loop, 16% -strand) and lack of a notable hydrophobic core. Five 
conserved disulphide bonds constitute the major stabilising force constraining the fold, 
as is typical for small disulphide-enhanced domains321,329. The heart-shaped TIL’ (length 
35 Å, width 20 Å) is formed of two almost perpendicular -sheets, 1:2 (aa 772-
775:806-809) and 3:4 (aa 814-817:820-823) that form a scaffold bearing a long 30 
residue loop, the 1-to-2 loop (Figure 2.28). This dominating loop (aa 776-805) 
connects strands 1 and 2 and encompasses an eight residue insertion between the 
second and third conserved TIL family cysteines (Figure 2.2), that creates an apex in 
the VWF TIL’ structure, the apical 1-to-2 loop (Figure 2.28). 
The second antiparallel -sheet, formed by strands 3 and 4, are connected by a 
reverse turn forming a small hairpin structure. There is a single turn of a 310-helix (aa 
824-826), with characteristic dHN(i, i+2) NOEs, at the extreme N-terminus of TIL’ that 
carries forth into domain E’. Solvent accessible surface calculations, determined by the 
Ooi number365, fail to identify a hydrophobic core and the TIL’ disulphide bonds act as 
architectural cross-braces reinforcing and stabilising the tertiary structure. Bridge 
Cys1767-Cys7808, orientates the N-terminus with respect to strand 2 and imposes 
constraints on its conformation, bridges Cys2776-Cys6804 and Cys3788-Cys5799 
stabilise the 1-to-2 loop that is anchored to the TIL’ C-terminus by bridge Cys4792-
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Cys10827, and lastly, bridge Cys8810-Cys9821 serves to orient the two antiparallel -
sheets with respect to one another (Figure 2.28). 
 
 
 
 
 
 
In well-defined contrast, the greater proportion of domain E’ (aa 829-863) is formed of 
a triple-stranded all anti-parallel -sheet; strands 3, 4 and 5 (length, 25 Å; width, 
10 Å). The disulphide bond connectivity was unambiguously assigned as Cys1829-
Cys4851, Cys2846-Cys6863 and Cys3849-Cys5858. The N-terminus of E’ contains a short 
double stranded -sheet, formed of strands 1 (aa 829-831) and 2 (aa 834-836), that 
is orientated with respect to strand 3 (aa 839-844) by the Cys829-Cys851 disulphide 
bond. Bridge Cys3849-Cys5858 retains strands 4 (aa 847-852) and 5 (aa 855-858), 
Figure 2.28: High resolution solution structure of VWF TIL’E’. A ribbon diagram of the lowest energy 
solution structure of TIL’E’ is shown. Two orientations are presented for clarity of appearance of the 
individual domains; TIL’ is dominant on the left and E’ is dominant on the right. Stick representations 
of disulphide bonds are coloured gold and their respective cysteines labelled. -sheets are 
numbered in the order in which they occur in the individual domains. Regions of the long TIL’ 1-to-
2 loop are designated descending or apical for ease of orientation.  
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which are collaterally supported by Cys1829-Cys4851 and Cys2846-Cys6863 (Figure 
2.28). 
The difference between the molecular surface area of the individual TIL’ and E’ 
domains (6,601  Å2 and 3,977 Å2, respectively) and that of the TIL’E’ molecule (10,879 
Å2) is only 301 Å2, indicating that there is minimal interaction between the two 
domains; this is further supported by the lack of inter-domain NOEs. The extension of 
domain E’, away from TIL’, is likely due to the one residue linker, Pro828, between the 
Cys boundaries of TIL’ and E’. This proline, together with the lack of a significant linking 
loop, may impart rigidity that maintains the relative orientation of the two domains. 
Although molecule TIL’E’ lacks a definitive hydrophobic core and the residues are 
predominantly solvent exposed, there are small clusters of largely buried residues in 
domain TIL’, namely at residues Thr789-Cys792, Gly807-Cys810, Met814-His817 in TIL’ 
and Cys827-Cys829 at the TIL’-E’ border (Figure 2.29). 
 
 
 
 
Interestingly, these residues appear to form a concave cleft-shaped pocket on the 
front face of the TIL’ molecule. This pocket is bound laterally by strand 2 on the left 
and an ascending segment of the 1-to-2 loop on the right; the superior border of the 
Figure 2.29: Accessible molecular surface of TIL’E’. Shown is the average estimated accessibility of 
the TIL’E’ family of ten lowest energy structures generated with the programme Procheck-NMR
367
 
(implementing the Ooi number method). Accessibility is calculated from the the Ooi number, which 
is simply the number of C atoms within a 14 Å radius
365
.  
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pocket is formed by strand 4 and the upper portion of loop 1-to-2 (Figure 2.30, left 
panel). Protein surfaces contain clefts and indentations of varying sizes and depths, 
and it is often the case that binding sites are found within the largest cleft on the 
protein surface366. Therefore, the buried pocket identified on the front face of TIL’ is 
likely to be of functional significance (Figure 2.30, right panel).  
 
 
 
 
 
 
 
The family of ten lowest energy TIL’E’ structures, with the exception of the extreme N- 
and C-termini, is well-defined, and has an average backbone pairwise RMSD (root 
mean square deviation) of 1.12 Å; the corresponding mean RMSDs of the TIL’ and E’ 
Figure 2.30: A buried pocket on the TIL’ surface. Residue clusters identified by accessibility analysis 
to be buried are: Thr789-Cys792, Gly807-Cys810, Met814-His817 in TIL’ and Cys827-Cys829 at the 
TIL’-E’ border. On the left is shown a ribbon representation of structure TIL’E’. Buried residues are 
mapped into the TIL’E’ structure and their side chains are represented by sticks (coloured grey). The 
buried residues form a pocket that is bordered laterally by strand 2 on the right and an ascending 
segment of the 1-to-2 loop on the left, superiorly the pocket is bound by strand 4 and the upper 
portion of the 1-to-2 loop. A surface representation of structure TIL’E’ is shown on the left, where 
it is clear that these resides form a concave cleft-shaped pocket on the front face of TIL’ (coloured 
grey).  
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domains in isolation are 1.37 Å and 0.34 Å, respectively. The RMSD of the TIL’ domain 
excluding the 1-to-2 loop is 0.81 Å. These differences are distinctly evident when the 
TIL’E’ backbone RMSD of each residue is plotted (Figure 2.31). Large RMSD deviations 
are strictly confined to domain TIL’, with a prominence in the TIL’ 1-to-2 loop (Figure 
2.31). Thereby, indicating that the 1-to-2 loop (aa 776-805) dominates the structural 
heterogeneity of TIL’ and alludes to its intrinsic dynamic character (Figure 2.32). 
 
 
 
Analysis of the geometric quality of the TIL’E’ ten lowest energy family reveals that it is 
composed of high quality structures (Figure 2.32), from which 95.4% of residues lie in 
the most favoured and additionally allowed regions of the Ramachandran plot367 
(73.1% in the most favoured and 22.3% in the additionally allowed region), and only 
3.4% and 1.2% in the generously allowed and disallowed regions, respectively 
(Appendix 5.3). Small disulphide-rich protein folds typically possess less secondary 
structure than larger proteins, and therefore the percentage of residues found in the 
most favoured regions of the Ramachandran plot for this type of structure is usually 
lower relative to high resolution crystal structures of larger proteins353. Nevertheless, 
low backbone RMSD between the family of ten lowest energy structures and their 
Figure 2.31: Per residue Backbone RMSD of the ten lowest energy TIL’E’ structures. The backbone 
RMSD calculated on a per residue basis for the family of ten structures with the lowest energy. 
Strikingly evident is that residues of the 1-to-2 loop of domain TIL’ (aa 776-805) are significantly 
less well defined that the rest of the protein. RMSD plotted by Dr D. Flemming Hansen. 
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Ramachandran statistics confirm that the calculated TIL’E’ structures are a precise 
representation of the experimental data, and hence, of the TIL’E’ molecule in solution.  
 
 
 
 
2.12. Structural homologues of TIL’E’ 
The VWF TIL’ domain is a structural homologue of the Ascaris protease inhibitor (TIL 
units) family. Serine protease inhibition by the TIL family is accomplished by the 
Laskowski mechanism, binding to the enzyme in a substrate-like fashion. TIL domain 
reactive site residues lie between the fifth and sixth conserved TIL family cysteines108, 
and are part of an exposed binding loop connecting strands 1 to 2, surrounding the 
hyper exposed P1 residue112. Stabilisation of the binding loop conformation, between 
Cys5 (P3) and Cys6 (P2’), is facilitated by two flanking disulphide bonds, linkages 3-5 and 
2-6. Disulphide loops of cysteines 1-7, 2-6 and 4-10 encompass the scissile bond during 
conversion from virgin to modified inhibitor, to ensure that the two peptide chains do 
not dissociate111.  
In the VWF TIL’ domain, position P1 corresponds to residue Met802 (Figure 2.33, panel 
A) and is solvent exposed, as is essential for hypothetical penetration of the P1 side 
chain into the S1 specificity pocket of a protease during complex formation. The 
dominant force for TIL inhibitor P1 binding is hydrophobic interactions, therefore 
excess steric bulk, -branching (Val and Ile), polarity and charge at this position are 
Figure 2.32: The family of ten lowest energy TIL’E’ structures. Ribbon representation of the TIL’E’ 
family of ten lowest energy structures are shown in four rotations of 90 about the y-axis. It is clear 
that the TIL’ 1-to-2 loop is conformationally heterogeneous whereas the -sheet regions of TIL’ 
and E’ as well as the top of the TIL’ 1-to-2 loop possess a high degree of definition.  
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deleterious to complex formation112,113,368. This leaves only TIL’, of the five VWF TIL 
domains, without physiochemical restrictions on its inhibitory potential, and a P1 Met 
is generally thought to inhibit chymotrypsin and chymotrypsin-like enzymes111 (Figure 
2.33, panel B). In addition, the reactive site loop is usually dynamic, as is evident for 
the VWF TIL’ 1-to-2 loop, in the uncomplexed state and becomes significantly 
rigidified upon complex formation369.  
Discussion of the potential inhibitory activity of domain TIL’, however, is made with 
extreme caution as reactive-site residues in inhibitor units are often hyper-variable, 
thus, it is seldom possible to tell from the sequence whether or not an inhibitor 
homologue is likely to have inhibitory activity108. Furthermore, the VWF TIL’ domain 
contains an eight residue insertion in the 1-to-2 loop, between the second and third 
conserved cysteines, that is not present in other members of the Ascaris family (Figure 
2.2), and the side chain of the P1 position of TIL’ (Met802) is directed towards the core 
of the domain in half of the ten lowest energy TIL’E’ conformers. Unlike the P1 
conformation of other Ascaris protease inhibitors (Figure 2.33, panel A), TIL’ Met802, 
in the lowest energy structure, does not significantly protrude from the protein 
scaffold and is partially buried, making it is difficult to conceive that in this position, 
Met802 is capable of serving as a protease recognition motif (Figure 2.33, panel C). 
Lastly, the function of VWF has been extensively studied, and as yet a serine protease 
inhibitory activity has not been found.  
Experimental studies are required to resolve the question of VWF TIL’ putative serine 
protease inhibition, as interestingly, VWF is perfectly placed for interaction with serine 
proteases of the coagulation cascade, of which factors XIa, Xa, IXa and VIIa, part of the 
S1 family that are inhibited by Ascaris107. 
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The VWF E’ domain adopts the same fold as subdomain 1 of VWC modules, belonging 
to the fibronectin I-like superfamily of disulphide-rich, all -structures that have arisen 
from a VWC ancestor. The prototypical VWC domain is an extended rod-like structure 
whose fold manifests a two subdomain architecture, termed subdomain 1 and 
subdomain 2101,118. N-terminal subdomain 1 is well-structured and of predominantly -
sheet configuration, from which the E’ domain evolved as a truncation. C-terminal 
subdomain 2 however, does not contain elements of secondary structure and the loop 
is constrained by disulphide cross links. Structure of the complex between the VWC 
module of crossveinless-2 and its cognate ligand (BMP-2), indicates that subdomain 1 
forms the functional subdomain with disulphide linkage 3-5 at the centre of the 
Figure 2.33: Reactive site residues of the Ascaris trypsin inhibitor-like family. Panel A shows the 
superposition of VWF TIL’ positions P3 (Met800) to P2’ (Cys804) coloured red, with the 
corresponding reactive site residues of AMCI-1
317
, BSTI
319
, ATI
318
and C/E-1
316
, that inhibit either 
chymotrypsin or trypsin, coloured in increasingly darker shades of grey. These are shown in stick 
representation, with the P1 position shown with a larger stick radius for emphasis. Hydrogen atoms 
are removed for clarity. A comparison of the binding site sequence in the 1-to-2 loop of all Ascaris 
inhibitors, for which a high resolution structure is known, are shown in panel B. In panel C is a 
superposition of the VWF TIL’ NMR structure (red) with that of AMCI-1 (grey; pdb: 1CCV
317
). The P1 
positions, bound by conserved Cys5 and Cys6, are indicated and shown as stick representations; VWF 
TIL’, Met802 and AMCI-1, Met40. The eight residue insertion on VWF TIL’ between conserved Cys2 
(Cys776) and Cys3 (Cys788) is coloured black on the VWF TIL’ structure.  
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binding interface101, however, recent data suggests an additional and distinct binding 
role for subdomain 2 of this VWC module370, thereby highlighting the versatility of 
VWC domains, and the spatial variability in binding epitopes.  
Superposition of N-terminal VWC subdomain 1 from human procollagen IIA118 and 
VWF domain E’ shows a clear fold level similarity with an RMSD of 1.33 Å (pairwise 
sequence identity, 30.6%; similarity, 38.9%) (Figure 2.34).   
 
 
 
 
Strong structural similarity is highly indicative of a divergent evolutionary 
relationship124, however, what this structural ancestry implies for protein fold and 
function space is not clear124,371. Whilst the coincidence of the same major structural 
elements in the same arrangement and topological connections implies functional 
inheritance372, reliable predictions still cannot be made.  
To retain a specific function through evolution, the local environment of a functional 
site must be preserved, even if other portions of the fold have been altered372. 
However, in view of the inter-cysteine sequence divergence of VWC domains and 
hence, inability to predict binding epitopes based on sequence alone118, coupled with 
the paucity of data regarding VWF C domain functions, the possibility of deriving a 
Figure 2.34: VWF domain E’ and subdomain 1 of VWC domains adopt the same fold. The three-
dimensional lowest energy structure of VWF E’ (far left; red) and the NMR structure (pdb: 1U5M)
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of von Willebrand type C (VWC) domain of human procollagen IIA
118
 (centre; grey), together with 
their superposition (far right) are shown in ribbon representation. Disulphide bonds are coloured 
gold and conserved Cys residues are numbered according to the order they occur in the protein 
sequence. 
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sensible hypotheses for the function of VWF E domains, becomes increasingly difficult. 
For most VWC modules, the cellular role has yet to be determined, however, 
regulating BMPs and TGF- signalling are the two most common functions attributed 
to VWC modules. There is emerging evidence that lateral self-association of VWF, 
forming large fibrous networks at sites of vascular injury, may confer an enhanced 
capacity for platelet capture by immobilised VWF, and this is mediated by VWC3 
subdomain 1 Cys2431-2453 and Cys2451-Cys2468 allosteric disulphide bonds (linkages 
1-4 and 3-5)178,358,373. In addition, under simulated in silico stretching, fibronectin I 
domains exhibited significant elongation and internal structural rearrangements that 
include changes in disulphide bond configuration. The extension of disulphide bonds 
under tension, is thought to contribute to the overall elongation of fibronectin I 
polymers in the extracellular matrix374. Structurally related clusters of proteins may be 
characterised by a specific distribution of functions unique to that fold375, and for that 
reason, the VWC subdomain 1 and E domain disulphide bonds may be revealed to 
facilitate shear dependent VWF extension, in which alignment of disulphide bonds 
along the axis of flow lead to local domain level extensions, the summation of which, 
unravel the globular VWF configuration. 
In summary, the high resolution solution structure of TIL’E’ was solved, and the 
disulphide bond topology unambiguously assigned. This represents the fundamental 
basis upon which a model of VWFFVIII complex formation may be built, and the 
structural and functional consequence of type 2N VWD mutations may be inferred.  
 
2.13. Conformational dynamism of TIL’E’  
Protein dynamics is intimately linked to molecular function, hence, the dynamic 
characterisation of VWF TIL’E’ is of great importance for elucidating the mechanism by 
which FVIII is stabilised in plasma. The most severe approximation to structure 
determination is the assumption that a protein can be represented by a single 
structure. It has long been recognised that stably folded proteins are dynamic, 
displaying motions across a broad hierarchy of timescales376–378 (Figure 2.35). 
Biological processes are often highly dependent upon and governed by, 
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conformational transitions, and there exists an intimate relation between protein 
motion and function. NMR is the most powerful technique for deconvoluting the 
dynamic motions of proteins, thus providing a more accurate representation of the 
conformational space sampled by a biomolecule and permitting the reconciliation of 
structure, dynamics and function376,379. As the symbiosis between protein dynamics 
and structure is essential to biological activity380, the structural dynamics of TIL’E’ were 
quantified experimentally by 15N nuclear spin relaxation experiments to provide 
mechanistic insight into TIL’E’FVIII binding. Analysis of relaxation data reveal 
interesting motional trends in TIL’E’; most strikingly, that there is a readily 
distinguishable mobility differential between TIL’ and E’.  
 
 
Backbone fluctuations on a sub-nanosecond timescale (picosecond to nanosecond) 
were measured by heteronuclear [1H]-15N NOEs (hetNOEs). Fast timescale motions act 
to stabilise the protein in its folded state and their presence is a necessary prerequisite 
for slower timescale dynamics involving large-scale collective motions376.  
The hetNOE value determined for each TIL’E’ residue is shown in Figure 2.36; hetNOE 
values below 0.6 indicate flexible, unstructured regions, whereas, values above 0.6 are 
consistent with rigid secondary structure. As for most proteins, the residues at the N- 
and C-termini of TIL’E’ are disordered, with low hetNOE values. These data clearly 
demonstrate that domain E’ is rigid, with a uniform distribution of hetNOE values 
around 0.65 (excluding the flexible C-terminal Asp864 residue) indicating low flexibility 
Figure 2.35: Time scales for protein dynamics. A schematic of the various molecular motions that 
can be probed by NMR experimentation, these span more than 12 orders of magnitude in timescale.   
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and an ordered structure. Whereas, domain TIL’ exhibits distinct localisation of 
residues in the TIL’ 1-to-2 loop with significantly reduced hetNOE values, namely 
residues Ala778, Asp779, Arg782, Glu784, Ser801 and Gly803, indicating a 
comparatively higher degree of flexibility in this region of TIL’ (Figure 2.36). 
Furthermore, flexibility in the immediate vicinity of TIL’ disulphide bridges is restricted, 
as evidenced by hetNOE values greater than 0.6 for all available Cys residues (Figure 
2.36), thereby, confirming their importance as structural bridges that maintain the 
tertiary structure of the TIL’ fold.  
 
 
 
 
VWF TIL’E’ is evidently a dynamic structure; thus far however, the dynamics of TIL’E’ 
have been isolated from the structure determination process. This gives rise to 
considerable uncertainty as to the distribution of conformations that the native TIL’E’ 
molecule encompasses. Therefore, an ensemble of structures that sample all 
conformations satisfying the steric and dynamic NMR derived data was calculated. The 
TIL’E’ conformational ensemble reveals distinct dynamicity in domain TIL’.  
The RCI-derived S2 order parameters, obtained from the backbone chemical shifts345 
(section 2.6, Figure 2.18), report on the amplitude of backbone motions on a timescale 
ranging from picoseconds to hundreds of microseconds346; RCI-S2 values range from 0 
Figure 2.36: Backbone TIL’ [
1
H]-
15
N NOEs: picosecond to nanosecond dynamics. Heteronuclear 
NOEs report on dynamics on the sub-nanosecond timescale. Heteronuclear amide NOE values are a 
measure for the dynamics of the local environment. Values below 0.6 indicate flexible unstructured 
regions, while stabilising structural elements give rise to values greater than 0.6. Secondary 
structure elements of TIL’E’ are depicted below the plot for clarity. Spectrum obtained at 600 MHz 
at 25 C. Data were not obtainable for all assigned residues due to weak or overlapped peaks. 
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(no orientational bias) to 1 (completely rigid)379,380, thereby characterising the spatial 
restriction of the motion of each residue in TIL’E’. In addition, dynamics on the 
picosecond to microsecond timescale are also encoded in RDCs381,382 which were 
combined with RCI-S2 parameters, and subsequently included in structural calculations 
to determine an ensemble of protein conformations that represent, simultaneously, 
the TIL’E’ structure and its associated dynamics (dynamic ensemble refinement). 
Accordingly, the structural ensemble represents a more faithful atomistic description 
of the conformational variability of the TIL’E’ native state, on a picosecond to 
microsecond timescale383 (Figure 2.37). Indeed, the TIL’ 1-to-2 loop is significantly 
more flexible than the remainder of TIL’E’ and samples a heterogeneous ensemble of 
conformations that interconvert on the picosecond to microsecond timescale. These 
loop fluctuations facilitate larger-amplitude domain motions, as this region of TIL’ was 
subsequently found to be coincident with slower dynamics, on the microsecond to 
millisecond timescale. 
 
 
 
 
Figure 2.37: Stereo view of the structural variability in the TIL’E’ ensemble. The method of dynamic 
ensemble refinement
383
 was implemented to give an ensemble of TIL’E’ structures that 
simultaneously represent the TIL’E’ structure and its picosecond to microsecond dynamics. 
Disulphide bonds were added explicitly into the ensemble structure calculation. The twelve-member 
ensemble is shown in grey. This is overlaid with the two lowest energy structures from the single 
structure calculations (red). The view is of a cross-eye stereo. The ensemble refinement calculations 
were performed by Dr D. Flemming Hansen.  
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Conformational exchange on the millisecond timescale overlaps with the time constant 
of dynamic processes relevant to higher-order functions of macromolecules, such as 
ligand binding. Therefore, Carr-Purcell-Meiboom-Gill (CPMG) relaxation dispersion 
experiments, that specifically probe microsecond to millisecond dynamics and are 
sensitive to low-populated thermally excited states (conformers with much lower 
populations), were performed on TIL’E’ to quantify such movements. The Rex factor is 
derived from the CPMG relaxation dispersion experiments; Rex is the relaxation rate 
due to conformational exchange, as nuclei sample various conformations and 
magnetic environments, and a value greater than 1.5 s-1 indicates microsecond to 
millisecond backbone mobility (conformational malleability). A first inspection of the 
CPMG data reveals dramatic compartmentalisation of slower motions in TIL’, 
particularly in the 1-to-2 loop (Figure 2.38). This confirms the existence of a TIL’ 
conformational sub-state with a lifetime in the millisecond range, while the E’ domain 
remains rigid on this timescale. Additionally, the presence of slower dynamics confirms 
that the incidence of a high RMSD in the ten lowest energy structures of TIL’ is 
correlated, in part, with the motion of the molecule, rather than simply a lack of 
structural constraints (Figures 2.24 and 2.31).  
A detailed analysis of the CPMG relaxation dispersions reveals that the ground state of 
TIL’E’ interconverts stochastically with a sparsely populated excited state (conformer); 
the lifetime of the excited state is approximately 0.48 ms and it has a population of 
3.5%. Because excited state conformers are only transiently formed and marginally 
populated, their structural characterisation eludes most biophysical methods. CPMG 
relaxation dispersion data, however, may be used to derive a structural model of the 
excited state and the dynamic processes observed experimentally384.   
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Conformational dynamism, as observed for VWF domain TIL’, is an inherent property 
encoded into the protein fold through the evolutionary selection of conformers 
required for function380. Protein excited states often have significant functional roles in 
molecular recognition and ligand binding, such as in conformational selection of the 
excited state that is primed for binding to the cognate ligand, and is sought out from 
an ensemble of conformations that are already populated in solution385. The TIL’E’ 
excited state may indeed be the conformer involved in recognition of the FVIII light 
chain in VWFFVIII complex formation. Consistent with this theory is the finding that an 
Figure 2.38: Microsecond to millisecond TIL’E’ dynamics. Conformational exchange processes 
generally occur on the microsecond to millisecond timescale and thus report on slower motions than 
[
1
H]-
15
N heteronuclear NOEs or S
2
 order parameters. CPMG experiments are made more robust by 
conducting the experiment at two external magnetic field strengths. Representative dispersion 
profiles are shown in the panel A for the conformationally dynamic residues Cys776 and Ser806 of 
TIL’ (red, 700 MHz; black, 500 MHz). The chemical exchange contributions, Rex, at 700 MHz are 
shown in panel B, where there is striking segregation of backbone millisecond dynamics in domain 
TIL’, while E’ is comparatively rigid on this timescale. Rex values greater than 1.5 s
-1
 indicate dynamics 
on a microsecond to millisecond timescale (conformational exchange). Data were not obtainable for 
all assigned residues due to weak or overlapped peaks. 
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increase in temperature augments the VWFFVIII associate rate constant252, as it is 
thought that interactions between proteins with preoptimised binding sites benefit 
from an increase in the kinetic energy of the system, whereas, the association of 
proteins requiring conformational adaptations for formation of complex, in an 
induced-fit model, are hampered by increases in temperature252,386. Furthermore, it is 
interesting to note, that residues forming the lateral and superior borders of the 
buried pocket on the front face of TIL’, identified by accessibility analysis (Figure 2.30), 
are dynamic on a microsecond to millisecond timescale (Lys790, Thr791, Gly807, 
Leu809, Val815 and His817) (Figure 2.38). Thus, conformational transition of the TIL’ 
pocket, forming an optimised FVIII light chain binding site, supports a conformational 
selection model for VWFFVIII complex formation.  
Crucially however, the appropriate control is required to confirm the functional 
importance of the dynamics revealed in domain TIL’, and to distinguish relevant 
dynamics from random fluctuations387. An approach would be to employ type 2N 
mutants and FVIII light chain binding experiments to alter the dynamics observed by 
NMR, so that changes in dynamics may be correlated with TIL’E’FVIII complex 
formation. 
A summary of the TIL’E’ dynamics is shown in Figure 2.39 and detailed in Appendix 5.4, 
from which it is clearly evident that the TIL’ 1-to-2 loop is strikingly dynamic on at 
least two timescales, whereas, the remainder of TIL’E’ provides a rigid scaffold 
supporting this conformationally dynamic entity. It is highly probable that the 
sequestration of dynamics localises the major FVIII binding site to the buried pocket on 
the front face of domain TIL’.  
128 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.39: Summary of the dynamic character of TIL’E’. The lowest energy structure of TIL’E’ is 
shown in ribbon representation. The combined dynamics of TIL’E’, wherein black C spheres 
represent [
1
H]-
15
N heteronuclear NOEs with values  0.6 (fast picosecond to nanosecond dynamics), 
and residues coloured red if Rex is greater than 1.5 s
-1
 (slower microsecond to millisecond dynamics; 
conformational exchange) and blue is Rex is less than 1.5 s
-1
. Residues are coloured grey where no Rex 
is available, either due to weak or overlapped peaks. It is clear that the -sheets of TIL’ and E’ form a 
rigid scaffold supporting the highly dynamic TIL’ 1-to-2 loop.  
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2.14. Structural characterisation of type 2N VWD mutations 
The solution structure and dynamic characterisation of VWF TIL’E’ allows a first 
detailed structural interpretation of type 2N VWD missense mutations that disrupt the 
VWFFVIII interaction; this provides the link between genetic pathology and clinical 
phenotype, and facilitates mapping of the FVIII binding region onto TIL’E’. The greater 
proportion of pathologic type 2N mutants are found in TIL’E’, with distinct clustering in 
the TIL’ 1-to-2 loop, and are thus, coincident with the TIL’ region of dynamicity 
(Figure 2.40).  
 
 
 
 
Interestingly, only two non-type 2N mutations are found in domain TIL’; type 1 VWD 
mutants Met771Ile and Arg782Gln. Of the remaining mutations reported236, excluding 
the 18 type 2N mutations in TIL’E’, two occur in the linker between the VWF 
prodomains and TIL’; Arg760Cys and Arg763Gly located at positions P4 and P1 of the 
consensus sequence of the furin site and obstruct propeptide cleavage and release of 
the mature VWF protein. In these cases of hereditary persistence of proVWF, it is 
Figure 2.40: Type 2N VWD mutations. Schematic of the domain localisation of all reported type 2N 
mutations. Shown are prodomains VWD2-C82-TIL2-E2 (D2 region) and the N-terminal domains of 
mature VWF; TIL’E’ (region D’, exons 18-20) and VWD3-C83-TIL3-E3 (region D3, exons 20-28). 
Mutations are given with the one letter amino acid code. A red bar localises the epitopes of potent 
FVIII binding blocking monoclonal antibodies.  
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assumed that the attached propeptide sterically hinders FVIII binding to the adjacent 
TIL’E’VWD3 region162,388,389. Two type 2N mutations are in domain VWD3 (Asp879Asn 
and Arg924Gln), four in domain C83 (Gln1053His, Cys1060Arg/Tyr and Glu1078Lys) 
and lastly, one in domain E3 (Cys1225Gly). Interestingly, four of five mutations in 
domains C83 and E3, involve the substitution of a Cys residue (Figure 2.40).  
Type 2N mutations in TIL’E’ that involve a cysteine residue (Cys788Arg/Tyr, Tyr795Cys 
and Cys804Phe in TIL’ and Cys858Ser/Phe in E’) are associated with a triple biological 
defect, that of aberrant multimerisation (typical of type 2A VWD), secretion and FVIII 
binding315,341,390,391. Cys788, Tyr795 and Cys804 localise to the 1-to-2 loop (Figure 
2.41). Evidence that these mutations induce a deleterious conformational change has 
been obtained by means of antigen-capture experiments with conformation-
dependent FVIII binding blocking mAbs315,341, thereby substantiating the importance of 
the TIL’ 1-to-2 loop in FVIII binding and that correct disulfide bond formation is 
critical to the folding and function of VWF. Introduction of a Cys residue (Tyr795Cys) 
causes a deviant supranormal multimerisation pattern315,391, whereas, breakage of 
disulphide bonds (Cys788Arg/Tyr, Cys804Phe and Cys858Ser/Phe) results in a 
reduction of high molecular weight forms315,341,390. Disulphide bond scrambling or 
suboptimal interaction with the VWF propeptide leading to aberrant multimerisation 
may block the secretion of higher molecular weight forms due to the multiplicity of 
errors with increasing molecular weight or there may be a dominant negative like 
effect, whereby heterozygous (and homozygous) dimers are retained in the ER; the 
reduction in the total number of dimers entering the Golgi compartments would lead 
to formation of only low and intermediate multimers, and consequently reduced 
secretion and FVIII binding, which are secondary effects.  
Of the type 2N mutations (Figure 2.40), three account for the majority of cases 
reported – Thr791Met and Arg816Trp in domain TIL’ and Arg854Gln in domain E’ 
(Figure 2.41). Mutant Arg854Gln is the most common, in absolute terms, occurring 
with polymorphic frequency10. As with most of the qualitative VWD variants, type 2N 
demonstrates good genotype-phenotype correlations; Arg854Gln mutant is associated 
with a mild phenotype and FVIII levels of 25%, while both the recurrent Thr791Met 
and Arg816Trp mutations result in FVIII levels of less than 10%312. All three of these 
131 
 
commonly reported type 2N substitutions are in immediate proximity to the TIL’ 1-to-
2 loop (Figure 2.41). The Arg854 mutant in domain E’, suggests an approximation of 
the E’ 4-to-5 loop to domain TIL’, this has been confirmed by the TIL’E’ solution 
structure (Figure 2.28 and Figure 2.41). 
 
 
 
 
The most precise locators of the FVIII binding site, however, are those mutations that 
are associated with a more severe type 2N phenotype; that is Glu787Lys (reported in 
only one patient thus far), Thr791Met and Arg816Trp310–312,391 in TIL’, all of which are 
largely buried (Figure 2.30 and Figure 2.42, upper panel). Surface charge mapping 
reveals that domain TIL’ is an electric dipole, with an almost diagonal partitioning of 
positive and negative charge (Figure 2.42, lower panel). Two of the severe type 2N 
mutations, Thr791Met, and Arg816Trp (which occurs at a position of strong charge 
conservation - Figure 2.2), together with Thr789Pro, Met800Val, Arg816Gln and 
His817Gln, circumscribe a pocket of concentrated positive charge density on the front 
face of TIL’ (Figure 2.42, lower panel), that is congruent with the burial of TIL’ residue 
Figure 2.41: Type 2N VWD mutants in TIL’E’. A ribbon representation of the TIL’E’ structure is 
shown, onto which all type 2N mutations reported in this region are mapped. Mutant residues are 
shown as black C spheres. Mutants are designated by their one letter amino acid codes. The 
structure on the right is rotated 160 about the y-axis, relative to the structure on the left. The 
structure on the left shows the front face of TIL’. There is clustering of type 2N mutants in the TIL’ 
1-to-2 loop.  
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clusters; that is, the pocket is bound laterally by strand 2 on the left and by an 
ascending segment of the 1-to-2 loop on the right, superiorly, the pocket is enclosed 
by strand 4 and the upper portion of the 1-to-2 loop (Figure 2.30 and Figure 2.42).  
 
 
 
 
The FVIII light chain N-terminal acidic a3 domain mediates high affinity binding to VWF, 
and it is thus, highly likely that the positively charged pocket on the front face of TIL’ is 
the binding site for the negatively charged a3 domain. Consequently, mutants 
Figure 2.42: Structural interpretation of VWD type 2N mutants in TIL’E’. The structures on the right 
are rotated 160 about the y-axis, relative to structures on the left. The structures on the left show 
the front face of TIL’. Top panel; a surface representation of TIL’E’ with positions of non-cysteine 
type 2N VWD mutations coloured green. Lower panel; electrostatic surface potential of TIL’E’ is 
shown (blue, negative charge; red, positive charge). 
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Thr789Pro, Thr791Met, Met800Val, Arg816Trp/Gln and His817Gln mediate their 
effects through perturbation of the correct configuration of this dynamic positively 
charged pocket. In addition, whilst clinically milder substitutions Thr789Pro, 
Met800Val, Arg816Gln and His817Gln result in a decreased residue volume, the 
severity of Thr791Met and Arg816Trp mutants are accounted for by the introduction 
large side chains that would conceivably hinder accommodation of the FVIII light chain 
a3 domain (Table 2.5). Moreover, loss of positive charge mediated my mutants 
Arg816Gln/Trp and His817Gln only compounds the deleterious effect on FVIII binding.  
Residues Arg782, Gly785 and Glu787 are in close proximity to this putative binding 
pocket (Figure 2.41 and Figure 2.42, upper panel), which suggests that the severe type 
2N mutation Glu787Lys and mutations Arg782Trp and Gly785Glu facilitate the FVIII 
binding defect through charge disruptions and perturbation of the 1-to-2 loop, the 
ascending and upper portions of which form the left superolateral border of the 
positively charged TIL’ pocket (Figure 2.41). An effect of the consecutive TIL’ Pro811 
and Pro812 residues in the loop to strand-3 confer conformational stiffness and 
introduce a turn that anchors strand 3. This effect serves to maintain the correct 
conformation of the positively charged TIL’ pocket, wherein, substitution Pro812Leu 
may perturb the binding pocket through a degree of unwanted flexibility (Figure 2.41).  
Although mutant Arg854Gln is clinically mild, the Arg854Trp variant causes a type 2N 
diathesis of moderately severe bleeding that, similarly to the type 2N Cys mutants, is 
associated with defective secretion and a significant abnormality of multimerisation, 
with lack of intermediate and high molecular weight VWF multimers392. The 
discrepancy between substitution to Gln or Trp at position 854 can be reasoned to the 
proximity of Arg854 in the E’ 4-to-5 loop to the TIL’ disulphide bridge Cys792-Cys827 
(linkage 4-10). Replacement of a positively charged linear arginine with the bulky 
hydrophobic ring of tryptophan at an exposed position ( 42.1 Å3, Table 2.5) is 
predicted to cause significant structural perturbation of the C-terminal TIL’ region, 
residues Leu824 to Cys827, encompassing the 310 helix and bridge Cys792-Cys827, 
which anchors the upper portion of the TIL’ 1-to-2 loop to the TIL’ C-terminus. This 
region borders the superior aspect of the positively charged putative FVIII a3 domain 
binding pocket in TIL’, to which the effects induced by mutant Arg854Trp are likely to 
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be propagated. In addition, Trp at this position may threaten the linkage of Cys792 to 
Cys827 that would in turn, destabilise the ascending segment of the TIL’ 1-to-2 loop 
that borders the positively charged pocket. These effects would act in concert to 
account for the reduced FVIII binding and multimerisation defect observed in mutant 
Arg854Trp. In contrast, evolution of a  40.7 Å3 cavity by substitution Arg854Gln 
(Table 2.5), would not be expected to cause such destructive structural alterations to 
TIL’, and hence, results in a milder phenotype, as E’ most probably contributes to FVIII 
binding through subsidiary contacts, whilst TIL’ is the principal FVIII binding site, by 
means of a3 binding.  
 Table 2.5: Type 2N VWD mutations in TIL’E’. Residue volumes are those of Pontius et al393. 
 
 
2.15. Conclusion of results 
In conclusion, most of the non-cysteine type 2N VWD mutations are clustered within 
dynamic regions of domain TIL’ and their effects converge on perturbation of the 
surface contour of the positively charged TIL’ pocket on the front face of TIL’. This 
localises the principal FVIII binding site, mediated by acidic FVIII domain a3, to this 
region of the VWF protein. A predominantly electrostatic interaction between VWF 
and the FVIII light chain is in agreement with the known dissociative effects of high 
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ionic strength and low pH on the VWFFVIII complex. Hence, based on the foregoing 
analyses, it is proposed that the E’ domain and the -sheets of TIL’ provide a rigid 
scaffold for the positively charged pocket of TIL’, which complements the charge 
distribution of the FVIII light chain a3 domain; thus electrostatic steering is the 
dominant force that orientates, with high specificity, the VWF and FVIII interfaces 
(Figure 2.43). The final stages of binding may then proceed via conformational 
selection of the excited TIL’ state, in which the TIL’ binding pocket concavity 
complements the binding surface of the a3 domain on FVIII. 
 
 
 
 
Figure 2.43: Mechanism of electrostatic VWFFVIII binding. Shown is the proposed mechanism of 
high affinity FVIII light chain (LCh) a3 domain binding to VWF TIL’ domain, by electrostatic steering 
forces.  
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3. Concluding remarks 
The fascinating mechanisms by which VWF maintains haemodynamic integrity have 
enthused scientific interest since 1926 when a consanguineous family from the Aland 
archipelago of Finland, affected by a curious bleeding disorder, came to the attention 
of Dr Erik von Willebrand394,395. Much of the function of the eponymous VWF protein 
has since been elucidated and knowledge of the epidemiology, genetics and molecular 
basis of VWD is rapidly expanding. Indeed, extensive clinical observations and 
laboratory studies have revealed that VWF is unique and unusual, both in terms of its 
multimeric structure and the mechanisms governing its participation in haemostatic 
processes. Furthermore, VWF is implicated in pathological processes beyond 
haemostasis, including angiogenesis, inflammation and tumour cell survival204. 
Most intriguingly however, is the capacity of VWF to undergo both domain-level and 
gross conformational transitions in regions of elevated rheologic shear forces138,396. 
The interaction sites of circulating (globular) VWF are buried and therefore, 
inaccessible to their ligands; allowing VWF to conduct a circulatory reconnaissance of 
the intact vasculature. The functional quiescence of VWF is perturbed by vascular 
damage, exposing subendothelial collagens, to which globular VWF is recruited. 
Subsequently, VWF undergoes structural transitions mediated through the local shear 
forces exerted on the tethered VWF molecule by flowing blood138, thereby, unravelling 
VWF into an elongated, haemostatically potent, biopolymer. Cryptic binding sites are 
thus revealed, and facilitate the capture and localisation of platelets to the denuded 
vessel wall. These first steps in the genesis of the primary platelet clot, as well as the 
transition of VWF from a paracrystalline highly ordered configuration when stored in 
WPBs to a disordered configuration in circulation, demonstrate that the conformation 
and dynamic malleability of VWF is fundamental to its haemostatic function71.  
Notwithstanding the significant advances in the characterisation of VWF function, little 
is known of the molecular structure that is critical to maintaining the delicate balance 
between bleeding and thrombosis. In particular, atomic-level insight into the VWF 
region that mediates FVIII stabilisation in plasma, is lacking. With the exception of the 
triplicated globular A domains62,63,190,194–197, structural studies on VWF have been 
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limited to low-resolution measurements that contribute to understanding the overall 
shape and flexibility of the molecule. Early metal-shadowing electron microscopy 
experiments137,139 revealed the head-to-head and tail-to-tail arrangement of VWF 
monomers within multimeric assemblies. Subsequent higher resolution negative stain 
electron microscopy studies have refined the overall size and arrangement of domains 
within VWF140 (Figure 3.1).  
A complete description of VWF function is dependent upon determination of atomic-
resolution three-dimensional domain structures. Crystallisation of the VWF A2 
domain190 revealed the mechanism by which A2 unfolds to expose the ADAMTS13 
cleavage site in the regulation of VWF multimer size and thrombogenicity188,189. The 
folded VWF A2 domain adopts an atypical Rossman fold, whereby amphipathic -
helices surround a central -sheet, in which the ADAMTS13 Tyr1605-Met1606 scissile 
bond is deeply buried190. In place of an 4-helix, present in domains A1 and A3, the A2 
domain contains a flexible 4-less loop that weakens the fold and reduces the force 
required for unfolding172,190. This structural instability is further compounded by the 
absence of a long-range N- to C-terminal disulphide bond, present in the neighbouring 
homologous A domains, that would otherwise protect the domain against unfolding by 
the shear forces in circulation190,397. The A2 crystal structure has also revealed a very 
rare vicinal disulphide bond between adjacent Cys1669 and Cys1670 at the C-terminus 
that acts as a molecular plug to impart rigidity and stabilise the hydrophobic core190,398. 
In regions of elevated shear flow however, the vicinal disulphide bond is pulled out, 
destabilising the A2 domain core and initiating unfolding to reveal the Tyr1605-
Met1606 scissile bond and expose the VWF Glu1660-Arg1668 cryptic exosite71. 
Consequently, the VWF A2 domain becomes susceptible to proteolysis by 
ADAMTS1371,172,190. Thus, the evolutionary structural adaptations of the VWF A2 
domain, revealed only when the high resolution structure was determined, predict 
that reversible unfolding and refolding regulate VWF cleavage by dynamic accessibility 
of a buried scissile bond190,397.  
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The formation of a disulphide bond between adjacent cysteine residues is  
 
 
It is thus evident that the interplay between structure and dynamics regulates both the 
function of the VWF protein and its ability to evolve and adapt to diverse sets of 
conditions necessary for maintaining haemostasis385. At the outset of the work 
described in this thesis, the molecular mechanisms governing formation of the 
biologically important VWFFVIII complex were unresolved. To reveal the structural 
adaptations of the FVIII binding region of VWF, the high resolution NMR structure of 
the D’ region was solved and its conformational dynamism characterised.  
Expression of TIL’E’ (D’) in E. coli and its subsequent purification to homogeneity, 
revealed that the monomeric TIL’E’ fragment, but not a further truncation to domain 
TIL’, represents the minimal folded VWF unit required to bind FVIII. This finding, 
together with the high resolution solution structure of TIL’E’, may have important 
implications for the development of improved haemophilia A therapeutics that rely on 
prolonging the half-life of FVIII in vivo. 
The VWF D’ region is composed of two independently folding domains: TIL’ and E’, 
whose folds are dominated by structural disulphide bridges. The topologically complex 
Figure 3.1: Overall dimensions of monomeric VWF. Shown is the domain architecture of mature 
monomeric VWF and the approximate lengths obtained by electron microscopy studies
137,139,140
. 
High resolution structures are shown below the domain schematic and are coloured red; these are 
the NMR structure of TIL’E’ (D’) and crystal structures of domains A1, A2 and A3. Structures shown 
in grey are homology models, of which modelling of TIL3E3 and TIL4 is based on the NMR structure 
of TIL’E’. The VWC and CK domains are modelled on pdb structures 1U5M
118
 (VWC domain of 
human collagen IIA) and 1XWD (CK domain of human follicle stimulating hormone)
407
, respectively. 
High resolution NMR and crystal structures reveal five functionally significant VWF domains (TIL’, E’, 
A1, A2 and A3) and homology predicts the majority of the remaining mature protein, with the 
exception of the VWD and C8 domains.  
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TIL’E’ disulphide bond connectivity was unambiguously determined. This newly assigns 
the Cys788-Cys799 (3-5), Cys792-Cys827 (4-10) disulphide bonds in domain TIL’ and all 
three disulphide bonds in domain E’, Cys829-Cys581 (1-4), Cys846-Cys863 (2-6) and 
Cys849-Cys858 (3-5), and confirms the three TIL’ Cys767-Cys808 (1-7), Cys776-Cys804 
(2-6) and Cys810-Cys821 (8-9) disulphide bonds determined biochemically42. Both TIL’ 
and E’ are of the small disulphide-rich, all- sheet class of proteins; the TIL’ domain is 
formed of two short -sheets and a long imposing loop that connects strands 1 to 2, 
whereas, the E’ domain is largely formed of a triple-stranded all anti-parallel -sheet. 
Domain TIL’ is strikingly dynamic and harbours a cluster of pathologic mutations that 
lead to decreased FVIII binding affinity (type 2N VWD). The major FVIII binding site on 
VWF is localised to a flexible, positively charged pocket on the front face of the TIL’ 
domain; a region that is perturbed by the majority of 2N VWD mutations. Surface-
charge mapping of the TIL’E’ NMR structure reveals a potential mechanism by which 
the strongly and oppositely charged VWF TIL’ pocket and FVIII a3 domain form a high 
affinity encounter-complex. Together, these findings describe the structural 
specialisation of VWF TIL’E’ in mediating FVIII binding and stabilisation in plasma, 
providing insight into the molecular basis of type 2N VWD.  
The FVIII binding site is contained within domains TIL’E’VWD3 (residues 767 to 1031). 
High affinity binding of the FVIII light chain acidic a3 domain to VWF is very likely to be 
mediated by the positively charged pocket of TIL’. However, the contributions to 
binding by the VWF VWD3 domain and the FVIII light chain domains C1 and C2, are yet 
to be determined. The next logical step in this study is the biochemical characterisation 
of the binding affinity of the FVIII light chain to VWF TIL’E’ and VWD3 domains. This 
would reveal differential binding affinity between TIL’E’ and VWD3 to the FVIII light 
chain and test the hypothesis that high affinity binding is mediated by domains TIL’E’. 
Ideally, FVIII binding studies will also include the full TIL’E’VWD3 region, to account for 
cooperativity between the domains in formation of the binding interface. However, 
recombinant expression of this 24 cysteine fragment in E. coli, will likely pose a 
significant challenge, whereas the eight cysteine VWD3 domain has already been 
successfully expressed. 
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Following characterisation of the VWF TIL’E’ and VWD3 binding kinetics, it would be of 
interest to determine the NMR structure of the VWD3 domain. This would reveal the 
entire FVIII binding region on VWF. Knowledge of the TIL’E’ and VWD3 structures may 
then be combined with NMR binding studies, to identify the precise TIL’E’VWD3 
binding face by mapping of contact residues in TIL’E’ and VWD3. This would confirm if, 
as suspected, TIL’E’ is the principal FVIII binding region on VWF, with subsidiary 
contacts to domain VWD3. Chemical shifts of residues at the interface of the 
TIL’E’FVIII or VWD3FVIII complex are likely to differ between the bound and free 
forms. The perturbation of the chemical shift upon complex formation can be used to 
map the interaction interface, and this data is subsequently used to restrain docking of 
the FVIII light chain onto the TIL’E’ and VWD3 NMR structures. In essence, the 15N-
HSQC spectrum is monitored when unlabelled FVIII light chain is titrated into the 
isotopically labelled VWF domain. These studies may be complemented by NMR cross-
saturation experiments and by TIL’E’FVIII co-crystallisation trials, that would facilitate 
the rigorous identification of contact residues in the complex. The dependence of the 
TIL’E’ and VWD interactions with FVIII on ionic strength and the effects of important 
type 2N missense mutations on complex formation may then also be studied in this 
manner. Type 2N VWD mutants in domains TIL’E’ have been expressed for biochemical 
and NMR studies to characterise changes in both the FVIII binding affinity and in the 
TIL’E’ structure and dynamics.  
The most immediate succeeding steps are those of finer characterisation of the 
VWFFVIII interaction, and the structural and dynamic perturbations upon inheritance 
of a type 2N VWD mutation, to build a detailed mechanistic model of VWFFVIII 
complex formation. However, a critical element of the work presented in this thesis 
has been the successful expression and purification of TIL’E’ in E. coli. This 
methodology forms a basis from which the recombinant production of the remaining 
cysteine-rich N- and C-terminal flanking regions may be optimised, leading to their 
structural characterisation. Of particular interest is the characterisation of the VWD 
and C8 domains, for which there are no known structural homologues. This would 
allow a high resolution structure of mature VWF to subsequently be assembled. In 
141 
 
view of the importance of VWF in common vascular diseases, its molecular structure is 
not only of basic scientific interest but is also of direct clinical importance.  
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4. Materials and Methods 
 
The methodologies for the studies presented in this thesis are outlined below.  
 
4.1. Multiple sequence alignments of TIL’ and E’ domain families 
The classical VWF D domains are annotated as containing VWD domains, C8 domains 
and trypsin inhibitor-like (TIL) domains in the protein family, Pfam399, database (VWD: 
PF00094; C8: PF08742; TIL: PF01826) and VWD and TIL domains in the universal 
protein source (UniProt; human VWF: P04275.4). The E domains, assigned in this study 
and by Zhou YF et al50, follow the VWF TIL domains. The Pfam database399 annotates a 
fibronectin I-like clan (CL0451) based on sequence homology that includes VWC 
domains. Their structural homology is corroborated by the structural classification of 
proteins (SCOP) database400 in which VWC subdomain 1 and fibronectin are classified 
to the fibronectin I-like superfamily (57603).  These databases are yet to include the 
VWF E domains in this superfamily.  
VWF (NP_000543.2) and homologous domain family sequence alignments were 
initially built using the programme MUSCLE401. These alignments were subsequently 
viewed and refined by eye, to account for cysteine conservation and hydrophobic 
residues, using the programme Jalview402; these multiple sequence alignments were 
used to define the VWF TIL’ and E’ domain boundaries.  
 
4.2. Construction of homology models 
The final structural templates, used to model domains TIL’ and E’, were principally 
based on two parameters; the highest sequence identity (similarity) and the least 
number of insertions and deletions in a pairwise alignment. Sequence identity (and 
similarity) was assessed by global pairwise alignment using the programme Needle 
(EMBOSS)114. VWF TIL’ was modelled against the NMR structure of Apis mellifera 
chymotrypsin/cathepsin G inhibitor-1 (AMCI-1; pdb: 1CCV), sharing 32.3% sequence 
indentity (37.1% similarity). Modelling of TIL’ based on this template required two 
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insertions, one of eight resides and another of one residue, and two single residue 
deletions. Domain E’ was modelled against the NMR structure of VWC subdomain 1 of 
human collagen IIA 30.6% (similarity 38.9%), requiring one single residue deletion. To 
induce Cys2-Cys6 bonding in domain E’, Cys6 was aligned to Cys8 of template 1U5M. 
Dictionary of Secondary Structure in Proteins (DSSP)403 assignments of the template 
structures were included into the pairwise alignments to correctly assign sequence 
gaps to loop regions, and to conserve the positions of the cysteine residues. Models 
were subsequently built and energy minimised with the programme Modeller 9v8 
using the automodel class404.  
 
4.3. Cloning of TIL’E’ into pET32b(+) vector - construct TRX-His6-TIL’E’ 
Plasmid pcDNA 3.1 FL-VWF containing the full length VWF cDNA was a kind gift from 
Dr Thomas AJ McKinnon. The VWF coding sequence corresponding to domains TIL’E’, 
residues 766-864 (one end residue), contains XhoI and NcoI restriction sites. These 
sites were removed by conservative site directed mutagenesis to facilitate cloning of 
this region into vector pET32b(+).   
The VWF TIL’E’ domains (residues 766-864) span bases 2296 to 2592 (297 bp) and 
contain an NcoI site at cDNA bp 2309-2314 (CCATGG) and an XhoI site at bp 2356-2361 
(CTCGAG) in domain TIL’. The following complementary mutagenic oligonucleotides 
(orientated 5’ to 3’) were used to remove these restriction sites in successive 
mutagenesis reactions by the introduction of mutations c.2310C>G, to remove the 
NcoI site and c.2358C>G, to remove the XhoI site: 
NcoI Forward:  ATC CTG TCG GCC CCC GAT GGT CAA GCT GGT G (31 bp) 
 Reverse:  CAC CAG CTT GAC CAT CGG GGG CCG ACA GGA T (31 bp) 
   
XhoI Forward: CGG GCT GAA GGG CTG GAG TGT ACC AAA AC (29 bp) 
 Reverse: GTT TTG GTA CAC TCC AGC CCT TCA GCC CG (29 bp) 
 
Mutagenesis of VWF cDNA was performed by the polymerase chain reaction (PCR), in a 
Corbin Research Thermal Cycler, using the (NcoI and XhoI) oligonucleotides outlined 
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above, and KOD XtremeTM Hot Start DNA Polymerase (Novagen). The reaction set up is 
outlined below:  
Table 4.1: KOD Xtreme polymerase reaction set up 
Component Stock Volume Final concentration 
Xtreme buffer 2 x 25 L 1 x 
dNTPs  2mM each 10 L 0.4 mM each 
ddH2O - 10 L - 
5’ primer 10 M 1.5 L 0.3 M 
3’ primer 10 M 1.5 L 0.3 M 
FL-VWF DNA template 378 ng/L 1 L 378 ng 
KOD Xtreme DNA polymerase 1 U/L 1 L 0.02 U/L 
Total reaction volume  50 L  
 
The following PCR temperature cycling protocol was used for mutagenesis: 
Table 4.2: Mutagenic PCR temperature cycling 
Step Temperature (C) Time Number of cycles 
Polymerase activation 94 30 s 1 
Denaturation 98 10 s  
Annealing 55 30 s 16 
Extension* 68 13 min 46 s  
Completion 68 10 min 1 
Hold 4 - - 
* Extension calculated at 1 minute per Kilo bp  
Successful PCR reactions were verified by agarose gel electrophoresis. An 0.7% w/v 
agarose gel was made by dissolving 0.35 g agarose in 50 mL 1 x TAE buffer and heating. 
A stock of 50 x TAE buffer was used (242 g Tris, 57.1 mL glacial acetic acid, 100 mL 0.5 
M EDTA at pH 8.0). The agarose solution was left to cool and 2.5 L of ethidium 
bromide (10 mg/mL) was added to a final concentration of 0.5 g/mL. The solution was 
poured into a gel frame containing a comb for well formation, and allowed to set at 
room temperature for 40 minutes. 5 L of PCR reaction product was mixed with 1 L of 
6 x DNA loading buffer (Novagen) and applied into the well. The TrackItTM 1 Kb Plus 
DNA ladder (Invitrogen) was used for reference, and the samples electrophoresed in 1 
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x TAE buffer at a constant voltage of 100V until the dye front had reached the end of 
the gel. The DNA bands were visualised under ultraviolet light by ethidium bromide 
fluorescence.  
Selection of mutant VWF cDNA was achieved by treatment with DpnI. The DpnI 
endonuclease (target sequence: 5’-Gm6ATC-3’) is specific for methylated and 
hemimethylated DNA and is used to digest parental DNA template and to select for 
mutation containing synthesised DNA. Plasmid DNA isolated from almost all commonly 
used strains of E. coli have been fully methylated in vivo by the endogenous Dam 
methylase and are therefore sensitive to cleavage by DpnI. In contrast, DNA 
synthesised in vitro using the conventional four deoxynucleotides is unmethylated and 
therefore completely resistant to cleavage. Consequently, DpnI can be used after the 
site directed mutagenesis to degrade residual methylated wild-type templates and to 
enrich for unmethylated DNAs synthesised in vitro. The DpnI reaction was set up as 
follows using reagents from New England Biolabs (NEB): 
Table 4.3: DpnI digestion reaction 
Component Volume (L) 
PCR product 40 
BSA (100 x) 0.5 
NEB Buffer 4 (10 x) 5 
ddH2O 3.5 
DpnI (20 U/L) 1 
 
The DpnI reaction (Table 4.3) was incubated for two hours at 37 C, and the 
endonuclease subsequently heat inactivated at 65C for 20 minutes. The reaction was 
then placed on ice awaiting transformation into NovaBlueTM (Novagen) competent 
cells for plasmid purification and sequencing, to confirm that both the XhoI and NcoI 
sites within the VWF TIL’ have been mutated.  
To 25 L of E. coli NovaBlueTM (Novagen) cells, 1 L or 1.5 L of DpnI digested mutated 
pcDNA 3.1 FL-VWF plasmid was added. The cells were incubated on ice for 30 minutes, 
followed by a heat shock of 45 seconds at 42C and placed back on ice for 1 minute. 
800 L of sterile LB (Luria Broth) media was added to the cells and incubated for one 
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hour in a 37 C orbital shaker at 200 rpm, to aid cell recovery and allow expression of 
the ampicillin resistance gene. 250 L of cells were then plated onto LB agar plates 
containing 50 g/mL ampicillin and incubated at 37 C for 12-16 hours, until the 
colonies were 2-3 mm in size.  
Single colonies were inoculated into 5 mL of sterile LB media containing 50 g/mL 
ampicillin and grown overnight. DNA was subsequently purified using the E.Z.N.A 
plasmid miniprep kit (Omega Bio-Tek). The mutations generated to remove TIL’ 
domain restriction sites were verified by sequencing (Source Bioscience) to ensure the 
absence of PCR-introduced errors and the presence of the desired mutations 
(c.2358C>G and c.2310C>G).  
VWF cDNA bp 2296-2592 (297 bp) encompassing domains TIL’E’ (residues 766 through 
864) was subsequently amplified from the correctly mutated pcDNA 3.1 FL-VWF 
plasmid. The forward primer was designed to amplify VWF from base number 2296 
and introduced 10 random bases followed by an NcoI restriction site before the start 
of the VWF sequence. TTT TTT CAT G random bases were inserted to reduce the GC 
content and melting temperature of the oligonucleotide; the last four bases of which, 
CAT G, also serve to increase NcoI specificity. Following the NcoI site, an additional two 
bases, GC, were added to keep the sequence in frame. The reverse primer amplified 
from VWF base number 2592 and, immediately following the VWF sequence, 
introduced a stop codon (TTA), a XhoI site and six random bases (CCG CCG), to increase 
XhoI specificity and the melting temperature of the primer. The oligonucleotides used, 
orientated 5’ to 3’ are outlined below, in which the restriction sites are shown in bold: 
Forward: TTT TTT CAT GCC ATG GGC TCC TGT CGG CCC CCG ATG Tm: 75.16 C  
Reverse: CCG CCG CTC GAG TTA ATC ACA CAC ATG GTC TGT GCA Tm: 74.00 C 
 
The amplification reaction was set up as outlined in Table 4.1, and the PCR 
temperature cycling protocol used for DNA amplification is shown in Table 4.4. A 0.7% 
w/v agarose gel confirmed amplification of PCR products. The resulting VWF product 
was double digested with restriction enzymes NcoI and XhoI, and their respective 
buffers (NEB). The 5.9 Kb pET32b(+) cloning vector contains a T7 promoter, N-terminal 
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thioredoxin and His6 tags, and a gene conferring ampicillin resistance. The vector has 
been modified to replace an enterokinase site with a Tobacco Etch Virus (TEV) 
cleavage site (ENLYFQG). To facilitate cloning of the VWF amplification product into 
vector pET32b(+) using restriction sites NcoI and XhoI, the vector was also digested 
with NcoI and XhoI restriction enzymes (NEB). The restriction enzyme digestion 
reaction components are outlined in Table 4.5. Digestion was allowed to proceed at 
37C for three hours to produce the VWF TIL’E’ insert and the linearised pET32b(+) 
vector. 
Table 4.4: Amplification PCR temperature cycling  
Step Temperature (C) Time Number of cycles 
Polymerase activation 94 2 min 1 
Denaturation 98 10 s  
Annealing† 74 30 s 30 
Extension* 68 20 s  
Completion 68 1 min 1 
Hold 4 - - 
†The annealing temperature is that of the lowest melting temperature (Tm) primer. * Total amplified 
DNA product is 330 bases, extension time calculated at 1Kb/minute giving 19.8 seconds. 
 
Table 4.5: XhoI and NcoI double digestion reaction  
Component Volume (L) 
VWF amplified DNA or Pet32b(+) vector 20 
XhoI 3 
NcoI 3 
BSA (100 x) 1 
NEB buffer 4 10 
ddH2O 63 
Total reaction 100 
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To purify the VWF TIL’E’ insert and pET32b(+) vector DNA prior to ligation, the samples 
were subjected to 0.7% w/v agarose gel electrophoresis. The DNA fragments were 
visualised by ethidium bromide fluorescence upon exposure to ultra violet light, and 
excised from the gel. The insert and vector DNA were purified from the gel slices using 
an E.Z.N.A gel extraction kit (Omega Bio-Tek) and eluted in 30 L elution buffer (10 
mM TrisHCL, pH 8.5) or water.  
The VWF TIL’E’ (aa 766-864) insert containing base pairs 2296 to 2592 and vector 
pET32b(+) were ligated using T4 DNA ligase and 10 x T4 DNA ligase buffer (NEB). Molar 
ratios of 1:3, 1:5 and 1:10 vector-to-VWF insert were used for cohesive end ligations. 
The amount of insert required for each molar ratio was determined using the equation 
below: 
                        (  )
            (  )
                         
  
Ligation reactions were incubated at 16C for 18 hours. T4 DNA ligase activity was 
subsequently quenched by heat inactivation for 10 minutes at 65C. 10 L of each 
ligation reaction was then transformed into 50 L of NovaBlueTM (Novagen) cells, 
plated on LB agar containing 50 g/mL ampicillin, and incubated overnight at 37C.  
Single bacterial colonies from each plate were screened by PCR to confirm the 
presence of the VWF TIL’E’ (bp 2296-2592; aa 766-864) insert using the VWF 
amplification (cloning) primers outlined above. Taq polymerase (NEB) was used for all 
PCR colony screening reactions. Sterile pipette tips were used to collect single colonies, 
which were mixed into a PCR tube containing the reaction components set in Table 
4.6. Simultaneously, that colony was also inoculated into 5 mL of LB media containing 
50 g/mL ampicillin and grown overnight at 37C in an orbital incubator at 200 rpm, 
for plasmid purification and sequencing upon indication of a positive PCR screen. 
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Table 4.6: Colony screen reaction conditions 
Component Volume (L) 
Taq ThermoPol buffer (10 x) 2.5 
Forward VWF amplification primer (10 M) 1.25 
Reverse VWF amplification primer (10 M) 1.25 
dNTPs (2mM each) 2.5 
Sterile ddH2O 17 
Taq DNA polymerase 0.5 
 
The temperature cycling protocol used for the colony screen is outlined below: 
Table 4.7: Colony screen PCR temperature cycling 
Step Temperature (C) Time Number of cycles 
Polymerase activation 95 5 min 1 
Denaturation 95 1 min  
Annealing† 69 1 min 30 
Extension 72 30 s  
Completion 68 1 min 1 
Hold 4 - - 
† Tm of lowest primer (74C) minus 5C.  
Two control PCR reactions were also set up. Negative control reactions contained no 
bacterial colony. Positive control reactions contained 0.5 L of restriction site mutated 
pcDNA 3.1 FL-VWF. PCR products of the screen were analysed by agarose gel 
electrophoresis for successful amplification of the VWF TIL’E’ insert.  
Plasmids containing the VWF insert were purified from the overnight cultures using the 
E.Z.D.N.A plasmid miniprep kit (Omega Bio-Tek) and digested with XhoI and NcoI 
restriction enzymes (NEB) to confirm clones containing the VWF insert of the expected 
size (300 bp). Correct clones were sent for sequencing (Source Bioscience). Construct 
TRX-His6-TIL’E’ (VWF bp 2296-2592; residues 766-864) with the correct sequence was 
used for protein expression, purification and TIL’E NMR structure determination.  
To produce construct TRX-His6-TIL’ (VWF residues 766-828) a stop codon (TAA) was 
inserted following VWF Pro828 (CCC) in construct TRX-His6-TIL’E’ (VWF bp 2296-2592; 
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residues 766-864), using the complementary pair of mutagenic oligonucleotides shown 
below (inserted bases are highlighted in capitals): 
Forward: gcc ctg gaa agg tgt ccc TAA tgc ttc cat cag ggc aag Tm: 76C 
Reverse: Ctt gcc ctg atg gaa gca TTA ggg ac acct ttc cag ggc Tm: 76C 
 
 
4.4. Cloning of TIL’E’ into pET29b(+) - construct His6-TIL’E’ 
Many difficulties were encountered in the generation of construct His6-TIL’E’ (VWF 
residues 766-864), for reasons which are unknown. Initially VWF sequence bp 2323 to 
2592, encompassing residues 775 through 864 (domains TIL’E’ but excluding residue 
767 Cys1 of TIL’) was amplified from pcDNA3.1 FL-VWF plasmid containing mutation 
c.C2358G to remove the XhoI restriction site in domain TIL’, and cloned into vector 
pET29b(+) containing an N-terminal His6 tag and kanamycin resistance, using 
restriction sites BamHI and XhoI (NEB). Repeated attempts to clone VWF bp 2296-2592 
(residues 766-864), containing the correct TIL’E’ domain boundaries into pET29b(+) 
vector, were unsuccessful. Cloning oligonucleotides for the insertion of VWF 
sequences into pET29b(+) are shown below: 
 
 VWF bp 2323-2592 (residues 775-864)   
Forward: TTT TTT GGA TCC GTG TGT CCC GCT GAC Tm: 66.5C 
Reverse: TGG TTG CTC GAG TTA ATC ACA CAC ATG GTC Tm: 66.8C 
   
 VWF bp 2296-2592 (residues 766-864)  
Forward: TTT TTT GGA TCC TCC TGT CGG CCC CCC ATG Tm: 70.9C 
Reverse: TGG TTG CTC GAG TTA ATC ACA CAC ATG GTC Tm: 66.8C 
           
Therefore, the VWF sequence (bp 2323-2592) corresponding to residues 755-864, 
cloned into vector pET29b(+), was extended by a pair of mutagenic oligonucleotides 
designed to insert the missing nine VWF residues (766-774). This resulted in the 
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construct His6-TIL’E’ (VWF bp 2296-2592; residues 766-864), that encompasses all 
conserved TIL’ cysteines. The mutagenic nine-residue insertion primers are shown 
below; inserted base pairs are capitalised. 
Forward: ctg tac ttc cag gga tcc TCC TGT CGG CCC CCC ATG GTC AAG 
CTG gtg tgt ccc gct gac aac 
Tm: 84 C 
Reverse: gtt gtc agc ggg aca cac CAG CTT GAC CAT GGG GGG CCG ACA 
GGA gga tcc ctg gaa gta cag 
Tm: 84 C 
 
These primers were successfully used with KOD XtremeTM Hot Start DNA Polymerase in 
a reaction setup as outlined in Table 4.1, using the temperature cycling protocol shown 
in Table 4.8. This facilitated the extension of the VWF sequence in pET29b(+) from bp 
2323-2592 (residues 775-864) to bp 2296-2592 (766-864), forming construct His6-
TIL’E’, which was eliminated from further study as expression produced disulphide 
isomers of incorrectly folded TIL’E’ molecules.  
Table 4.8: Nine-residue insertion mutagenisis PCR reaction 
Step Temperature (C) Time Number of cycles 
Polymerase activation 94 30 s 1 
Denaturation 98 10 s  
Annealing 55 30 s 18 
Extension* 68 5 min 41 s  
Completion 68 10 min 1 
Hold 4 - - 
* calculated at 1 Kb/minute 
 
4.5. Expression of TRX-His6-TIL’E’ in E. coli SHuffle cells 
Construct TRX-His6-TIL’E’ (residues 766-864; bp 2296-2592) cloned into the E. coli 
pET32b(+) vector containing an N-terminal thioredoxin (TRX) and His6 tag was used for 
all further studies. The TRX domain aids the formation of eight disulphide bonds and 
the His6 tag allows purification by nickel affinity chromatography (Ni-NTA) - was used 
for all further studies. The TIL’E’ (VWF residues 766-864) fusion protein was expressed 
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in SHuffle cells337 and grown in either LB media or M9 minimal media. An LB agar plate 
containing 50 g/mL ampicillin was inoculated with SHuffle cells337, that had been 
transformed with plasmid pET32b(+) TRX-His6-TIL’E’ and grown overnight at 37 C.  
Isotope labelled TIL’E’ for NMR studies, was grown in M9 minimal media 
supplemented with 2.5 g/L 13C-D-glucose and 1 g/L 15NH4Cl, as the sole source of 
carbon and nitrogen, respectively. For single isotope labelling, 15NH4Cl was substituted 
for NH4Cl and 
13C-D-glucose was substituted for D-glucose (10 g/L). Components of 1L 
of M9 minimal media are outlined below: 
M9 base pH 7.4  1 L 
15NH4Cl 1 g 
13C-D-glucose 2.5 g 
1 M MgSO4 1 mL 
0.1 M CaCl2 1 mL 
Micronutrient solution 1 (1000 x) 1 mL 
Micronutrient solution 2 (10 000 x) 0.1 mL 
Thiamin/biotin solution (1000 x) 1 mL 
Ampicillin (1000 x) 1 mL 
  
M9 base:  
Na2HPO4 6 g 
KH2PO4 3 g 
NaCl 0.5 g 
Adjusted to pH 7.4 and autoclaved  
  
Micronutrient solution 1 (1000 x)  
CaCl2 1.5 g 
Na2EDTA 3 g 
FeCl3 2.5 g 
  
Micronutrient solution 2 (10 000 x)  
CuSO4 2.4 g 
MnSO4 1.8 g 
ZnSO4 0.27 g 
CoCl2 0.27 g 
  
Thiamin/biotin solution (1000 x)  
Thiamin 0.1 g 
D-Biotin 0.1 g 
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Isotopically labelled cell cultures were initiated by inoculating 50 mL of M9 minimal 
media with a single transformed bacterial colony and grown overnight in an orbital 
shaker (220 rpm) at 30oC to an OD600 of 0.5.  
The following morning, cells of the overnight culture were gently pelleted by 
centrifugation for 7 minutes at 4000 rpm. The cells were resuspended in 8 mL of fresh 
M9 media, which was used to inoculate 800 mL M9 media in a 2L flask (often 3.2 L of 
isotope labelled TIL’E’ was grown). Cells were subsequently grown by shaking (200 
rpm) at 30oC to an OD600 of 0.4; after which time, the temperature was lowered to 
16oC and the cells were grown to an OD600 of 0.6. At this point, over-expression of TRX-
His6-TIL’E’ was induced by the addition of 0.4 mM IPTG and cells were incubated for a 
further 16 hours at 16oC. The cells were harvested by centrifugation (4000 rpm, 20 
minutes, 4C) and subsequently flash frozen in liquid nitrogen and stored at -80C prior 
to lysis.  
For 10% fractionally 13C-labelled TRX-His6-TIL’E’, the M9 media was supplemented with 
10% 13C-D-glucose and 90% unlabelled glucose to drive the stereospecific labelling of 
leucine and valine methyl groups. Unlabelled TRX-His6-TIL’E’ for biochemical studies 
was grown in LB media containing 50 g/mL ampicillin.  
 
4.6. Purification of TIL’E’ 
TRX-His6-TIL’E’ cell pellets were thawed on ice and resuspended in 35 mL of wash 
buffer (20 mM sodium phosphate, 500 mM NaCl, 40 mM Imidazole, pH 7.4) by 
vortexing without pause to prevent the formation of foam. The cell suspension was 
then spiked with: 1 tablet of Complete protease inhibitor cocktail (Roche), 0.25% of the 
anionic detergent IGEPAL, lysozyme to a final concentration of 0.01 mg/mL and DNase 
(5-10 g/mL). The cells were subsequently broken by triple-pass through a French 
press and incubated for 30 minutes, under continuous rocking at 4C, to complete 
lysis. Cellular debris and nuclei were removed by centrifugation at 20 000 rpm in a 
Sorvall SS34 rotor for 40 minutes.  
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The cleared SHuffle cell337 cytoplasm is then filtered through an 0.22 m syringe filter 
and loaded onto a His-Trap Ni-NTA column (5 mL; GE Healthcare) pre-equilibrated with 
wash buffer. The bound TRX-His6-TIL’E’ protein (28.6 kDa) was eluted using an AKTA 
FPLC system (Amersham) by the application of a shallow (20 column volume) linear 
gradient of increasing imidazole (0-500 mM) with the following elution buffer: 20 mM 
sodium phosphate, 500 mM NaCl, 40 mM, pH 7.4. Bound TRX-His6-TIL’E’ elutes at an 
imidazole concentration of 100-150 mM. Elution fractions were analysed by 4-20% 
Tris-glycine SDS-PAGE under non-reducing conditions. Fractions containing monomeric 
TRX-His6-TIL’E’ proteins are pooled (20 mL) and dialysed against 20 mM sodium 
phosphate, 100 mM NaCl, pH 7.4, to reduce the imidazole concentration and reach 
optimal conditions for TEV proteolysis.  
His-tagged TEV protease (21 kDa) is stable when stored in 30% glycerol, 20 mM 
monobasic phosphate buffer, 250 mM NaCl and 10 mM -mercaptoethanol. Crucially, 
the reducing agent -mercaptoethanol is removed by dialysis against 20 mM sodium 
phosphate, 100 mM NaCl, pH 7.4, prior to proceeding with proteolysis of TRX-His6-
TIL’E’. For the TEV cleavage reaction, TEV protease is added to TRX-His6-TIL’E’ in the 
ratio of 1 OD280 TEV per 5-10 OD280 of TRX-His6-TIL’E’; the reaction was incubated on a 
gently rocking platform at room temperature for three hours, and then at 4C 
overnight to complete cleavage. Most of the TRX-His6-TIL’E’ protein, however, is 
cleaved within the first two hours.  
Following cleavage, imidazole is added to the cleavage reaction to a final concentration 
of 40 mM, and subsequently applied again to the His-Trap Ni-NTA column (5 mL; GE 
Healthcare), pre-equilibrated with wash buffer (20 mM sodium phosphate, 500 mM 
NaCl, 40 mM Imidazole, pH 7.4). The N-terminal TRX-His6 tag (17.3 kDa) binds to the 
nickel column, whereas TIL’E’ remains unbound, and is thus collected in the binding 
and washing flow-through fractions. TEV-cleaved TIL’E’ is formed of 103 residues, the 
amino-terminal four residues (GAMG) are artefacts of cloning. The TIL’E’ pool is then 
concentrated and loaded onto a 16/60 Superdex 75 column (GE Healthcare) pre-
equilibrated with running buffer, 20 mM, as a final purification step. TIL’E’ consistently 
elutes in a single symmetrical peak at 73 mL. Non-reducing SDS-PAGE (4-20% Tris-
glycine) was used to analyse the size exclusion chromatography elution fractions. 
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Monomeric TIL’E’ (11.3 kDa) in 20 mM sodium phosphate, 100 mM NaCl, pH 7.4 is 
concentrated to 450 L with final sample concentrations obtained ranging from 0.5-1 
mM. Protein concentration was determined by measurement of the UV absorbance at 
280 nm, using an extinction coefficient of 0.836 for a 0.1% (mg/mL) solution. TIL’E’ in 
the absence of an N-terminal thioredoxin tag and thioredoxin-tagged domain TIL’ 
(residues 766-828) were expressed and purified in essentially the same way. 
 
4.7. Ellman’s assay 
Free thiol groups in purified TIL’E’ were quantified by molar absorptivity. That all 
cysteine residues were engaged in disulphide bonding was verified by an Ellman’s 
assay (DTNB, 5,5’-dithio-bis-(2-nitrobenzoic acid)). DTNB reacts with a free sulfhydryl 
group to yield a mixed disulphide bond and TNB (2-nitro-5-thiobenzoic acid), which can 
be detected spectrophotometrically at 412 nm. The thiol content of purified 
monomeric TIL’E’ was zero, as demonstrated by non-absorbance at 412 nm during the 
assay. Ellman’s reagent was purchased from Thermo Scientific.  
 
4.8. Nanoelectrospray ionisation mass spectrometry 
Recombinant TIL’E’ (10 M) was buffer exchanged into 100 mM ammonium acetate 
(pH 7.0) for mass spectrometry analysis on a Synapt HDMS (Waters) mass 
spectrometer. A 2.5 L aliquot of TIL’E’ was delivered to the mass spectrometer by means 
of nanoelectrospray ionisation (nanoESI) using gold-coated capillaries. The 
experiments were kindly performed by Dr Konstantinos Thalassinos.  
 
4.9. Blotting with recombinant FVIII 
Binding of TRX-His6-TIL’E’ to full length FVIII was shown by dot blot analysis. 
Reconstituted recombinant FVIII, Helixate NextGen 0.25 g/IU (CSL Behring), was 
buffer exchanged into 20 mM Sodium Phosphate, 100 mM NaCl, pH 7.4 to a 
concentration of 1 g/L. FVIII (125 ng, 250 ng, 500 ng and 1 g) was blotted onto a 
nitrocellulose membrane and left to dry at room temperature for 1 hour. The 
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membrane was washed twice in TBS buffer (10 mM Tris.Cl, 100 mM NaCl, pH 7.5) at 
room temperature and subsequently blocked with 5% non-fat milk in TBS containing 
0.05% tween 20 (TBS-T). This was followed by three wash steps, twice with TBS-T and a 
final wash with TBS. The membrane was then incubated for two hours at room 
temperature in blocking buffer (5% non-fat milk in TBS-T) containing 0.79 mg/mL TRX-
His6-TIL’E’. Following washing of the membrane, twice in TBS-T and once in TBS, it was 
subsequently incubated with horseradish peroxidase (HRP)-conjugated anti-(penta)His 
antibodies (Qiagen), diluted 1 in 1000 in blocking buffer, for one hour at room 
temperature. The membrane was washed again, and the binding of TRX-His6-TIL’E’ to 
the immobilised FVIII was revealed by ECL chemiluminescence (SuperSignal West Pico 
Chemiluminescent Substrate, Thermo Scientific). A control blot in which FVIII (62.5 ng, 
125 ng, 250 ng, 500 ng and 1 L), TRX-His6-TIL’E’ (30 ng) and BSA (250 ng) were spotted 
onto the membrane and detected with HRP-conjugated anti-His antibodies, was 
generated by the same procedure; importantly however, the control blot was not 
incubated with TRX-His6-TIL’E’ in blocking buffer.  
 
4.10. Blotting with mAb 418 
mAb 418 is a potent FVIII binding-blocking antibody that recognises the unreduced N-
terminus of von Willebrand factor (epitope residues 765-816)237,313. An aliquot of 
mouse mAb 418 (0.65 mg/mL) was a kind gift from Dr Peter J Lenting. TIL’E’ (0.45 
mg/mL) was reduced with 10 mM dithiothreitol (DTT) and subsequently alkylated in 
the dark with a molar excess (30 mM) of iodoacetamide. 1 L of a 1 M DTT solution 
was added to 100 L of TIL’E’ (10 mM final DTT concentration) and incubated on the 
bench (at room temperature) for 30 minutes. To the reduced TIL’E’, 1.1 L of 300 mM 
iodoacetamide was added to a final concentration of 30 mM; to alkylate and block the 
newly formed TIL’E’ thiol groups, and thereby, prevent their re-oxidisation. The 
alkylation reaction was immediately covered in aluminium foil, placed in a cupboard 
and allowed to proceed in the dark for 30 minutes.  
Both native TIL’E’ and reduced and alkylated TIL’E’ were blotted onto a nitrocellulose 
membrane in increasing amounts of 56.25 ng, 112.5 ng, 225 ng and 450 ng. The 
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membrane was allowed to dry at room temperature for one hour. Following washing 
with TBS buffer the membrane was incubated with blocking buffer (5% non-fat milk in 
TBS-T) for one hour at room temperature. The membrane was then washed three 
times; twice with TBS-T buffer and once with TBS buffer, and subsequently incubated 
with mAb-418 (diluted 1 in 1000) in blocking buffer for two hours at room 
temperature. Following washing, twice in TBS-T and once in TBS buffer, the membrane 
was then incubated with secondary HRP-conjugated anti-mouse IgG antibody (diluted 
1 in 1000) in blocking buffer for one hour at room temperature. The membrane was 
washed three times (twice in TBS-T, then once in TBS buffer) prior to ECL 
chemiluminescence detection to reveal binding of mAb-418 to TIL’E’.  
 
4.11. NMR experimental setup 
NMR experiments were recorded by Dr D. Flemming Hansen and Dr John Kirkpatrick, 
at 25C (298 K) on a Varian INOVA 600 MHz spectrometer and Bruker Avance III 500 
MHz and 700 MHz spectrometers. The 600 MHz and 700 MHz spectrometers were 
equipped with cryogenic inverse triple-resonance probes, and the 500 MHz 
spectrometer with a room temperature inverse triple-resonance probe. NMR data 
were processed with NMRPipe405. Spectral analysis, peak picking and assignments 
were performed using the programme Sparky (Goddard TD and Kneller DG, SPARKY 3, 
University of California, San Francisco).  
 
4.12. TIL’E’ samples for NMR studies 
15N- and 13C15N-labelled TIL’E’ samples were prepared for NMR spectroscopy at 
concentrations of 0.5-1 mM in 20 mM sodium phosphate (Na2HPO4/NaH2PO4), 100 
mM NaCl, 10% D2O at pH 7.4. Samples used for backbone RDC measurements were 
prepared by adding Pf1 bacteriophage (ASLA Biotech) at a concentration of 6 mg/mL or 
C12E5/n-hexanol (Sigma-Aldrich) at 3% w/w C12E5, r = 0.94 (were r is the molar ratio of 
C12E5 to hexanol). 
 
158 
 
4.13. Chemical shift assignment 
Backbone chemical shift assignments were obtained using standard triple-resonance 
experiments recorded at 600 MHz, including HNCO, HNCA, HN(CO)CA, HN(CA)CO and 
HNCACB spectra, supplemented with 15N-HSQC-NOESY-HSQC and HN(CACO)NH 
spectra. Side chain assignments were obtained from CC-TOCSY (total correlation) type 
experiments recorded at 600 MHz, including CC(CO)NH-TOCSY, HCC(CO)NH-TOCSY and 
HCCH-TOCSY. Each NH strip of the CC(CO)NH-TOCSY spectrum, will contain peaks for 
all carbon nuclei in the side chain of residue i-1, whereas, each NH strip of the 
HCC(CO)NH-TOCSY spectrum will contain peaks for all hydrogen nuclei in the side chain 
of residue i-1. In the HCCH-TOCSY spectrum, each CH strip will contain peaks for all the 
hydrogen atoms attached to all other carbon atoms in the same side chain. The 
prochiral methyl groups of valine and leucine were stereospecifically assigned 
according to the method of Neri et al349. The TIL’E’ assigned chemical shift list is found 
in Appendix 5.2.  
 
4.14. Backbone dihedral angles and RCI-S2 order parameters 
Backbone dihedral angle constraints,  and , were calculated from the backbone 
chemical shifts (15N, 1HN, 13CO, 13C and 13C)  using the programme TALOS+345. 
Dihedral angles that were classified as dynamic or bad by the TALOS+ algorithm345 
were excluded; 108 angles were used as restraints in the TIL’E’ structure calculations. 
The TALOS+ programme345 also calculates the RCI-derived order parameter S2 using 
the backbone chemical shifts; this calculation is based on the method of Berjanski and 
Wishart344; a table of predicted RCI-S2 values for TIL’E’ is given in Appendix 5.4.  
 
4.15. NOESY experiments 
1H-1H distance restraints for TIL’E’ structure calculations were extracted from two 
nuclear Overhauser enhancement spectra (NOESY); 15N-NOESY-HSQC and 13C-NOESY-
HSQC spectra, recorded at 600 MHz (140 ms mixing time) and 700 MHz (120 ms mixing 
time), respectively. In the 15N-NOESY- HSQC each strip contains NOEs from one NH 
group to all other hydrogen atoms in close proximity, whereas, each strip of the 13C-
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NOESY-HSQC spectrum contains NOEs from one CH group to all other hydrogens 
nearby. NOEs were manually assigned, in all three dimensions, and in total 954 unique 
inter-residue distance restraints were obtained (Table 4.9). The intensities of the NOEs 
were used as input for the programme CYANA 3.0 in subsequent structure calculations. 
In addition, 1540 intra-residue NOEs were assigned but where not used in the 
structure calculation, as they provide very limited structural information. 
Table 4.9: Summary of NOE distance restraints. 
Unique
 1
H-
1
H NOEs Number 
 Inter-residue 954 
Sequential(1) 383 
Short-range(2-3) 121 
Medium-range(4-5) 97 
Long-range(>5) 353 
 
 
4.16. Residual dipolar couplings 
Vector orientations were calculated from experimental residual dipolar couplings 
(RDCs) obtained in two nearly orthogonal alignment media, Pf1 phage and C12E5/n-
hexanol. 1HNi-
15Ni RDCs were measured at 500 MHz in both alignment media using a 2D 
IPAP-15N-HSQC pulse sequence. 15Ni-
13COi-1, 
1HNi-
13COi-1, 
13COi-
13Ci,
 1HNi-
13Ci-1, 
13Ci-
13Ci and 
13Ci-
1Hi RDCs were measured at 500 MHz in the C12E5/n-hexanol alignment 
medium only. 15Ni-
13COi-1 and 
1HNi-
13COi-1 RDCs were measured using a 2D IPAP-
E.COSY-15N-HSQC experiment. 13COi-
13Ci  and 
1HNi-
13Ci-1 RDCs were measured using a 
3D IPAP-HNCO(J-CA) sequence; 13Ci-
13Ci RDCs were measured using a 3D in-phase 
HN(CO)CA(J-CB) sequence; 13Ci-
1Hi RDCs were measured using a 3D IPAP-
(HA)CA(CO)NH sequence. A total of 361 RDC restraints were obtained. VWF TIL’E’ 
residues undergoing significant internal dynamics, as indicated by a 1[H]-15N NOE value 
of 0.6 or below or where the 1[H]-15N NOE could not be obtained, were excluded from 
the single structure calculations. However, all RDC measurements were included in the 
ensemble refinement calculation, which simultaneously represents the TIL’E’ structure 
and its intrinsic picosecond to microsecond dynamics. Back-calculation of RDCs from 
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an RDC-refined TIL’E’ NMR structure was undertaken with the programme Module 
1.0363. 
 
4.17. TIL’E’ structure calculation with CYANA 3.0 
Lists that include assigned peak positions and peak intensities of the 13C-edited and 
15N-edited NOESY spectra and assigned chemical shifts were exported from Sparky 
(Goddard TD and Kneller DG, SPARKY 3, University of California, San Francisco) and 
used as input files for CYANA 3.0364. Backbone dihedral angles obtained from 
TALOS+345 were included in the standard manner with the command read aco. The 
eight TIL’E’ disulfide bonds (Cys767-Cys808, Cys776- Cys804, Cys788- Cys799, Cys792-
Cys827, Cys810-Cys821, Cys829-Cys851, Cys846-Cys863 and Cys849-Cys858) were 
explicitly implemented as constraints during the calculation using the ssbond 
command in CYANA 3.0. The stereospecifically assigned Val and Leu methyl groups 
were entered into the initialisation file with the command atom stereo for Val772, 
Val775, Val805, Val815, Val822, Val842, Val850, Val862 and Leu774, Leu781, Leu786, 
Leu797, Leu809, Leu824.  
Vector orientation restraints (RDCs) were included with the suggested weight of (WRDC) 
0.01 and initial starting parameters for the alignment tensor, Dmax = 15.7 Hz, R = 0.45 
(C12E5/n-hexanol) and Dmax = -15.7 Hz, R=0.45 (Pf1 phage) were estimated from 
histograms of the experimentally obtained RDCs. However, both the orientation and 
the size of the alignment tensors were optimised during the structure calculation and 
it was found that the specific starting values of the alignment tensors did not change 
the final family of structures.   
The command peakcheck was used to check the NOESY spectra peak lists against the 
assigned chemical shift list for errors in assignment. Automatic distance calibration 
implemented in CYANA 3.0364, converts NOE peak intensities into distance constraints. 
Upper distance limits are applied using an average distance limit for automatic 
calibration of 5 Å and the command calibration. The distance modify command was 
used to remove redundant and irrelevant restraints such as reciprocal NOEs, NOEs for 
which there exists no conformation that would violate it, and fixed distance NOEs such 
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as between geminal hydrogen atoms. The distances check command was used to 
assess how well supported an NOE is by surrounding NOEs. Finally, a total of 100 
structures were calculated using 10000 steps of torsion angle molecular dynamics and 
the 10 structures with lowest energy, and no NOE violations greater than 0.5 Å were 
selected to represent the solution structure of VWF TIL’E’. 
 
4.18. Heteronuclear 1[H]-15N NOE and CPMG experiments 
Differential flexibility on a picosecond to nanosecond timescale for the TIL’E’ molecule 
was quantitatively assessed by backbone heteronuclear 1[H]-15N NOE experiments and 
on the microsecond to millisecond timescale by constant time TROSY-based CPMG 
relaxation dispersion experiments, which were recorded at two field strengths (500 
MHz and 700 MHz). For both experiments peak intensities were extracted by the 
programme FuDA406. For the CPMG experiments, peak intensities for the different 
values of CPMG and ICPMG were converted to effective transverse relaxation rates (R2
eff) 
according to: 
  
   (    )   
 
 
    
    
     (     )
  
An approximation of the exchange contribution, Rex, was subsequently calculated by : 
       
   (       )    
   (       ) 
A table of all TIL’E’ RCI-S2, 1[H]-15N NOE and Rex values are given in Appendix 5.4.  
 
4.19. Ensemble refinement calculation 
The ensemble refinement calculations were performed by Dr D. Flemming Hansen 
using the programme Xplor-NIH. RDCs and RCI-derived S2 order parameters from 
backbone chemical shifts (TALOS+)345 were included as dynamical restraints. All 
experimentally determined RDCs were used. A twelve-member ensemble was 
calculated and two full sets of RDCs (15N-CO and 13CO-13C) were initially excluded and 
used for cross-validation along with 13C methyl chemical shifts. 
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5. Appendix 
 
5.1. Intron-exon junctions in proVWF 
 
Domain Exon 
(length bp) 
5’ Splice donor 3’ Splice acceptor Splice junction phase 
VWFD-C8-TIL-E      
VWD1 3 (165) ATT.G 
Ile73.Gly74 
GG.GAC 
Gly74.Asp75 
1 
VWD1 4 (103) CAA.AG 
Gln107.Arg108 
A.GTC 
Arg108.Val109 
2 
VWD1 5 (209) GAA.G 
Glu177.Gly178 
GG.ACC 
Gly178.Thr179 
1 
VWD1 6 (125) TAT.GA 
Tyr185.Asp186 
C.TTT 
Asp186.Phe187 
2 
C81 to TIL1 linker 7 (217) TGC.A 
Cys291.Ser292 
GC.CCA 
Ser292.Pro293 
1 
TIL1 8 (123) CCT.G 
Pro332.Glu333 
AG.GGA 
Glu333.Gly334 
1 
E1 9 (112) ACC.TG 
Thr369.Cys370 
C.ATT 
Cys370.Ile371 
2 
E1 to VWD2 linker 10 (47) CCA.G 
Pro385.Gly386 
GG.GAG 
Gly386.Glu387 
1 
VWD2 11 (137) CAG 
Gln431 
TGT 
Cys432 
0 
VWD2 12 (139) AAA.G 
Lys477.Gly478 
GT.GAC 
Gly478.Asp479 
1 
VWD2 13 (101) AAG 
Lys511 
CTG 
Leu512 
0 
C82 14 (196) ATG.A 
Met576.Thr577 
CC.AGG 
Thr577.Arg578 
1 
C82-TIL2 Linker 15 (216) TGT.G 
Cys648.Glu649 
AG.CTG 
Glu649.Leu650 
1 
E2 16 (241) ATG.TG 
Met728.Cys729 
C.TAC 
Cys729.Tyr728 
2 
E2 to TIL’ linker 17 (95) CGC.A 
Arg760.Ser761 
GC.AAA 
Ser761.Lys762 
1 
TIL’ 18 (161) ATG 
Met814 
GTC 
Val815 
0 
E’ 19 (104) ACT.TG 
Thr848.Cys849 
T.GTC 
Cys849.Val850 
2 
VWD3 20 (139) CAG 
Gln895 
GAT 
Asp896 
0 
VWD3 21 (135) GAG 
Glu940 
GTG 
Val941 
0 
VWD3 22 (147) CAG 
Gln989 
GAG 
Glu990 
0 
VWD3 to C8 linker 23 (141) AAA 
Lys1036 
GTG 
Val1037 
0 
C83 24 (114) CTG 
Leu1074 
GTG 
Val1075 
0 
C83 to TIL3 Linker 25 (157) TGC.C 
Cys1126.Pro1127 
CC.CAG 
Pro1127.Gln1128 
1 
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TIL3 26 (159) CCA.G 
Pro1179.Gly1180 
GG.AAA 
Gly1180.Lys1181 
1 
E3 27 (136) ATT.TG 
Ile1224.Cys1225 
C.CAC 
Cys1225.His1226 
2 
D4N 33 (44) AGG 
Arg1888 
CCC 
Pro1889 
0 
D4N 34 (178) CCC.T 
Pro1947.Cys1948 
GC.GTG 
Cys1948.Val1949 
1 
VWD4 35 (221) GAG 
Glu2021 
GTG 
Val2022 
0 
VWD4 36 (193) TGT.G 
Cys2085.Gly2086 
GG.ATC 
Gly2086.Ile2087 
1 
C84 to TIL4 Linker 37 (342) TGT.G 
Cys2199.Ala2200 
CT.ATG 
Ala2200.Met2201 
1 
VWC      
VWC1 38 (200) CAG 
Gln2266 
TTC 
Phe2267 
0 
VWC1 39 (103) AAA.G 
Lys2300.Ala2301 
CT.CCC 
Ala2301.Pro2302 
1 
VWC1 to VWC2 linker  40 (75) TGT.G 
Cys2325.Val2326 
TG.TGT 
Val2326.Cys2327 
1 
VWC2 41 (105) TGC.G 
Cys2360.Ala2361 
CC.TGC 
Ala2361.Cys2362 
1 
VWC2 to VWC3 linker 42 (206) AAG 
Lys2429 
GTG 
Val2430 
0 
VWC3 43 (150) TCG 
Ser2479 
GGC 
Gly2480 
0 
VWC4 44 (111) AGT 
Ser2516 
GTC 
Val2517 
0 
VWC4 to VWC5 linker 45 (181) TGT.G 
Cys2576.Glu2577 
AG.CGC 
Glu2577.Arg2578 
1 
VWC5 46 (41) GGG 
Gly2590 
CCC 
Pro2591 
0 
VWC5 47 (117) CTG 
Leu2629 
GGT 
Gly2630 
0 
VWC6 48 (99) AAG 
Lys2662 
CTG 
Arg2663 
0 
VWC6 49 (129) GGA 
Gly2705 
GGT 
Gly2706 
0 
VWC6 50 (40) ACA.T 
Thr2718.Cys2719  
GT.GAG 
Cys2719.Glu2720 
1 
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5.2. VWF TIL’E’ chemical shift assignment 
 
Chemical shifts are given in ppm; no chemical shift indicates unassigned or unobserved resonances.  
Residue HN H H H H H C C C C C N N N 
S766               
C767 8.184           123.547   
R768               
P769  4.565 2.323,1.922  3.791,3.555  62.078 30.636  50.454     
P770  4.564 2.305,2.152 2.008,1.437 3.524,3.480  64.007 33.632 24.545 49.539     
M771 8.759 4.346 2.056,1.782 2.725,2.271  1.928 57.932 33.859 34.256  18.044 123.176   
V772 8.855 4.301 1.974 0.887,0.825   59.732 35.145 21.357,19.573   116.266   
K773 8.448 4.371 1.770,1.605 1.242,1.210   56.715 33.170 25.207   125.383   
L774 9.145 4.549 1.919,1.498 1.592 0.865,0.901  54.112 43.288 28.227 24.974,25.383  132.136   
V775 8.578 4.149 1.931 0.860,0.864   61.132 32.365 20.987,20.981   127.590   
C776 8.643 4.291 2.962,2.691    56.014 40.082    129.201   
P777  4.497 2.290,2.100 2.154,2.062 3.801,3.613  62.350 32.151 27.459 50.442     
A778 8.553 4.120 1.376    53.417 18.882    124.507   
D779 8.116 4.505 2.748,2.635    53.654 40.387    114.322   
N780 7.669 4.656 2.809,2.813  7.623,6.892  53.230 38.076    115.834 111.505  
L781  4.287 1.659,1.596  0.918,0.847  55.807 41.758  25.022,23.143     
R782 7.897 4.303 1.946,1.736 1.642,1.540 3.180,3.182  55.632 29.732 27.129 43.128  117.867   
A783 7.345 4.215 1.349    52.261 20.466    123.746   
E784 8.061 4.542 2.273,1.885 2.131,1.710   56.544     119.157   
G785               
L786  4.315 1.666,1.576 1.600 0.895,0.835  55.313 42.152 26.986 25.081,23.503     
E787 8.165           121.770   
C788               
T789   4.085 1.224    70.366 21.424      
K790 8.762 5.059 1.863,1.845 1.655,1.621  2.925,2.928 54.874 34.598 24.691  42.477 128.269   
T791 9.410 5.450 4.953 1.217   58.958 72.724 21.387   116.019   
C792 8.587 4.376 3.181,3.034    57.480 36.316    115.821   
Q793 8.303 4.127 1.945,1.863 2.155,2.162  7.329,6.751 58.102 29.341 34.424   115.926  111.938 
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Residue HN H H H H H C C C C C N N N 
N794 7.925 4.760 3.316,2.628  7.396,7.010  51.927 39.325    117.107 108.104  
Y795 7.310 3.885 3.384,2.739  6.952 6.702 63.779 39.078  133.344 118.227 120.190   
D796 8.291 4.507 2.793,2.472    54.482 41.078    113.579   
L797 7.787 4.406 1.742,1.490 1.566 0.912,0.813  53.959 42.569 26.865 25.301,22.659  120.878   
E798 8.490 4.120 1.909,1.863 2.241,2.168   56.295 30.252 26.298   122.509   
C799               
M800  4.588 2.008,1.925 2.498,2.414   54.180 31.754 32.049      
S801 8.374 4.288 3.924,3.698    58.207 63.324    118.194   
M802  4.677  2.687,2.491   54.482  32.366      
G803 8.035 4.081,3.601     45.423     111.120   
C804 8.463 4.556 3.105,2.843     38.600    126.270   
V805  4.218 2.007 1.055,1.029   62.334 34.050 21.145,21.330      
S806 8.484 4.528 4.186,3.848    59.211 64.191    126.084   
G807 8.516 4.320,3.916     45.758     107.758   
C808 8.554 5.227 2.825,2.798    54.413 41.276    120.532   
L809 9.410 4.686 1.737,1.600 1.748 0.883,0.834  53.774 45.572 27.044 25.905,24.858  125.794   
C810 9.188 4.522 2.271,2.144    54.090 36.633    119.162   
P811               
P812               
G813  4.328,3.662     44.936        
M814 8.297 5.043 1.957,1.755 2.447,2.050  1.933 54.425 37.090 33.534  18.403 118.736   
V815 9.126 4.576 1.825 0.734,0.571   58.879 35.361 23.542,19.578   113.319   
R816 8.490 4.980 1.821,1.776 1.633,1.520 3.112,3.075  55.602 31.287 27.370 43.535  122.532   
H817 9.100 4.858 3.006,2.840  6.896 7.793 56.971 34.758  117.027 138.910 126.203   
E818 8.953 3.563 1.915,1.893 1.714,1.587   57.676 26.921 35.712   125.530   
N819 8.687 4.407 2.986,2.866  7.569,6.904  53.973 38.074    114.182 113.597  
R820 8.027 4.750 1.893,1.832 1.750,1.572 3.190,3.192  54.554 33.324 26.545 43.533  118.232   
C821 8.703 5.477 2.878,2.728    53.980 40.976    117.965   
V822 9.671 4.625 2.025 0.885,0.691   58.996 36.362 21.682,19.875   119.418   
A823 8.552 4.356 1.388    52.418 18.618    125.768   
L824 7.979 3.782 1.410,1.135 1.123 0.182,0.310  58.182 42.411 26.685 22.890,25.021  123.359   
E825 8.950 4.025 2.018,2.008 2.165,2.167   58.502 28.267 36.068   113.695   
R826 8.153 4.245 2.060,1.835 1.741,1.528 3.174,3.171  54.554 29.158 26.950 42.526  118.469   
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Residue HN H H H H H C C C C C N N N 
C827 7.601 4.224 3.019,2.744    55.125 37.198    119.490   
P828  4.437 1.970,1.496 1.682,1.426 3.226,3.170  62.458 33.668 26.386 49.726     
C829 8.424 4.328 1.955,1.536    56.386 42.435    112.961   
F830 8.799 5.831 3.080,2.956  7.109 7.239 57.1245 42.551  132.054 131.598 118.787   
H831 9.441 4.968 2.988,2.868  6.682 7.482 57.755 33.828  118.872 138.664 123.887   
Q832  3.733 2.087,1.650 1.746,1.334  7.273,6.785 56.512 26.732 33.404     111.289 
G833 8.665 4.206,3.693     45.486     104.219   
K834 7.951 4.670 1.901,1.832 1.430,1.208 1.677,1.680 2.918,2.917 54.931 35.124 25.305 28.949 42.349 122.208   
E835 8.216 4.332 1.828,1.704 1.942,1.841   55.614 31.797 36.920   122.599   
Y836 8.937 4.431 2.809,2.502  7.227 6.990 57.231 41.874  133.347 118.515 124.173   
A837 8.676 4.357 1.295    49.933 17.807    124.606   
P838  3.854 2.260,1.774 1.979,1.937 3.478,3.389  63.884 31.167 28.326 50.032     
G839 9.487 4.369,3.407     44.966     113.317   
E840 8.254 4.486 2.553,2.416 2.562,2.337   57.610 31.261 38.679   120.804   
T841 8.132 5.752 3.957 1.096   59.984 72.217 21.464   110.916   
V842 8.459 4.204 1.081 -0.411, -  
0.446 
  59.688 35.482 20.212,18.397   117.320   
K843 8.017 4.811 1.667,1.509 1.249,1.221 1.531,1.530 2.868,2.808 54.855 33.297 25.529 29.130 41.898    
I844 8.039 3.995 1.478 0.703 
0.839,0.246 
0.076  60.858 38.347 26.765,16.839 12.200  125.653   
G845  3.984,3.662     47.357        
C846 8.522 4.929 3.191,3.189    58.558 37.971    122.743   
N847 8.165 4.923 2.724,2.451  8.262,7.901  53.858 41.629    121.769 118.942  
T848 8.250 4.613 3.936 1.094   62.341 70.460 21.606   115.576   
C849 9.054 5.544 2.732,2.595    54.867 50.459    124.212   
V850 8.888 5.046 1.971 0.940,0.923   59.590 35.195 20.202,21.444   122.162   
C851 8.382 4.170 2.585,1.798    54.727 36.915    128.312   
R852 9.051 4.309 1.654,1.650 1.538,1.470   3.170,3.115  56.304 32.883 27.026 43.304  132.067   
D853 9.328 4.204 2.732,2.565    55.745 39.142    128.437   
R854 8.607 3.274 2.065,1.915 1.443,1.385 3.146,2.981  58.401 28.561 28.766 43.223  108.225   
K855 7.712 4.524 1.756,1.701 1.411,1.367 1.725,1.671 3.024,3.028 53.875 36.106 24.041 29.110 42.201 121.587   
W856 8.366 4.812 3.024,2.881  7.353 9.618,6.723 55.886 30.257  127.360 119.588 120.035  126.126 
N857 9.268 5.068 2.917,2.776  7.093,6.919  52.832 39.532    125.356 113.428  
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Residue HN H H H H H C C C C C N N N 
C858  5.712 3.016,2.977    55.808 47.903       
T859 8.221 4.183 4.012 1.358   62.852 70.176 21.732   112.700   
D860 8.038 4.649 2.554,2.496    52.707 40.809    120.286   
H861 8.654 4.655 3.041,2.938  7.044 7.854 55.554 30.875  120.696 138.890 120.257   
V862 8.687 3.982 2.008 0.944,0.999   62.929 31.843 21.349,21.206   123.478   
C863 8.700 4.844 3.532,2.831    52.964 37.591    125.981   
D864 8.041 4.345 2.618,2.534    55.939 42.176    127.664   
 
The assigned atoms, C (129.002) and H (7.131) of Phe830 and C2 (123.627), C2 (113.591), C3 (123.071), H2 (6.092), H2 (6.552) and H3 (6.768) of Trp856 are not included in 
the TIL’E’ shift table due to space constraints.  
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5.3. Ramachandran plot of ten lowest energy TIL’E’ NMR structures 
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5.4. Picosecond to millisecond dynamics of TIL’E’ 
 
Dynamic residues, [
1
H]-
15
N NOEs and RCI-S
2
 less than 0.6 and Rex greater than 1.5 s
-1
 are coloured red. 
Residue  Secondary structure [
1
H]-
15
N NOEs (ps-ns) RCI-S
2
 (ps-s) Rex (s
-1; 
s-ms) 
S766     
C767   0.788  
R768     
P769   0.734  
P770   0.754  
M771  0.740.02 0.764 3.62  0.07 
V772 
TIL’ 1 
0.60  0.04 0.793 8.40  0.50 
K773 0.70  0.02 0.784 2.17  0.20 
L774 0.69  0.08 0.813  
V775 0.63  0.02 0.815 2.42  0.20 
C776  0.66  0.04 0.817 16.23  1.07 
P777   0.766  
A778  0.46  0.07 0.730 2.75  1.49 
D779  0.58  0.02 0.704 13.64  0.65 
N780   0.677 7.54  0.85 
L781   0.642  
R782  0.42  0.05 0.601 14.00  0.15 
A783   0.551  
E784  0.52  0.03 0.524 5.51  0.04 
G785     
L786   0.528  
E787   0.528  
C788     
T789   0.844  
K790 
Upper portion of TIL’ 
1-to-2 loop 
0.76  0.03 0.862 6.57  0.12 
T791 0.65  0.02 0.884 8.50  0.63 
C792 0.72  0.01 0.875 0.67  0.26 
Q793 0.64  0.03 0.860 3.02  0.38 
N794 0.69  0.02 0.853 1.56  0.07 
Y795 0.67  0.01 0.865 2.89  0.09 
D796 0.75  0.02 0.852 2.76  0.05 
L797 0.72  0.01 0.819 1.84  0.10 
E798   0.794  
C799     
M800   0.671  
S801  0.42  0.02 0.658 13.31  0.38 
M802   0.674  
G803  0.55  0.03 0.704 19.13  0.27 
C804     
V805   0.699  
S806 
TIL’ 2 
0.70  0.07 0.742 16.10  0.42 
G807 0.72  0.03 0.772 14.74  0.19 
C808 0.67  0.03 0.867 -0.28  0.18 
L809 0.75  0.04 0.862 6.22  0.65 
C810   0.858  
P811     
P812     
G813   0.786  
M814 TIL’ 3 0.68  0.01 0.818 0.33  0.04 
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Residue  Secondary structure [
1
H]-
15
N NOEs (ps-ns) RCI-S
2
 (ps-s) Rex (s
-1; 
s-ms) 
V815 0.72  0.02 0.885 5.12  0.28 
R816  0.886  
H817 0.78  0.02 0.879 5.92  0.35 
E818  0.68  0.02 0.871 -0.60  0.22 
N819   0.881  
R820 
TIL’ 4 
0.68  0.01 0.897 0.58  0.09 
C821 0.61  0.02 0.907 0.42  0.10 
V822 0.75  0.02 0.884 0.49  0.20 
A823 0.77  0.02 0.859 1.29 0.01 
L824 
310-helix 
0.77  0.04 0.849 -0.21  0.15 
E825 0.74  0.01 0.858 0.26  0.11 
R826 0.70  0.03 0.841 0.70  0.11 
C827  0.76  0.01 0.835 0.68  0.06 
P828   0.835  
C829 
E’ 1 
0.73  0.02 0.868 0.13  0.10 
F830 0.71  0.01 0.876 0.57  0.01 
H831 0.72  0.01 0.851 0.17  0.12 
Q832   0.815  
G833  0.73  0.03 0.753 -0.08  0.15 
K834 
E’ 2 
0.69  0.01 0.722 -0.16  0.06 
E835 0.61  0.01 0.679 -0.10  0.13 
Y836 0.68  0.02 0.688 0.01  0.00 
A837  0.56  0.01 0.696 -0.40 0.03 
P838   0.713  
G839 
E’ 3 
0.70  0.01 0.743 -0.20  0.01 
E840 0.73  0.02 0.784 -0.01  0.06 
T841 0.72  0.01 0.855 0.07  0.09 
V842 0.70  0.01 0.864 0.50  0.08 
K843 0.66  0.02 0.847 -0.17  0.03 
I844 0.63  0.01 0.821 -0.39  0.02 
G845   0.806  
C846   0.778  
N847 
E’ 4 
 0.796  
T848 0.65  0.01 0.834 -0.12  0.02 
C849 0.66  0.01 0.907 -0.48  0.05 
V850 0.70  0.01 0.919 -0.10  0.09 
C851 0.65  0.01 0.915 -0.91  0.10 
R852 0.74  0.01 0.905  
D853  0.65  0.01 0.908 -1.08  0.01 
R854  0.66  0.01 0.901 0.06  0.11 
K855 
E’ 5 
 
0.70  0.01 0.859 0.28  0.05 
W856 0.63  0.01 0.853 0.98  0.04 
N857 0.66  0.01 0.852 -0.55  0.09 
C858  0.879  
T859  0.67  0.01 0.782 0.32  0.06 
D860  0.58  0.01 0.710 0.36  0.01 
H861  0.58  0.01 0.607 -0.07  0.06 
V862  0.51  0.01 0.561 -0.30  0.02 
C863  0.40  0.01 0.514 -0.96  0.14 
D864  -0.15  0.01 0.504 -0.62  0.03 
Data from both experiments were not obtainable for all assigned residues owing to some peaks being 
very weak or overlapped and consequently excluded from further analysis. 
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